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Obesity is one of today’s biggest public health problems. Overnutrition 
associated with a sedentary lifestyle is leading to an escalating global epidemic 
of overweight and obesity called “globesity”. Obesity is a complex condition, due 
to associated comorbidity and challenging social and psychological dimensions, 
affecting all age and socioeconomic groups in both developed and developing 
countries. In 1995, an estimated 200 million adults worldwide were classified as 
obese. As of 2000, the number of obese adults has increased to over 300 
million,1 and is anticipated to increase even further.2 
In 2018, 50.2% of the Dutch adult population had overweight (BMI ≥25 kg/m2) 
and 15% was classified as obese (BMI ≥30 kg/m2). Men have higher rates of 
overweight (53.3% versus 47.2% in women), whereas women have higher rates 
of obesity (16.9% versus 13.0% in men)3. Obesity poses a major health risk 
especially for serious non-communicable diseases, including diabetes mellitus, 
cardiovascular disease, hypertension and stroke, specific types of cancer 1 and 
non-alcoholic fatty liver disease (NAFLD).4,5 
Non-alcoholic fatty liver disease 
NAFLD is the most widespread liver disease in Western society, with a 
prevalence up to 25% among the population.6 The term NAFLD comprises both 
simple steatosis, a more benign form of fat accumulation, present in the 
majority of patients, and non-alcoholic steatohepatitis (NASH).7 NASH is a 
chronic inflammatory state that develops in about 30% of NAFLD patients and 
leads to an overall increase in morbidity and mortality due to the progression to 
fibrosis, cirrhosis and hepatocellular carcinoma (HCC).8,9 
Pathophysiology 
NAFLD is a lifestyle related disease with both hepatic and extra-hepatic 
complications. The complex pathophysiology is multifactorial and not yet fully 
elucidated. Factors reported to be involved include amongst others diet, host 
genetics, metabolic factors like insulin resistance, oxidative stress and 




Excess calorie consumption leading to obesity and related comorbidities,12 
results in lipid accumulation in the liver, mainly in the form of triglycerides, and 
is the major risk factor for NAFLD.6 With regard to macronutrient composition, 
especially high intake of saturated fats, animal proteins, and also simple sugars 
like fructose, have been associated with NAFLD. A Western diet is characterised 
by a high consumption of these components,13, 14 and therefore considered a 
clear risk factor. In addition, snacking, a common feature of the Western diet, 
has also been shown to increase liver fat content independent of caloric load.15  
Once nutrients have been taken up by the enterocytes they are transported to the 
liver via the portal circulation. Chylomicrons present in the circulation have to 
be transported through the vascular endothelium to be metabolized and/or 
stored by tissues. Under physiological conditions, liver sinusoidal endothelial 
cells (LSECs) are major regulators of the bidirectional lipid exchange between 
blood and the liver parenchyma. LSEC fenestrae allow efficient transfer of 
lipoproteins, chylomicron remnants and other macromolecules, from the 
sinusoidal blood to the space of Disse, and vice versa. Animal models and in 
vitro studies using primary LSECs have shown that LSECs undergo 
morphological and functional changes during the process of liver steatosis, 
characterised by loss of fenestrae (i.e. defenestration). It has been shown that 
this can occur early in the course of NAFLD and can promote steatosis.16 For 
example, a study in mice deficient of Plasmalemma Vesicle Associated Protein 
(PLVAP), a protein required for the formation of fenestrae, showed development 
of extensive multivesicular steatosis, steatohepatitis and fibrosis around three 
weeks of life.17 This indicates that fenestrae may have a role in NAFLD 
pathophysiology. Up to now, studies in human liver samples are lacking, mainly 
as detailed evaluation of the LSECs and their fenestrae is not possible in 
immersion fixed tissue samples, due to collapse of the sinusoids.18 However, 
recently techniques have been developed that allow perfusion-type fixation of 
needle18 and wedge liver biopsies.19 
Genetics 
Genetic factors were found to regulate susceptibility to liver damage as based on 
results of a study in twins showing that hepatic steatosis and hepatic fibrosis are 
heritable traits.20 At present, several genetic associations have been identified in 
patients with NAFLD, but only a minority has been validated. Polymorphisms in 




6 superfamily, member 2 (TM6SF2) are among the best characterised 
polymorphisms and have been shown to promote the development of NASH and 
related liver damage.21 They have been reported in 1422 and 12%23 of NAFLD 
patients, respectively. PNPLA3 encodes adiponutrin, a lipase that regulates both 
triglyceride and retinoid metabolism. Exact mechanisms through which 
PNPLA3 acts are however unknown and it should be noted that the PNPLA3 
polymorphism (I148M) is neither sufficient nor required to cause NASH, 
cirrhosis, or liver cancer.21 The TM6SF2 polymorphism reduces hepatocyte very 
low-density lipoprotein secretion and is associated with NASH and liver fibrosis. 
This suggests that proper trafficking of lipids is necessary to prevent 
lipotoxicity.21 Furthermore, a lower risk of developing carotid plaques and a 
lower incidence of cardiovascular events was seen in patients with this 
polymorphism.24 More recently, the rs641738 variant in the gene membrane 
bound O-acyltransferase domain containing 1 (MBOAT1) and the rs72613567 
variant in the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene have 
also been linked to NAFLD.25, 26 Overall, there is evidence that about half of the 
steatosis variability is inherited.27 However, despite various associations being 
identified, host genetics cannot fully explain which patients are at risk of 
developing progressive disease, other factors are also involved. Therefore, at 
present, genotyping is not yet recommended as routine procedure, but may be 
considered in selected patients in case of lacking features of insulin resistance 
and in clinical studies.28 
Metabolic factors: Insulin resistance, oxidative stress and lipotoxicity 
NAFLD is characterised by an excess of hepatic free fatty acids (FFA), resulting 
from an imbalance between an increased availability and a reduced removal of 
FFA. Apart from a high dietary intake, major sources of FFA in NAFLD are 
dysregulated lipolysis in adipose tissue and de novo lipogenesis,29 which both 
are induced by insulin resistance (IR).27,30 Furthermore, in case of IR-induced 
impairment of insulin uptake in extrahepatic tissue, the liver will receive an 
overload of glucose and insulin. This will induce liver synthesis of FFAs through 
activation of SREBP-1c [sterol regulatory binding protein-1c] and ChREBP 
[carbohydrate response element binding protein].27 The two major ways to 
process this excess FFA in hepatocytes are mitochondrial beta-oxidation and re-
esterification to form triglycerides.30 In simple steatosis, it is thought that the 
excess FFA leads to triglyceride accumulation in the form of lipid droplets. This 
is considered a non-toxic, safe form of storage for lipids in the liver. However in 
Chapter 1 
14
NASH, enhanced FFA metabolism takes place via mitochondrial β-oxidation, 
leading to the formation of toxic lipid species (such as ceramides, 
diacylglycerols, lysophosphatidylcholine). These can induce endoplasmic 
reticulum stress, hepatocellular injury and cell death contributing to 
fibrogenesis and genomic instability predisposing to cirrhosis and 
hepatocellular carcinoma.30  
NASH patients do have higher oxidative stress levels as compared to patients 
with simple steatosis.27 Enhanced free fatty acid metabolism via mitochondrial 
β-oxidation is considered a crucial pro-oxidizing factor in NASH. Two percent of 
the oxygen consumed by hepatocytes is transformed into radical oxygen species 
(ROS) by mitochondria under basal conditions. Enhanced oxidative stress in 
mitochondria by excess free fatty acids may further damage organelle function. 
This contributes to a vicious circle, since ROS generation by the damaged 
respiratory chain is increased, which further damages the respiratory chain. In 
this way oxidative stress can play a crucial role in NAFLD progression, since 
oxidative damage to lipid, protein and DNA molecules can trigger several 
inflammatory and fibrogenic signalling pathways (NF-ĸB and TGF-β/SMAD3-
signalling pathway).27 Iron is also a well-known pro-oxidant and can thereby 
play a role in generating reactive oxygen species.27 An association between 
NAFLD and iron overload has been shown, with increased hepatic iron found in 
NAFLD patients. Hepatic iron can be present in three histologic patterns; in the 
hepatocytes (hepatocellular (HC) iron), in the reticuloendothelial system (RES) 
or as a mixed pattern (stainable iron in both HC and RES). NAFLD patients with 
RES iron were found to show more severe NAFLD, according to the NAFLD 
Activity Score (NAS).31 It is hypothesised that increased iron depositions can 
increase oxidative stress by catalysing the production of ROS through the Fenton 
reaction. In addition, iron is suggested to exacerbate IR through alteration of 
insulin signalling in adipocytes and hepatocytes. Iron as well as blood iron-
transporter transferrin have been shown to induce insulin resistance of glucose 
transport in adipocytes through a mechanism independent of fatty acids in an in 
vitro model of isolated rat adipocytes.32 Furthermore, hyperinsulinaemia and 
hence insulin resistance without impaired glucose tolerance has been 
demonstrated in patients with idiopathic haemochromatosis in the non-
cirrhotic stage.33 Additionally, ferritin, the iron storage protein, is known to 
inhibit the secretion of apolipoprotein B post-translationally in rat liver 
microsomes.34 Serum ferritin is used as a measure of iron overload, but also 




NAFLD,35,36 but the exact cause of hyperferritinaemia in NAFLD, being iron 
overload or inflammation, still remains unclear.   
Skeletal muscles 
Excess FFA do not only affect the liver, but also impact several other organs. 
Ectopic FFA accumulation in skeletal muscle has been recognized as an early and 
important source of peripheral IR in NAFLD.27 In muscle tissue, fat can 
accumulate within the cytoplasm of myofibres (intra-myocellular lipids; IMCL) 
or in adipocytes located between muscle fibres (extra-myocellular lipids).37 High 
IMCL levels have been associated with IR, but the exact underlying mechanism 
is unclear.38 Interestingly, exercise has also been shown to increase IMCL levels, 
as insulin-sensitive muscles of highly trained athletes have similar IMCL content 
compared to old type 2 diabetes mellitus patients. This is known as the ‘athlete 
paradox’, which suggests that IMCL accumulation per se does not lead to insulin 
resistance, but specific lipid species or lipid turnover dynamics may play a 
role.37,38  
Intestinal involvement 
Evidence is increasing that also intestinal factors may contribute to the onset 
and/or progression of NAFLD. Intestinal epithelial integrity is essential to 
separate luminal contents from the interstitium and the systemic compartment. 
This is amongst others determined by the integrity of the epithelial barrier 
through tight junctions that seal the paracellular space. Intestinal permeability 
may increase in response to several factors, such as luminal nutrients, mucosal 
immune mediators and pathogens.39 An abnormally increased permeability has 
been associated with several gastrointestinal and systemic diseases.40-42  
Increased intestinal permeability leads to translocation of bacteria or parts of the 
bacterial membrane, subsequently leading to increased concentration of 
lipopolysaccharide (LPS), called endotoxaemia, which can dysregulate the 
inflammatory tone and insulin sensitivity.43,44 Animal studies have suggested 
that a high-fat diet or a high-fructose diet can induce increased intestinal 
permeability and metabolic endotoxaemia by altering the intestinal tight 
junctions proteins, mainly zonula occludens-1 and occludin. A high-fat diet can 
affect the intestinal barrier by the secretion of bile acids, induction of pro-
inflammatory mediators and by influencing the intestinal microbiota.45 A high-
fat diet has been shown to increase the proportion of LPS-containing microbes in 
the gut.43 Furthermore, in adolescents with NAFLD, postprandial endotoxin 
Chapter 1 
16
levels were increased compared to healthy subjects in response to fructose, but 
not glucose, beverages (consumed with meals) in a 24-h feeding challenge.46 
Fructose also directly affects hepatic lipid metabolism, leading to hepatic 
steatosis.47 
Human data on intestinal permeability in NAFLD patients are limited. In NAFLD 
patients, intestinal permeability has been studied using urinary extraction of 
(51)Cr-ethylene diamine tetraacetate ((51)Cr-EDTA),48 lactose/mannitol ratio,49
and by measuring serum zonulin levels.50 Using these methods, an increased
intestinal permeability in NAFLD patients compared with healthy control
subjects was observed in some studies.48-50 However, this increased intestinal
permeability was not confirmed by other investigators.51,52 Some studies showed
an increased intestinal permeability only in NASH and not in simple
steatosis,50,53 however another study did not confirm this.48 Further studies are
warranted directly comparing well defined simple steatosis with NASH and with
control subjects.
In addition to dietary factors and inflammatory mediators, the intestinal barrier
might be directly affected by intestinal bacteria and their products. The
intestinal microbiome further provides colonisation resistance, affects epithelial
cell and immune functioning and comprises a large metabolic activity. Several
studies have observed changes in microbiota composition in NAFLD. It has been
shown that concentrations of Gram-negative bacteria such as Enterobacteria are
increased, whereas protective bacteria such as Faecalibacterium prausnitzii are
decreased in NAFLD patients.54 Although the exact role of the intestinal
microbiome in the pathogenesis of NAFLD is not fully elucidated, the observed
perturbations may further contribute to the pro-inflammatory phenotype of
NAFLD.54
Diagnosis 
NAFLD is mostly asymptomatic, generally resulting in silent disease 
progression. To date, a liver biopsy is the most sensitive test for detecting and 
staging NAFLD and so far is the only reliable method to diagnose NASH.28 Due to 
its invasiveness, high costs and risk of complications, liver biopsy is however 
not suitable to diagnose large populations or for (repeated) disease 
monitoring.55 In clinical practice, only subjects at high risk of NASH, usually 
based on elevated aminotransferase levels, are generally considered to undergo 




non-invasive tool to diagnose NASH is lacking, however, at present, non-
invasive tools are available for the assessment of steatosis and fibrosis.  
Non-invasive assessment of steatosis 
Several imaging techniques have been evaluated for the detection of steatosis. 
Ultrasound is a widely available and rather inexpensive diagnostic tool, with a 
high sensitivity when liver steatosis is more than 33%. However, sensitivity is 
poor when the degree of liver steatosis is less than 30%.57,58 A promising new 
technique is the addition of controlled attenuation parameter (CAP), that 
measures the degree of ultrasound attenuation by hepatic fat simultaneously 
with liver stiffness measurements.59 This ultrasonic attenuation coefficient is an 
estimate of the total ultrasonic attenuation (go-and-return path) at 3.5 MHz and 
is expressed in dB/m.60 CAP has shown to also reliably detect low grades of 
steatosis.61 A technique with a very high sensitivity in case of low degrees of 
steatosis is magnetic resonance imaging (MRI), including MR spectroscopy. This 
technique is able to detect hepatic fat at a percentage greater than 5.56% very 
accurately. The down side of this technique are the high costs and limited 
availability.62 Computed tomography does not substantially improve sensitivity 
in case steatosis is mild and it has the disadvantages of radiation exposure and 
increased costs.11 Table 1.1 provides an overview of sensitivity and specific 
values of the different techniques for moderate-severe and all degrees of 
steatosis.63,64 
Table 1.1  Overview of sensitivity and specificity for steatosis 
Moderate-severe steatosis 
(≥30% OR 33%) 
All degrees of steatosis 
(≥3% OR 5%*/≥5%) 
US* Sensitivity 81.8% - 100.0% 53.3% - 66.6% 
Specificity 98% 77.0% - 93.1% 
CT* Sensitivity 72.7% - 82% 
Specificity 91.3% - 100% 
CAP# Sensitivity 67% 91% 
Specificity 97% 79%
MRI* Sensitivity 76.7% - 90.0% 
Specificity 87.1% - 91% 
MRS* Sensitivity 80.0% - 91.0% 
Specificity 80.2% - 87.0% 
*Data from Lee SS, Park SH. World J Gastroenterol 2014;20:7392-7402. #Data from Francque S,
Lanthier N, et al. Acta Gastroenterol Belg 2018;81:55-81. 
Abbreviations: ultrasound (US); computed tomography (CT); controlled attenuation parameter
(CAP); magnetic resonance imaging (MRI); magnetic resonance spectroscopy (MRS).
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Non-invasive assessment of fibrosis 
Fibrosis can be assessed by transient elastography (TE) and magnetic resonance 
elastography (MRE). TE is fairly accurate in the detection of hepatic fibrosis but 
more reliable for diagnosing advanced fibrosis65 (see Table 1.2 for cut-off values 
and accuracy). While MRE may be even more reliable than TE, it is a costly 
technique that is not widely available.66  
Table 1.2  Cut-off values of transient elastography64 
Type of probe Stage of fibrosis Reported 
cut offs 
(kPa) 
Sens (%) NPV (%) Spec (%) Cut off (kPa) 
M Probe ≥2 6.7-7.8 67-88 84 61-84 7,9 
≥3 >8-10.4 65-100 95 75-93 8.7
4 >8-10.4 78-100 99 87-98 10.3 
XL Probe ≥2  89 7.2
4 98 7.9 
Abbreviations: sensitivity (Sens), negative predictive value (NPV), specificity (Spec). Table adapted 
from Francque et al. 64  
In addition to imaging techniques, some predictive models for fibrosis have 
been developed based on clinical parameters and measures. The NAFLD fibrosis 
score (NFS) is the best validated score and can help to identify patients with 
more severe disease, who may need a liver biopsy. The NFS is calculated using 
various parameters, including age, body mass index, presence/absence 
hyperglycaemia, platelet count, albumin level, and ratio of aspartate 
aminotransferase (AST) to alanine aminotransferase (ALT).67 Other non-invasive 
scoring systems for fibrosis include FIB-4 index, AST/platelet ratio (APRI) index 
and BARD score. It should be noted that all these scoring systems, including the 
NFS, yield high negative predictive values (NPV) but poor positive predictive 
values (PPV). Therefore, they are best applied to exclude subjects without 
advanced fibrosis, thus avoiding unnecessary liver biopsies.68 
Up to now, accurate non-invasive tools to diagnose NASH are largely lacking. 
Although some parameters and scoring systems have been evaluated, none are 
available for use in daily clinical practice. There is an urgent need for non-
invasive methods to detect NASH among the general population. In the near 
future, general practitioners (GPs), as gatekeepers of our healthcare system, are 
going to play a major role in adequately identifying and managing these patients 






Diet and physical exercise are considered the mainstay treatment for the 
majority of patients with NAFLD.11,28 Weight loss is widely acknowledged to be 
beneficial and the degree of liver histological improvement is directly 
proportional to the amount of weight loss.11 A weight loss of 10% of body weight 
was shown to be associated with histological benefit in NASH patients, such as 
improvement of liver fat, degree of hepatic inflammation and fibrosis and also 
improvement of serum liver enzymes.69 However, it is common knowledge that 
sustained weight loss is very difficult to achieve. Therefore, other treatment 
options should also be considered. 
Pharmacological treatment of NASH 
Drug therapy should be considered for progressive NASH, those with significant 
fibrosis (≥F2) but also for early-stage NASH with increased risk of fibrosis 
progression, i.e. diabetes mellitus, metabolic syndrome, persistently increased 
ALT, high necro-inflammation and age >50 years. However, the optimal type 
and duration of therapy is still unknown.28 Among promising pharmacological 
agents for progressive NASH, insulin sensitizers, anti-oxidants and bile acids 
have been studied most widely. With the insulin sensitizers, thiazolidinediones, 
also called glitazones (peroxisome proliferator-activated receptor (PPAR) 
gamma agonists), improvement of all histological features, except for fibrosis 
has been demonstrated and resolution of NASH was achieved more often (85%) 
than with placebo (58%).70-72 However, the side-effects of thiazolidinediones are 
a concern, including weight gain, increased risk of bone fractures in women and 
rarely also congestive heart failure.28 Liraglutide (an incretin mimetic) showed 
histologic remission of NASH without worsening fibrosis in a small pilot trial,73 
but further research is necessary. 
Vitamin E, an anti-oxidant, was found to improve steatosis, inflammation and 
ballooning and induced remission of NASH in 36% of patients (versus 21% in 
placebo arm).72 There are, however, concerns with regard to the long-term 
safety of vitamin E, relating to increased risks for overall mortality,74 
haemorrhagic stroke75 and prostate cancer in males older than 50 years.76 
Ursodeoxycholic acid, a bile acid, has been studied in several randomised 
controlled trials and showed biochemical but not histological improvements of 
NAFLD.77-79 Obeticholic acid, a synthetic farnesoid X receptor agonist, has been 
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shown to improve all NASH lesions and improve fibrosis in the FLINT trial.80 
However, there is a concern with regard to safety and tolerability of obeticholic 
acid related to increased low-density lipoprotein (LDL)-cholesterol levels and to 
pruritus.28 
Data on lipid-lowering drugs, such as statins, are limited. Statins reduce LDL-
cholesterol and prevent cardiovascular risk, with no benefits or harm on liver 
disease. Currently, there are no data to support their use specifically for NASH.28 
 
Although several drugs have been studied, up to now, no drug has been 
approved for NASH by regulatory agencies, and any drug treatment would be 
off-label. Due to the multifactorial origin of the NASH it is unlikely that one 
specific drug will cure or prevent this disease. 
Probiotics and prebiotics 
In addition to lifestyle interventions and pharmacological therapy, the potential 
of functional foods receives increasing attention. Probiotics, prebiotics and 
synbiotics have been studied, but most of the available data have been obtained 
in animal or in vitro studies. While the results of these studies are promising, 
data from human intervention studies are scarce.81 In one small-sized human 
proof-of-concept study, it was shown that compared with placebo, a probiotic 
mixture resulted in a significant reduction in intrahepatic triglyceride content in 
patients with hepatic steatosis.82 
Bariatric surgery 
Bariatric surgery is an option for reducing weight and metabolic complications 
in patients unresponsive to lifestyle changes and pharmacotherapy. Several 
types of bariatric surgeries are known, such as the gastric sleeve and the Roux-
and-Y gastric bypass, though a preference for a certain type of bariatric 
procedure cannot be given.83 A recent cohort study with 1-year follow-up 
showed that bariatric surgery associated weight loss cleared NASH in 85% of 
patients and improved fibrosis in 34%.84 The possible benefits of bariatric 
surgery should be balanced against peri- and postoperative complications.28 
Liver transplantation 
In case lifestyle and other interventions failed and end-stage liver disease has 
developed, a liver transplantation can be considered as the only curative option. 




for liver transplantation has increased by 170%. In the near future, it is expected 
that NAFLD will probably become the leading indication for liver 
transplantation due to the still rising prevalence of NAFLD.12 Liver 
transplantation is an accepted procedure in NASH patients with end-stage liver 
disease, with comparable overall survival to other indications, despite its 
invasiveness and the higher cardiovascular mortality.28 It should be noted that 
there will not only be an increased need for liver transplantations, with the 
rapidly growing prevalence of NAFLD, also the pool of potential liver donors is 
impacted, as it is expected that a higher proportion of potential liver donors will 
have steatosis or steatohepatitis and might be declined for liver transplantation 
use.85 
Aims and outline of this thesis 
With the growing epidemic of overweight and obesity, the prevalence of NAFLD 
is expecting to rise enormously over the coming years. Due to the progressive 
nature of NASH, it is important to identify patients at risk of progressive disease 
in an early stage, to prevent progression, promote quality of life and reduce 
healthcare costs. The studies presented in this thesis were undertaken to gain 
more insight in underlying pathophysiological mechanisms of NASH, focussing 
on ultrastructural changes, the role of ferritin and myosteatosis. Furthermore, 
this thesis addresses the non-invasive diagnosis of NASH and the awareness and 
knowledge of general practitioners on NAFLD to investigate possibilities for 
early diagnosis. 
First, we aim to study the liver ultrastructure, especially fenestration, in human 
liver biopsy samples of NAFLD patients, comparing patients with and without 
NASH, using transmission electron microscopy (chapter 2). We hypothesise 
that fenestrae size and number decrease as the severity of NAFLD increases. 
Serum ferritin levels can be used as a measure of iron overload, but can 
also reflect inflammation. Both inflammation and iron overload have 
been associated with NAFLD. We hypothesise that hyperferritinaemia in 
NAFLD predominantly is an expression of inflammation rather than iron 
overload. We performed an extensive review of the available literature 
(chapter 3) and evaluated the relation between serum ferritin and histologic 
NAFLD severity in a large cohort of patients with biopsy proven NAFLD 
(chapter 4) to test our hypothesis. 
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Furthermore, NAFLD is considered to be a multisystem disease and can affect 
extra-hepatic organ systems leading to cardio-vascular disease, type 2 diabetes 
mellitus, chronic kidney disease and colorectal cancer. One of the potential 
mechanisms is based on myosteatosis, which is thought to be an early sign of 
peripheral insulin resistance, which plays a role in NAFLD. In chapter 5 we aim 
to investigate whether myosteatosis is associated with the amount of hepatic fat 
and the presence of liver fibrosis.  
Accurate non-invasive diagnosis of NASH is needed to facilitate future research 
and patient care. In chapter 6, we report on an extensive systematic literature 
search and meta-analyses with available non-invasive diagnostic biomarkers 
and scores for NASH, with liver biopsy as a reference standard.  
Even when the gold standard of liver biopsy is used, a large variation in NASH 
prevalence is shown, especially within bariatric studies.  In chapter 7 we search 
for a possible explanation for the variation in NASH prevalence within bariatric 
studies. In this chapter, we focus on the impact of direct preoperative 
interventions. 
The rising prevalence of NAFLD and its related comorbidities confront us with 
the challenge to adequately detect and manage these patients at the level of the 
general population in order to prevent end-stage liver disease. Therefore, we 
performed a survey among general practitioners with the aim to investigate the 
current knowledge and common practices concerning NAFLD among Dutch 
general practitioners (chapter 8). 
In chapter 9, the general discussion, the findings of the various chapters are 
summarised and new insights are discussed, allowing an overview with future 
perspectives and new leads, focussing on pathophysiology, diagnosis, pitfalls in 
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Electron microscopic observations in  
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Non-alcoholic fatty liver disease (NAFLD) is a widespread liver disease in 
Western society, but its multifactorial pathogenesis is not yet fully understood. 
Ultrastructural analysis of liver sinusoidal endothelial cells (LSECs) in animal 
models and in vitro studies, shows defenestration early in the course of NAFLD, 
promoting steatosis. LSECs and fenestrae are important in the transport of lipids 
across the sinusoids. However, human ultrastructural data, especially on LSECs 
and fenestrae, are scarce. 
This study aimed to explore the ultrastructural changes in perfusion-type fixed 
liver biopsies of NAFLD patients with and without non-alcoholic steatohepatitis 
(NASH), with a special focus on LSECs and their fenestration.  
Liver biopsies from patients with NAFLD were fixed using two perfusion 
techniques, jet and injection fixation, for needle and wedge biopsies 
respectively. Ultrastructural changes were studied using transmission electron 
microscopy. NASH was diagnosed by bright-field microscopy using the SAF 
score (Steatosis, Activity, Fibrosis). 
Thirty-seven patients were included, of which twelve patients (32.4%) had 
NASH. Significantly less defenestration was found in NASH compared to 
noNASH samples (p=0.002). Other features, i.e. giant mitochondria and 
fenestrae size did not differ between groups. Furthermore, we described new 
structures, i.e. single cell steatonecrosis and inflammatory fat follicles that were 
observed in both groups. 
Concluding, defenestration was more common in noNASH compared to NASH 
in human liver samples. Defenestration was not related to the degree of steatosis 
or fibrosis. We speculate that defenestration can be a protective mechanism in 
simple steatosis which is lacking in NASH.  




Non-alcoholic fatty liver disease (NAFLD) is the most widespread liver disease in 
Western society, with a prevalence up to 25%.1 It is strongly associated with 
overweight and obesity.2,3 The term NAFLD comprises both steatosis and non-
alcoholic steatohepatitis (NASH).4 NASH is an inflammatory state that develops 
in about 30% of NAFLD patients with significantly increased morbidity and 
mortality due to progression to fibrosis, cirrhosis and hepatocellular 
carcinoma.5,6 
The pathophysiology of NASH is still poorly understood and is considered to 
have a multifactorial aetiology, involving dietary factors, host genetics, insulin 
resistance, lipotoxicity and microbiome perturbations.7 Studying ultrastructural 
changes in human liver biopsies may help to provide leads to further elucidate 
the pathophysiology of NAFLD. 
Only a limited number of human studies have been performed that focused on 
ultrastructural changes in NAFLD. These studies showed autophagic vesicles8 
and lipolysosomes in liver biopsies of NAFLD patients,9 with giant lipolysosomes 
in case of severe steatosis.9 Furthermore, Mallory-Denk body formation, 
‘cellular enlargement’ and dilatation of the endoplasmic reticulum have been 
observed in NASH patients.10 Mitochondria have also been studied because of 
their role in beta-oxidation, showing crystalline inclusions and giant 
mitochondria in some, but not all cases of NASH.11,12 Ahishali et al. reported 
larger mitochondrial diameter in NASH livers compared to fatty livers, but did 
not report a difference in the presence of giant mitochondria comparing NASH 
and fatty liver samples.13 However, a shortcoming of studies on ultrastructural 
changes is the rather small numbers of NAFLD and/or NASH patients included, 
ranging from 4 to 23, and only one study made a direct comparison of adult 
NAFLD patients with versus without NASH.13 Animal models and in vitro 
studies have also revealed interesting ultrastructural findings in NAFLD, 
especially with regard to liver sinusoidal endothelial cells (LSECs). LSECs are 
highly specialised endothelial cells at the interface between blood derived from 
the visceral adipose tissue and the gut on one side and hepatocytes and hepatic 
stellate cells on the other side. They have a unique phenotype, they lack a 
basement membrane and have fenestrae organised into sieves that regulate the 
transport of macromolecules, including lipids and lipoproteins across the 
sinusoid.14 Studies in animal models and in vitro studies have shown that the 
diameter and porosity of fenestrae show a negative correlation with excessive 
lipid15,16 and endotoxin17 exposure. A study in mice, deficient of Plasmalemma 
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Vesicle Associated Protein (PLVAP), a protein coding gene required for the 
formation of fenestrae in LSECs, showed development of extensive 
multivesicular steatosis, steatohepatitis and fibrosis at around three weeks of 
life.18 This suggests that loss of fenestrae (defenestration) of LSECs may be an 
early step in the course of NAFLD.14 Due to the limited preservation of LSECs and 
their fenestrae by immersion fixation, as used in previous human electron 
microscopy studies, data on LSECs and their fenestrae in human samples is 
scarce.14 During immersion fixation, the fixative penetrates the tissue by 
diffusion, on its way fixating the tissues from the periphery to the centre. This 
leaves the centre of the tissue unfixed for almost an hour19 and only allows 
studying the well-fixed peripheral parenchymal cells. Sinusoidal cells and 
sinusoids collapse and lose details due to this improper fixation.20  
To overcome this problem, we developed perfusion fixation methods for needle 
and wedge biopsies,19,20 which significantly improved the preservation of the 
sinusoids, sinusoidal cells and endothelial fenestrae, enabling high resolution 
transmission electron microscopy (TEM) of all hepatic cell types in human liver 
biopsies. Depending on the size of the tissue sample, wedge versus needle liver 
biopsy, different perfusion fixation techniques need to be used, namely 
injection19 and jet20 fixation respectively. Our aim was to explore the 
ultrastructural changes in human liver biopsies of NAFLD patients with and 
without NASH, with a special focus on LSECs and their fenestration. We 
hypothesised that fenestrae size and number decrease as the severity of NAFLD 
increases. 
Methods 
Patients and tissue sampling 
For the current explorative study, samples were available from patients with 
NAFLD undergoing a liver biopsy either for clinical reasons or as part of a 
research project. From all participants paraffin embedded needle biopsies were 
available for standard bright-field microscopy evaluation. Needle liver biopsies 
were obtained using a 16G needle and a biopsy gun (Bard Magnum Reusable 
Core Biopsy System). Additionally, biopsy samples were collected for 
transmission electron microscopy (TEM) analysis. Liver wedge biopsy specimen 
were taken from 19 patients with NAFLD, between October 2016 and October 
2017 in the Zuyderland Medical Centre. Before inclusion, NAFLD had been 
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diagnosed using imaging. The samples were collected during surgery 
(cholecystectomy [n=1] and bariatric surgery [n=18]) as part of a study 
identifying non-invasive markers for NASH. This study was approved by the 
Medical Ethics Committee Zuyd and registered at clinicaltrials.gov 
(NCT02717000). All participants gave written informed consent prior to 
participation. Another 20 needle liver biopsies for TEM analysis were available 
as residual material from routine liver biopsies obtained from patients with a 
diagnosis of NAFLD based upon routine histopathological evaluation for clinical 
reasons at MUMC+ between 2011 and 2016. The Medical Ethics Committee 
AzM/UM had approved the use of the samples for the present study. The current 
study was performed according the declaration of Helsinki (latest amendment of 
2013, Fortaleza, Brazil). 
Clinical evaluation 
The medical history, body mass index (BMI) and routine biochemical tests 
including bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transferase 
(GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
fasting glucose, ferritin, total cholesterol, triglycerides, high-density 
lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), 
were collected prospectively for the patients from the Zuyderland Medical 
Centre using standardised registration forms and by retrospective review of the 
patients’ medical files for the clinical MUMC+ patients. 
Bright-field microscopy 
Liver needle biopsies for bright-field microscopy analysis were fixed in 4% 
formalin and embedded in paraffin. Hematoxylin-eosin stained sections were 
used for NAFLD scoring according to the SAF score (Steatosis, Activity and 
Fibrosis)21 by an experienced liver pathologist blinded to the clinical context and 
laboratory parameters. NASH was defined by score A≥2 including at least 1 
point for ballooning and 1 point for inflammation. A score of A<2 or the absence 
of ballooning was defined as ‘noNASH’.21 
Transmission electron microscopy (TEM) 
TEM analysis was performed on needle and wedge liver biopsies. From 
19 patients, wedge biopsies were obtained during surgery at Zuyderland Medical 
Centre. A portion of approximately 5 by 5 mm was subjected to injection 
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fixation for TEM analysis, according to the method described by Wisse et al.19 In 
short, a needle is used to inject the fixative into the wedge biopsy at a rate of 
approximately 1 ml/min. As injection of the fixative is not possible in needle 
biopsies, due to the smaller size, the technique of jet fixation as described by 
Vreuls et al. was used in 20 needle biopsy samples. This technique sprays the 
fixative with a constant pressure onto the liver tissue.20 
All perfusion-fixed biopsies were studied by TEM (FEI Tecnai G2 Spirit BioTWIN 
iCorr microscope, FEI company, USA) at the Nanoscopy Unit of Maastricht 
University (M4I). The magnification was calibrated with a 463 nm line grid, 
before representative images of each biopsy were taken. Measurements of 
fenestrae diameter were done with Image J software (Rasband, National 
Institutes of Health, Bethesda, Maryland, USA). Defenestration was defined by 
no or hardly any fenestrae found in well-fixed livers with preserved fine 
structured details, after scrutinising the whole samples. 
Statistical analysis 
Patient characteristics and ultrastructural findings were reported as absolute 
numbers and percentages for categorical variables and as mean with standard 
deviation (SD) or median and range, according to the normality of the 
distribution, for continuous variables. Findings were compared between NAFLD 
patients with and without NASH according to the SAF score using the 
independent t-test for normally and the Mann-Whitney U test for non-normally 
distributed data. Differences in dichotomous variables between groups were 
tested using the Chi-square test with Fisher exact when necessary. A two-sided 
p-value of <0.05 was considered statistically significant. All calculations were
performed using SPSS version 24 statistical software (IBM Statistics for
Macintosh, Chicago, IL, USA).
Results 
Baseline characteristics 
In total, 19 wedge biopsy samples and 20 needle biopsy samples were available 
for TEM evaluation and 39 paraffin embedded needle biopsies for standard 
bright-field microscopic evaluation.  
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One needle biopsy sample was of insufficient quality to perform a reliable 
bright-field microscopic scoring and was therefore excluded. All other biopsies 
contained a sufficient number of portal tracts to allow for correct evaluation of 
the hepatic architecture. With regard to the TEM samples, one needle biopsy 
was of insufficient quality for evaluation by TEM and was therefore excluded.   
Finally, biopsies of 37 patients were included in the analysis (see Supplementary 
Figure S2.1: flowchart of patient routing). Patient characteristics, BMI, routine 
biochemical test results at time of inclusion and bright-field microscopic results 
for the total group and subgroups (NASH/noNASH) are presented in Table 2.1.  
All patients had NAFLD on initial histologic evaluation or imaging, which was 
confirmed in 30 of them upon revision of the biopsy specimen for the current 
study. Twelve patients were classified as having NASH according to the SAF 
score. None of the patients had cirrhosis (F4) or overt pathology other than 
NAFLD on bright-field microscopic analysis. Patients with NASH showed higher 
ALP, ALT and AST levels as compared to noNASH patients (all p<0.05).  
TEM analysis of Liver Sinusoids 
An overview of the TEM findings comparing NASH with noNASH samples is 
given in Table 2.2 and findings of individual patients are presented in 
Supplementary Table S2.1. The results of both jet and injection fixation are 
comparable and meet the criteria for good fixation as given by Wisse et al.,19 
being open sinusoids, intact topography and fine structure for all cell types. 
Examples of representative images, for both jet and injection perfusion fixation 
are given in Supplementary Figure 2.2A/B. Thirty-three of the 37 samples 
showed successful perfusion fixation, the other four samples showed results 
comparable to immersion fixation. 
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Gender (male/female) 17/20 (46%/54%) 6/6 (50/50%) 11/14 (44/56%) 0.732 
Age (years) 48.4 (11.9) 49.3 (14.5) 48.0 (10.7) 0.769 
BMI (kg/m2) 34.6 (6.0) 31.9 (5.9) 35.9 (5.7) 0.063 
Bilirubin (μmol/L) 11.0 (6.7) 14.0 (7.8) 9.6 (5.8) 0.106 
ALP (U/L) 119.9 (81.9) 170.7 (114.8) 95.6 (46.1) 0.048 
GGT (U/L) 121.4 (180.6) 228.7 (268.6) 69.8 (85.9) 0.068 
AST (U/L) 45.4 (34.1) 74.0 (41.6) 31.6 (18.5) 0.005 
ALT (U/L) 69.9 (63.9) 118.3 (68.9) 46.6 (47.1) 0.001 
Fasting glucose* (mmol/L) 6.4 (3.5) 8.6 (6.1) 5.2 (0.0) 0.171 
Ferritin* (μg/L) 238.7 (226.1) 335.8 (158.1) 202.3 (239.6) 0.133 
HDL-C* (mmol/L) 1.18 (0.32) 1.3 (0.4) 1.1 (0.3) 0.258 
LDL-C* (mmol/L) 2.97 (1.37) 3.4 (1.9) 2.7 (1.0) 0.272 
Total cholesterol* (mmol/L) 5.03 (1.59) 5.7 (2.0) 4.7 (1.3) 0.075 
Triglycerides* (mmol/L) 2.03 (1.41) 2.9 (2.0) 1.6 (0.8) 0.051 
SAF-Steatosis  
   S0 7 (19%) 0 (0%) 7 (28%) 
   S1 21 (57%) 6 (50%) 15 (60%) 
   S2 6 (16%) 3 (25%) 3 (12%) 
   S3 3 (8%) 3 (25%) 0 (0%) 
SAF-Activity  
   A0 5 (13%) 0 (0%) 5 (20%) 
   A1 18 (49%) 0 (0%) 18 (72%) 
   A2 5 (13%) 3 (25%) 2 (8%) 
   A3 8 (22%) 8 (67%) 0 (0%) 
   A4 1 (3%) 1 (8%) 0 (0%) 
SAF-Fibrosis  
   F0 7 (19%) 0 (0%) 7 (28%) 
   F1 16 (43%) 2 (17%) 14 (56%) 
   F2 13 (35%) 9 (75%) 4 (16%) 
   F3 1 (3%) 1 (8%) 0 (0%) 
   F4 0 (0%) 0 (0%) 0  (0%) 
Table 2.1 shows an overview of the baseline characteristics of the included participants, showing 
demographic characteristics, blood tests and histology results based on bright-field microscopy. 
Continuous variables are expressed as mean ±standard deviation (SD), and tested using the 
independent sample T-test. Categorical variables are expressed as absolute figures and percentages 
and tested using the Chi-square test with Fisher exact when necessary. A two-sided p-value of <0.05 
was considered statistically significant. Abbreviations: Body mass index (BMI), alkaline phosphatase 
(ALP), gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), non-alcoholic steatohepatitis (NASH). *For these parameters 1-3 subjects are 
missing per subgroup NASH or noNASH. 
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Table 2.2.  Ultrastructural findings in perfusion fixed human NAFLD samples studied using 











































































































*4 samples are missing due to insufficient perfusion fixation. Abbreviations: non-alcoholic fatty 
liver disease (NAFLD), non-alcoholic steatohepatitis (NASH),single cell steatonecrosis (SCSN). 
 
Sinusoidal endothelial cells 
Perfusion fixation (Figure 2.1A) preserved the fine structure of the liver 
sinusoids (Figure 2.1B) and sinusoidal cells including the fenestrae (Figure 
2.1C), and was successful in 33 out of 37 samples. Fenestrae were observed in 
seventeen cases, of which in eleven cases the fenestrae size could be measured. 
Of these eleven cases, six had NASH and five did not. The median fenestrae size 
did not differ in samples of patients with NASH versus noNASH (121.0nm 
(116.0-138.0) versus 120.0nm (93.0-128.0) respectively, p=0.792, 
Supplementary Table S2.2). 
Defenestration was identified in 16 cases, for a representative image see Figure 
2.1D. Significantly less liver biopsies samples of patients with NASH (9%) 
showed defenestration as compared to the noNASH group (68%) (p=0.002) 
(Table 2.2 and Supplementary Table S2.3). Defenestration was not associated 
with the severity of steatosis or fibrosis (data not shown, p>0.3 for both). 
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Sinusoidal lipid embolisms, defined as single large fat droplets blocking the 
sinusoid, were observed in nine of the noNASH and one of the NASH samples 
(45% versus 8% respectively, p=0.050) (Figure 2.1E/1F). 
Kupffer cells and Stellate cells 
Kupffer cells were observed in 32 cases (Figure 2.2A). In these cells, lipofuscin 
was seen in five of ten NASH (50%) and 11 of 22 noNASH samples (50%) 
(p>0.999) (Figure 2.2B). No apparent signs of storage disease of any substance 
were found.  
In 32 cases, stellate cells were visualised using TEM (Figure 2.2C), which showed 
a normal appearance. Intracellular lipid droplets were observed in 30 of these 
cases. 
Using TEM, fibrosis was found in 24 cases (75% versus 60%, NASH versus 
noNASH, respectively, p=0.476), of which the majority was seen perisinusoidal. 
In the bright-field microscopic analysis, 16 cases showed F1, 13 F2, one F3 and 
seven cases showed no fibrosis.  
TEM analysis of Parenchymal cells 
TEM analysis of parenchymal cells could be performed in all 37 perfusion-fixed 
samples. Perfusion fixation showed intact fat droplets within the parenchymal 
cells (Figure 2.3A).  
Giant mitochondria in the parenchymal cells, as defined by a large size, 
abnormal shape and crystalline inclusions, were seen in 18 cases (36% in NASH 
versus 58% in noNASH, p=0.289, Figure 2.3B). Parenchymal lipofuscin was 
observed in 31 cases (83% in NASH and 91% in noNASH, p=0.561, Figure 2.3C, 
Table 2.2). 
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Figure 2.1  A Low magnification TEM of  a NASH liver needle biopsy sample, fixed by jet fixation. 
The picture shows parenchymal cells (white *) with different sizes of fat droplets (*) and 
open sinusoids (¥). Note the openness of the sinusoids and the preserved topography 


























fixed noNASH liver needle biopsy, showing parenchymal cells (white *) together with 
one liver sinusoidal endothelial cell (white ¥), a Kupffer cell (§) and a stellate cell (white 
§) (respectively from top to bottom), together surrounding an open sinusoidal lumen (¥) 
free of plasma and blood cells. This picture shows the normal topographical
arrangement of these cell types that is lost in immersion fixation. A normal space of
Disse (<) separates the endothelial lining from the parenchymal cells. The Kupffer cell
shows endocytosed electron dense material (white †) and the stellate cell (previously
named fat-storing cells or Ito-cells) contains two fat droplets (*). C TEM picture at higher 
magnification from a jet-fixed needle biopsy of a NASH patient. Fenestrae within the
endothelial lining are observed when the lining is obliquely cut during sectioning for
TEM. Because of the isotonicity of the fixative and the inclusion of the cells in epoxy
resin, the size of the fenestrae is presumed to be preserved to represent the size in vivo. 
Fenestrae are grouped in thin, slightly electron dense cytoplasmic sieve plates (pointed
out by the black arrow). D TEM figure of a defenestrated sinusoid of a noNASH patient. 
There are no or hardly any fenestrae in well-fixed livers with preserved fine structured
details (black arrow). This condition is called pseudocapillarisation, capillarisation or
defenestration by some authors (wedge biopsy, injection fixation). E and F Fat droplets
(*) in the liver sinusoids (¥) of noNASH patients (sinusoidal lipid embolism) (injection
fixation). Phagocytoses of whole fat droplets or parts of it, by e.g. Kupffer cells or other 
cells was not observed. Furthermore, it is unclear how long fat droplets remain in the
sinusoids before being degraded. 
In addition to ‘known’ ultrastructural findings, a new observation was seen 
which occurred in a minority of samples (24%). First, gigantic fat droplets were 
observed in the middle of the parenchymal cell showing disintegration of the 
cytoplasm and disruption of the usual arrangement of organelles (42% in NASH 
versus 16% in noNASH, p=0.116, Figure 2.4A). In addition, a more complex, 
but probably further developed situation was observed, in which inflammatory 
cells, mainly polymorphonuclear granulocytes, and red blood cells, formed a 
circle around the large fat droplet (Figure 2.4B). Cells with these features did not 
colocalise, but were spread out in the steatotic region. In none of the samples 
apoptosis was observed. 
Second, a substance was found in several fat droplets across our study samples; 
namely a filamentous precipitate, that resembles the filamentous structure of 
Mallory-Denk-Bodies (Supplementary Figure S2.3A/S2.3B). 
Electron microscopic observations in perfusion-fixed human NAFLD biopsies 
41
2 
Figure 2.2  A TEM picture of a Kupffer cell (§) on top of a parenchymal cell. Kupffer cells have an 
irregular shape and a rough surface. These cells are exposed to the sinusoidal (¥) blood 
flow and phagocytose foreign cells and materials present in the blood. This particular 
Kupffer cell shows the absence of phagocytosed material, but displays the presence of 
numerous small lysosomes which are the electron dense granules in the cytoplasm 
(pointed out by the white arrow). Injection fixation of a wedge biopsy of a noNASH 
patient. B TEM picture of a Kupffer cell (§) in a jet-fixed needle biopsy of a noNASH 
patient, showing the presence of phagocytosed material of different density (lipofuscin) 
(black arrow). Other cell types, such as a red blood cell (at the bottom) (white ‡) and 
several white blood cells (white +), probably lymphocytes, are present. C TEM picture 
(needle biopsy, noNASH patient, jet-fixation) of a stellate cell (white §) which is an 
inhabitant of the space of Disse. In other words, these cells are always covered by the 
endothelial lining (white ¥ in inset). Therefore, the cell is shielded from the sinusoidal 
blood flow. Within the cytoplasm of the cell we observe fat droplets (white arrow in 















Figure 2.3 A In steatosis, the fat droplets (*) in parenchymal cells (white *) can grow to proportions 
that largely exceed the size of a normal parenchymal cell. In most cases we only find a 
single large fat droplet per cell. Open sinusoids (¥) are present at several sides of the 
parenchymal cells. (wedge biopsy, injection fixation, noNASH patient). B A giant 
mitochondrion is shown (wedge biopsy, injection fixation, noNASH patient). The size 
of giant mitochondria varies between normal and gigantic. Always, crystals (black 
arrow) can be recognized in the matrix of these intriguing organelles. Apart from the 
variety in size, the giants also show different shapes and content. They can be round, 
oval, cylindric, or branched. Their occurrence is regional, but it is not yet clear whether 
their presence is zonal (portal or central). They never populate all parenchymal cells. 
They are absent in the livers of experimental animals like rats, mice, rabbits, guinea 
pig. C TEM picture of a parenchymal cell in which the nucleus (#) is surrounded by 
lipofuscin containing residual bodies (black arrow), which are in fact old (retired) 
lysosomes with reduced or even absent digesting capacity. Normally lysosomes are 
oriented to the bile canaliculi, but in the case of larger numbers, they are more 
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Figure 2.4  A TEM figure with a clear example of single cell steatonecrosis (SCSN). The cell shows 
disorganisation of the cytoplasm resulting in a free suspension of organelles (white *), 
probably in Brownian movement. A large fat droplet (*) is supposed to have introduced 
necrosis in this parenchymal cell. The organelles are more or less confined within the 
boundaries of the cell or the still intact endothelial lining. Two red blood cells (white ‡) 
are present. It is not yet clear to what extend this situation contributes to developing the 
inflammatory aspect of steatohepatitis (wedge biopsy, injection fixation, noNASH 
patient). B TEM figure of an inflammatory fat follicle (IFF). Remarkably, in IFF a 
monolayer of polymorphonuclear neutrophils (PMNs) (black arrow) is surrounding the 
fat droplet (*). The presence of PMN’s suggest that these cells take care of digesting the 
large fat droplet and at the same time might contribute to the inflammatory process 
(needle biopsy, jet fixation, NASH patient) 
Discussion 
The current study used perfusion-type fixation to explore the ultrastructural 
changes in liver biopsy samples of NAFLD patients, comparing patients with and 
without NASH Successful perfusion was obtained in 89.2% (33/37) as judged by 
the following criteria: open sinusoid, intact topography and fine structure for all 
cell types, including endothelial fenestrae.19,22 Significantly less defenestration 
was found in NASH compared to noNASH samples, while fenestrae size and the 
presence of other features, i.e. giant mitochondria, did not differ between 
groups. Furthermore, new structures were identified, i.e. single cell 
steatonecrosis and inflammatory fat follicles, in a subset of both groups. 
This study used perfusion fixation as it allows for proper fixation of all cell types, 
including the sinusoids and sinusoidal cells, whereas in immersion fixation only 
the well-fixed peripheral parenchymal cells can be studied.19 TEM liver biopsy 









different perfusion techniques were used. Injection fixation was used in wedge 
biopsies. With this technique the fixative is injected into the wedge biopsy.19 It is 
not possible to use this technique in needle biopsies, due to the smaller tissue 
sample. Therefore, the technique of jet fixation, spraying the fixative onto the 
biopsy sample, was used in the needle biopsies.20 Vice versa, it is not possible to 
use jet fixation in wedge biopsies as the size of the wedge biopsies is too big and 
perfusion would not take place. The results of both jet and injection fixation are 
comparable to perfusion through the portal vein in animal studies.23  
In the current study, special attention was paid to the LSECs and fenestrae since 
they serve as a sieve and play an important role in the transport of lipids across 
the sinusoid. The hypothesis of the study was that fenestrae size and number 
decrease as the severity of NAFLD increases. Unexpectedly, we showed that 
defenestration was more prevalent in the noNASH samples compared to NASH 
samples. In addition, defenestration was not related to the degree of steatosis or 
fibrosis.  
Based on the current findings and the fact that defenestration is seen more in 
simple steatosis, instead of in NASH, one could argue that defenestration is a 
protective mechanism to handle the excess in lipids and perhaps other toxic 
substances, such as bacterial products. If defenestration plays a role in 
inhibiting the entry of chylomicron remnants into the space of Disse18; it could 
protect the liver from receiving more lipids. On the other hand, defenestration 
also impairs the passage of VLDL excretion towards the sinusoidal lumen, 
thereby causing hepatic lipid accumulation.14 Furthermore, inhibition of lipid 
uptake by defenestration has been proposed to lead to stimulation of de novo 
lipid (DNL) synthesis and thereby induces steatosis.18 This is due to the fact that 
hydroxymethylglutaryl-CoA reductase (HMGCR), the rate limiting enzyme for 
hepatocyte cholesterol synthesis, is no longer inhibited when chylomicron 
remnants and dietary cholesterol do not cross the fenestrae, thereby activating 
endogenous cholesterol synthesis in hepatocytes.24 However, one could argue 
that in case of defenestration, DNL could be performed at a pace that does not 
overwhelm beta-oxidation and re-esterification within the liver. This would 
enable the liver to store the fat as triglycerides in lipid droplets, instead of 
metabolising them. This fits in the current view on the pathophysiology of 
NAFLD, which proposes that NASH and simple steatosis are independent twin 
conditions. Steatosis in NASH is being seen as a benign epiphenomenon rather 
than a causal factor of inflammation and fibrosis, which are the two main 
hallmarks of NASH.25 In NASH, the metabolization of free fatty acids and 
cholesterol leads to formation of toxic lipid species. However, the underlying 
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mechanisms of the formation of lipotoxic intermediates at molecular levels 
remain unknown.26 Whereas triglyceride accumulation in the form of lipid 
droplets in simple steatosis may serve as a non-toxic, safer form of storage for 
lipids in the liver.27  
When comparing fenestrae size between NASH and noNASH samples, we found 
no significant difference (121.0 (116.0-138.0) nm in NASH and 120.0 (93.0-
128.0) nm in noNASH). Fenestrae size in humans without liver pathology show 
a diameter of 107 (±1.5) nm.28  
Our finding in human samples are not in line with the animal model findings of 
Herrnberger et al.,18 studying PLVAP deficient mice. PLVAP is known to be 
critical for the development of fenestrae. PLVAP deficient mice developed 
extensive multivesicular steatosis, but also steatohepatitis and fibrosis at 
around three weeks of life.18 This stresses the added value of human studies as 
animal models do not recapitulate all pathological features of human NAFLD or 
NASH. Furthermore, they do not capture the large inter-individual variation 
with regard to host genetics and environmental factors.29 
The presence of giant mitochondria in this study showed no difference 
between patients with and without NASH, these findings are in line with 
Ahishali et al.13 Giant mitochondria have been considered to represent an 
intermediate phase in evolution of steatohepatitis, regardless of the source of 
hepatic fat deposition.12 However, their exact role in the pathophysiology in 
NAFLD is unclear. Based on our findings, they might play a role in NAFLD, 
but that role is not limited to steatohepatitis.  
In the current study, new structures were identified and described, namely 
single cell steatonecrosis (SCSN) and inflammatory fat follicles (IFF). SCSN 
shows an enormous fat droplet in a single parenchymal cell in a well advanced 
stage of necrosis. In addition, this condition may further develop into a situation 
where the large central single fat droplet is surrounded with a monolayer of 
inflammatory cells, such as polymorphonuclear granulocytes, but also by red 
blood cells. We propose the term ‘inflammatory fat follicle (IFF)’ for this feature. 
It has been shown that accumulating lipid droplets can mechanically distort the 
intracellular environment, as lipid droplets are stiffer than the surrounding 
cytosol, thereby leading to cellular damage. Baldini et al.30 have studied the 
biomechanics of cultured steatotic hepatocytes and showed that hepatocyte cell 
stiffness and cell viability are directly influenced by the extent of triglyceride 
accumulation and the size of lipid droplets. Furthermore, the swelling of 
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parenchymal cells may lead to the narrowing of local sinusoids, and contribute 
to vascular resistance. The size of the fat droplets in severe steatosis exceeds the 
diameter of parenchymal cells and sinusoids considerably.31 Previous research 
in rats showed an increase in intrahepatic resistance with hemodynamic impact 
in relation to severe steatosis.32 This study observed sinusoidal lipid embolisms 
in both NASH and noNASH patients. One could argue that these can also be a 
contributing factor to vascular resistance.  
 
When interpreting the results of this study, it is important to note several 
limitations. Liver biopsy samples were obtained via two different routes. Needle 
biopsy samples were collected via percutaneous liver biopsies in outpatients 
with liver enzyme abnormalities as part of clinical care. Wedge biopsy samples 
were collected during bariatric surgery in overweight patients. Consequently, 
the liver biopsies originate from different parts of the liver, more peripherally 
for the wedge biopsies versus more centrally for the needle biopsies. 
Furthermore, it should be noted that the patients who underwent bariatric 
surgery followed a calorie restricted diet before surgery.33 Defenestration has 
been linked to diets varying in content of macronutrients in animal models,15,34 
suggesting that a diet based on caloric restriction reduces defenestration. 
However, a larger part of the noNASH group underwent bariatric surgery and a 
calorie restricted diet, still showing more defenestration compared to the NASH 
group. Therefore, we think that this calorie restricted diet did not have a major 
impact on our results.  
It should also be noted that only small parts of the liver are evaluated by electron 
microscopy. It is known that histologic lesions in NAFLD are unevenly 
distributed throughout the liver and a sampling error can occur when studying 
lesions using bright-field microscopy.35 Therefore, it is difficult to quantify 
parameters for the total organ. In seven patients with steatosis on imaging, 
steatosis could not be confirmed, when revising the liver biopsy with bright-
field microscopy for the current study. Further supporting that sampling errors 
cannot be excluded. However, when excluding these samples from the analysis 
for defenestration, the difference between groups remained significant 
(p=0.005, data not shown). 
To our knowledge, this is the first study on fenestrae in perfusion fixed human 
NAFLD liver samples using TEM. Previous studies used immersion 
fixation,8-13,36,37 leaving the centre of the biopsy improperly fixed, which does 
not allow for accurate analysis of sinusoids and sinusoidal cells.20 Second, a 
relatively large sample size was included, directly comparing NASH versus 
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noNASH samples, whereas other studies included smaller sample sizes,8-12,37 or 
studied animal models.18,38 
In conclusion, we demonstrated that perfusion type-fixation techniques are 
feasible, for both needle and wedge liver biopsies, in human NAFLD liver 
samples. By using these techniques, new ultrastructural details, such as SCSN 
and IFF, were revealed. An almost complete lack of fenestrae (defenestration) in 
NAFLD patients without NASH was found. Defenestration may be a protective 
mechanism to handle the excess in lipids and perhaps other toxic substances 
and may serve as a possible explanation why some patients develop NASH and 
others do not. Future studies are needed to further investigate the role of these 
findings within the multifactorial aetiology of NASH. 
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Figure S2.1 Flowchart of patient routing 
Figure S2.2 Figures A (left) and B (right) show parenchymal cells with different size of fat droplets 
and open sinusoids. Figure S2.2A is an image of a needle biopsy samples fixed by jet 
fixation, figure S2.2B is an image of a wedge biopsy sample fixed by injection 
fixation. Both figures show the openness of the sinusoids and the preserved 
topography and fine structure of cells. 
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Fenestrae size (nm)§ 121.0 (116.0-138.0) 120.0 (93.0-128.0) 
§ Fenestrae size could be measured in eleven samples. No statistically significant difference based on
Mann-Whitney U test (p=0.792). Continuous variables are expressed as median (minimum-
maximum), and categorical variables as absolute figures and percentages. Abbreviations:
non-alcoholic steatohepatitis (NASH), nanometre (nm). 
Table S2.3 Defenestration in NASH vs noNASH 
noNASH NASH Total
Fenestrae not present (defenestration) § 15 1 16
Fenestrae present 7 10 17 
22 11   33* 
*4 biopsies are missing due to insufficient perfusion fixation for fenestrae scoring using transmission 
electron microscopy (TEM). §A statistical significant difference was found using Chi-square test,
p=0.002 (two sided). Categorical variables are expressed as absolute figures. Abbreviations: non-
alcoholic steatohepatitis (NASH). 
Figure S2.3 A (left) Large fat droplets sometimes contain precipitates of fibrillar and membranous 
materials. The amount can vary between a small quantity and sometimes abundant 
masses. This filamentous precipitate could be incompletely digested cytoskeletal 
material that due to its lipophilic nature is collected by the fat droplet. Importantly, 
no compartmenting intracellular membrane is to be seen between the fat droplet and 
the cytoplasm, giving free access to lipophilic substances. Perhaps, this filamentous 
material may be similar to the material of the Mallory Denk bodies (needle biopsy, jet 
fixation, noNASH patient). B (right) Transmission electron microscopy (TEM) picture 
at higher magnification showing a more detailed image of the membranous 
component of the precipitate. In our study fat is preserved due to type of fixation, 
resulting in this image in which we observe that lipophilic material is mixed well with 
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Hyperferritinaemia, observed in inflammation, in iron overload as well as in the 
combination of both, is found in about 30% of non-alcoholic fatty liver disease 
(NAFLD) patients. We summarised the evidence regarding the potential cause of 
hyperferritinaemia in NAFLD, as this may affect the indicated therapy.  
A systematic literature search was conducted in EMBASE, PubMed, MEDLINE 
and the Cochrane library. 
In the majority of NAFLD patients, hyperferritinaemia is due to inflammation 
without hepatic iron overload. In a smaller group, a dysmetabolic iron overload 
syndrome (DIOS) is found, showing hyperferritinaemia in combination with 
mild iron accumulation in the reticuloendothelial cells. The smallest group 
consists of NAFLD patients with haemochromatosis. Phlebotomy is only 
effective with hepatocellular iron overload and should not be the treatment 
when hyperferritinaemia is related to inflammation, whether or not combined 
with DIOS. Treatment with lifestyle changes is to date probably the more 
effective way until new medication is becoming available. 




Non-alcoholic fatty liver disease (NAFLD), strongly associated with overweight 
and obesity, is the most common liver disorder in Western society, with a global 
prevalence of around 25%.1 NAFLD ranges from hepatic steatosis2 to non-
alcoholic steatohepatitis (NASH), progressive liver fibrosis, cirrhosis and an 
increased risk to develop hepatocellular carcinoma.3 It is considered the hepatic 
manifestation of the metabolic syndrome in which a generalised systemic 
inflammation plays an important role in the initiation and progression of 
diabetes mellitus and cardiovascular diseases.4,5 The incidence of NASH is 
expected to increase even further over the next decades, which stresses the need 
to elucidate factors involved in disease progression. Diagnostic markers are 
urgently needed to identify NAFLD patients that progress to advanced liver- and 
systemic diseases. Serum ferritin is increased in about 30% of patients with 
NAFLD.6,7 Ferritin is an acute phase protein but also a storage protein for iron 
within cells, being most pronounced in hepatocytes and macrophages.8,9 Small 
amounts of ferritin are present in the circulation reflecting the body iron stores 
in healthy control subjects. Elevated serum ferritin levels can also occur in 
patients with mutations in genes involved in iron homeostasis, such as 
hereditary haemochromatosis (HH) (e.g. HFE mutations),10,11 or in the case of 
beta-thalassaemia trait.12 Transferrin saturation levels are usually increased 
(>45%) in hyperferritinaemia caused by HH.13  
In 34.5% - 51.5% of NAFLD patients dysmetabolic iron overload syndrome 
(DIOS) is present.14,15 DIOS is characterised by hyperferritinaemia with only a 
mild increase of both liver and body iron stores.  It is associated with various 
compounds of the metabolic syndrome in the absence of any identifiable genetic 
mutation or other causes of iron excess.16 As iron plays a role via the Fenton 
reaction in the generation of oxidative stress and thereby causes disease 
progression, it is important to distinguish if hyperferritinaemia is due to 
classical hepatic iron overload or is the expression of inflammation. If hepatic 
iron overload in the classical pattern is the primary cause of hyperferritinaemia, 
therapeutic bloodletting is the only therapeutic option. While in inflammation-
related hyperferritinaemia or in patients with DIOS, lifestyle changes such as a 
hypocaloric diet and physical activity are recommended instead of 
phlebotomies. 
Therefore, the aim of this systematic literature search was to evaluate the role 
and value of hyperferritinaemia as a marker of iron overload or inflammation in 





A systematic literature search was performed in PubMed, Cochrane Library, 
MEDLINE and EMBASE up to 31st of October 2017 using the following 
(truncated) keywords: `Non*alcoholic fatty liver disease’, `NAFLD’, `Fatty liver`, 
`Hepatic steatosis` or `Liver steatosis` in any combination with `Hyperferritin*’ 
and `Ferritin` and `Dysmetabolic iron overload syndrome`, `Dysmetabolic iron 
overload`, `Dysmetabolic hepatic iron overload`, `Dysmetabolic hepatic 
overload syndrome`, `DIOS‘, `DHIOS` or `iron overload`. This resulted in a total 
number of 530 hits (117 PubMed, 9 hits Cochrane Library, 252 EMBASE and 152 
MEDLINE).  
We excluded studies in which the population primarily consisted of patients 
with hyperferritinaemia, obesity, diabetes and/or metabolic syndrome when 
they did not report on the role of hyperferritinaemia in NAFLD. We also 
excluded studies performed in vitro, in animals, in minors, in languages other 
than English, case reports, conference abstracts, reviews, and duplicates. 
Titles and abstracts of all 530 hits were screened, leaving 152 articles, of which 
the full text was checked. The initial screening was done by a single author 
(WM) and in case of doubt the reference was checked by a second author (PV). In 
case of disagreement on eligibility, the two reviewers came to consensus after 
discussing the article with a third reviewer (DJ or GK). Furthermore, eligible 
papers were cross-checked for references, which resulted in six additional 
papers. Finally, 42 papers were included in the current review (Figure 3.1). We 
assessed the quality of the included studies with regard to the risk of bias 
(Supplementary Table S3.1). Not all articles were described in detail also due to 
limited description of results applicable to the subject of the review.17-19 
Results 
HFE mutations and iron regulators in NAFLD 
The frequency of mutations in genes involved in iron homeostasis has been 
studied in NAFLD patients with hyperferritinaemia12,15,20-34 (Supplementary 
Table S3.2). The overall prevalence of HFE mutations for p.C282Y ranged from 
0-7.9% and 5-23.5% for homozygosity and heterozygosity, respectively. For
p.H63D the prevalence was between 1-5.6% and 13-44.4% for homozygosity
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and heterozygosity, respectively. Some studies found a significantly higher 
prevalence of HFE mutations (i.e. for homozygosity20 or heterozygosity20,28,29,30 
of p.C282Y and/or heterozygosity of p.H63D28) in NAFLD patients versus control 
subjects. The majority of studies however, did not show significant differences 
in the presence of HFE mutations between NAFLD patients and control 
subjects.12,15,24-27,31,33 Furthermore, no relation was observed between HFE 
mutations in NAFLD patients with high versus low serum ferritin22 or with the 
presence or absence of iron overload.23,32  




In addition to the HFE mutations, the beta-thalassaemia trait, alpha-1-
antitripsin mutation (AAT) and the p.Ala736Val variant of transmembrane 
protease serine 6 (TMPRSS6) were investigated in NAFLD. A significantly higher 
prevalence of the AAT mutation was found in NAFLD patients (±10%) compared 
to healthy control subjects (±3.5%).12,21 The prevalence of beta-thalassaemia was 
9.1% in patients with NAFLD, there was no prevalence available in the control 
group.12 One study assessing the prevalence of the p.Ala736Val variant of 
transmembrane protease serine 6, did not find a significant difference between 
NAFLD patients and healthy control subjects.25  
The regulators of iron homeostasis  focussing on serum transferrin receptor-1 
(TfR1), TfR2, divalent metal transporter-1 (DMT-1), ferroportin, hepcidin and 
hemojuvelin were also studied in NAFLD patients, but results were 
inconsistent.12,21,23-25,34-41  
No significant correlations were found between NAFLD patients (NASH and 
hepatic steatosis (HS)) compared to control subjects in duodenal or serum  DMT-
1 mRNA levels,23,39,41 TfR1 and 2 mRNA  levels,23,35,36,41 and serum, duodenal 
and hepatic ferroportin concentration.23,24,35,38,39,41 Increased hepcidin levels 
were found in three studies23,35,39 measuring hepcidin in NAFLD patients (NASH 
and HS) compared to control subjects. Furthermore, increased hepcidin levels 
were found to be associated with hepatic lobular inflammation and NAFLD 
activity scores (NAS)40 and iron in reticuloendothelial cells12 (Supplementary 
Table S3.2).  
An important up-stream regulator of hepcidin expression is hemojuvelin. Two 
studies23, 37 investigating hemojuvelin found lower levels in NAFLD patients 
versus control subjects. Lower copper levels were associated with higher ferritin 
levels and increased prevalence of siderosis and hepatic iron in NAFLD 
patients.24 Hepatic 8-oxodG levels, a product generated by hydroxyl radicals, 
was found to be positively correlated with body and hepatic iron deposition 
markers in NAFLD patients.42  
Different patterns of hepatic iron deposition  
The pattern of hepatic iron deposition can vary between iron deposition in the 
hepatocytes (classical iron overload), iron deposition in the reticuloendothelial 
cells or a combination of both cell types also called the mixed pattern. The 
histological NAS score,43 assessing histological injury of NAFLD patients, is 
found to be significantly higher in patients with iron depositions in the 
reticuloendothelial cells,14,22,44 when compared to iron depositions in 
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hepatocytes (classical iron overload) or to iron deposition in the mixed patter.44 
Patients with depositions in reticuloendothelial cells or mixed pattern were also 
found to have significantly higher serum ferritin than those with no iron 
overload or the hepatocyte pattern.44 Furthermore, also a correlation was found 
between elevated serum ferritin levels and increased NAS.22 
Hyperferritinaemia related to inflammation  
In addition to the standard inflammatory serum biomarkers measured in NAFLD 
patients, ferritin is often found to be significantly higher in NASH patients when 
compared to controls or patients with HS.27,36,37,42,45-47 In several of these 
studies,36,37,45 serum iron parameters were also investigated, however no 
significant difference in iron status was found between the groups. 
A wide range of indirect and direct inflammatory parameters were found to be 
significantly higher in NAFLD or NASH patients when compared to control 
subjects (e.g. aspartate aminotransferase, thioredoxin, C-reactive protein, 
alpha-2-macroglobulin, ceruloplasmin, malondialdehyde, hepatic 8-oxodG, 
nitric oxide, interleukin-6, interleukin-8 and tumour necrosis factor alpha). 
Most studies also found ferritin levels to be significantly higher in NASH 
patients compared to controls and/or patients with HS and NAFLD patients 
compared to control subjects27,36,37,42,45-49 (Supplementary Table 3.2). Most of the 
studies showed no signs of biochemical or histological iron overload to explain 
the higher ferritin levels.2,27,36,37,45,48,49 Ferritin showed a significant positive 
correlation with lobular inflammation,2,22,44 portal inflammation,2,50 higher 
NAS,22,44 severity of steatosis,22,26,44,51 presence of fibrosis,2,22,26,44,51 presence of 
NASH48 and ballooning.22,44 
Effect of interventions on hyperferritinaemia in NAFLD 
The proposed treatment of hyperferritinaemia depends on its aetiology. 
Moderate to vigorous physical exercise showed to decrease steatosis 
accompanied with significantly improved levels of serum ferritin as well as lipid 
peroxidation and adiponectine.52 Eicosapentaenoic acid, an antilipidemic agent 
also showed to improve hepatic steatosis, fibrosis hepatic ballooning and lobular 
inflammation as well as ferritin levels in NASH patients.53  
Phlebotomy therapy in NAFLD patients showed a significant decrease in ferritin 
and iron status23,42,54,55 but also in parameters related to inflammation, e.g. 
alanine aminotransferase,23,42,54 tumour necrosis factor-alfa23 and hepatic 
8-oxodG levels (a DNA base-modified product generated by hydroxy radicals).42 
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In contrast, Adams et al. did not find improvement in liver enzymes, hepatic fat 
or insulin resistance during ferritin reduction by phlebotomy in patients with 
NAFLD in a randomised, controlled trial comparing phlebotomy and life style 
advices with life style advices only.55  
Discussion 
This literature review aimed to summarise the evidence for iron overload and/or 
inflammation as a possible cause of hyperferritinaemia observed in patients 
with NAFLD. In more severe forms of NAFLD like NASH and advanced fibrosis, 
systemic inflammation is present in the majority of patients.22 This low grade 
systemic inflammation has generally no characteristic laboratory abnormalities, 
but hyperferritinaemia is frequently observed and this raises the question 
whether this is an expression of this low grade systemic inflammation in 
NAFLD. 
With this extended literature review, three groups could be distinguished. First, 
the majority of NAFLD patients that have hyperferritinaemia without evidence 
of hepatic iron overload or HFE mutations. These NAFLD patients are most likely 
to have hyperferritinaemia related to ferritin release from damaged 
hepatocytes56 and/or related to the systemic inflammatory status (Figure 3.2). 
Secondly, hyperferritinaemia in NAFLD can also be explained as part of DIOS. In 
which inflammation up-regulates the hepcidin levels resulting in impaired iron 
export from the cells causing diminished iron availability23 which can lead to 
mild hepatic iron overload in reticuloendothelial system cells whether or not 
combined with iron in hepatocytes. About 30% of NAFLD patients have DIOS, 
which consists of hyperferritinaemia in combination with only a mild increase 
of both liver and body iron stores associated with various compounds of the 
metabolic syndrome in the absence of any identifiable genetic mutation or other 
causes of iron excess.16 The finding of a normal or moderately increased 
transferrin saturation supports DIOS. Iron overload in DIOS probably plays a 
prominent role in the pathophysiology of NAFLD, as it can generate reactive 
oxygen species and thereby lead to oxidative stress57 causing severe cellular 
dysfunction, organ damage and promotes the development of insulin resistance 
and hepatocellular inflammation attributing to NAFLD progression.58,59 
The third group is relatively small, consisting of NAFLD patients with 
identifiable p.C282Y homozygote HFE mutations (up to 7.9%). In the majority of 
these patients the increased serum ferritin levels are found in combination with 
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elevated transferrin saturation (>45%). Therefore, screening for 
haemochromatosis mutations in NAFLD with hyperferritinaemia should be 
considered in case transferrin saturation is also elevated.60 The influence of the 
iron regulators (i.e. TfR1/2, ferroportin) was the subject of many studies 

















Figure 3.2 Hyperferritinaemia is observed in case of inflammation or in case of iron overload. In 
non-alcoholic fatty liver disease (NAFLD) a minority of patients has significant hepatic 
iron overload, caused by mutations in the haemochromatosis gene or other mutations. 
However, in the majority of patients, there is no evidence of hepatic iron overload, in 
this case inflammation and hepatocyte damage can contribute to elevated serum 
ferritin levels. An up-regulation of hepcidin levels in inflammation can result in 
impaired iron export from the cells, which can lead to mild hepatic iron overload in 
hepatocytes, and/or reticuloendothelial system cells (RES). Excess iron will contribute 
to the disease progression, since it will generate reactive oxygen species and lead to 
oxidative stress through the Fenton reaction. 
 
 
Liver biopsy is still the gold standard as diagnostic tool in NAFLD staging and is 
also useful to measure iron status. However, many patients are not willing to 
undergo a biopsy. MRI is a good alternative to measure the liver iron 
concentration (LIC) to determine iron accumulation in patients with 
hyperferritinaemia. The reference value for the LIC is below 36 μmol/g dry 
weight but the LIC can also be elevated without liver iron excess (e.g. in patients 
with obesity or the metabolic syndrome). For this reason it is suggested to only 
diagnose iron overload in case the LIC exceeds 150 μmol /g dry weight.16,61 It 
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should be noted that others also use three times the upper limit of normal.62 
When increased iron accumulation is suspected, patients should be screened for 
haemochromatosis and therapeutic phlebotomies should be considered. In case 
of a hyperferritinaemia accompanied by a normal transferrin saturation there is 
no need for HFE screening or therapeutic phlebotomy since the 
hyperferritinaemia is most likely related to inflammation whether or not 
combined with DIOS. In these patients phlebotomy has not been proven more 
effective than lifestyle changes.59 In case of a clear inflammatory state, anti-
inflammatory treatment and lifestyle changes should be considered.16  
Based on the above, we suggest a diagnostic and therapeutic algorithm for the 





















Figure 3.3 Diagnostic and therapeutic algorithm for the approach of hyperferritinaemia in patients 
with NAFLD. *Advice based on Deugnier et al. 2017. Abbreviations: Non-alcoholic fatty 
liver disease (NAFLD), Transferrin saturation (TSAT), dysmetabolic iron overload 
syndrome (DIOS),  liver iron concentration (LIC). 
 
 
This review has several strengths, its focused question with appropriate 
inclusion criteria, an extended search over a widespread period of years in four 
databases. We also assessed the quality of the included articles with regard to 
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the risk of bias (Supplementary Table S3.1). A major limitation is the 
heterogeneity of the included studies with regard to their objectives, study 
population and methods. Furthermore, the studies are often based on relatively 
small retrospective and/or selective cohorts, which makes the results difficult to 
interpret. Besides, different methods were used to diagnose NAFLD and NASH, 
and liver biopsy was not always used as golden standard.33,34,36 Another 
limitation is the possibility of selection bias in the studies, as some included 
NAFLD/NASH patients were referred for HFE mutation screening because of 
their hyperferritinaemia enlarging the a priori chance for positive 
mutations.20,30 Also, multiple studies by the same authors are included and it 
cannot be ruled out that overlapping populations were used. 
In conclusion, in the majority of cases, hyperferritinaemia in NAFLD seems to be 
mainly related to inflammation. In some cases this can lead to mild hepatic iron 
accumulation in reticuloendothelial- or mixed pattern as an expression of DIOS, 
that is strongly related to the metabolic syndrome. Only in case of elevated 
transferrin levels, typically seen in classical iron overload (hepatocyte pattern) 
screening for HFE mutations should be performed. Phlebotomy is only effective 
when classical iron overload is proven. Lowering iron content probably 
decreases the generation of oxidative stress that plays a role in liver- and 
systemic inflammatory reactions. Large population studies will be necessary to 
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Background and Aim 
Insulin resistance (IR) plays a central role in the complex pathophysiology of 
non-alcoholic fatty liver disease (NAFLD). IR is linked to fat infiltration in 
skeletal muscle (myosteatosis) and loss of skeletal muscle mass and function 
(sarcopenia). The clinical significance of myosteatosis in NAFLD is not well 
investigated. In this exploratory study we aimed to investigate the association 
between myosteatosis and NAFLD related hepatic and systemic variables in a 
well characterised NAFLD cohort.  
Methods 
We cross-sectionally studied forty-five NAFLD patients. The muscle fat fraction 
(MFF) was measured with chemical shift Magnetic Resonance Imaging (MRI). In 
addition, the hepatic fat fraction (MRI), liver stiffness (FibroScan®) and 
appendicular skeletal muscle mass (Dual-energy X-ray absorptiometry) were 
analysed. 
Results 
The median hepatic fat fraction was 15.64% (IQR 12.05-25.13) and significant 
(F2-F3) liver fibrosis (liver stiffness ≥7kPa) was diagnosed in 18 NAFLD patients 
(40%). MFF was not correlated with hepatic fat fraction (r=-0.035, p=0.823) and 
did not differ between subjects with or without significant fibrosis (p=0.980). No 
patient was diagnosed with sarcopenia based on the skeletal muscle mass index. 
In a linear regression model, anthropometric parameters, including body mass 
index (BMI) (p=0.018) and total body fat percentage (p=0.005), were positively 
associated with MFF while no association with insulin resistance (HOMA-IR) was 
observed.  
Conclusion 
Myosteatosis did not correlate with the degree of hepatic steatosis or fibrosis in 
this well characterised NAFLD cohort, but was positively correlated with total 
body fat percentage and BMI.  




Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in 
the Western society, with an estimated prevalence of 20%-30%.1 Its progressive 
form, non-alcoholic steatohepatitis (NASH) is characterised by a chronic 
progressive liver and systemic inflammation. In particular, NASH can progress 
to liver fibrosis, liver cirrhosis and hepatocellular carcinoma (HCC).2 In 
addition, patients with NAFLD are at increased risk to the development or 
progression of  diabetes mellitus and cardiovascular diseases.3 
The pathogenesis of NAFLD is not completely elucidated. Factors that are 
thought to be involved are dietary habits, gut microbiota perturbations and 
metabolic-toxic factors, such as insulin resistance (IR).4,5 It is thought that IR is a 
key driver in the pathogenesis of NAFLD and worsens with progression to NASH 
and liver fibrosis.6 IR contributes to NAFLD through dysregulated lipolysis in 
adipose tissue resulting in excessive delivery of fatty acids to the liver.6 Skeletal 
muscle is quantitatively the major contributor to whole body insulin-mediated 
glucose disposal. Fat accumulation in skeletal muscle (myosteatosis) negatively 
affects insulin sensitivity.7,8  
Myosteatosis is believed to be a precursor of IR and sarcopenia, and might be an 
early manifestation of NAFLD disease progression.9,10 Myosteatosis comprises 
fat infiltration within myocytes (intramyocellular lipids [IMCL]) and between 
myofibres within the fascia of the muscles (intermyocellular-intrafascial adipose 
tissue). Recent data suggests that both, IMCL and intermyocellular-intrafascial 
adipose tissue are associated with IR.7,11,12 The exact mechanism remains 
unclear but lipid metabolites and muscle inflammation are thought to play a 
role.10,12 
The degree of myosteatosis, determined as the muscle fat fraction (MFF) can be 
measured reliably with chemical shift Magnetic Resonance Imaging (MRI) 
showing excellent agreement with histopathologic findings.13 Although MRI is 
not able to distinguish between IMCL and intermyocellular-intrafascial adipose 
tissue, good correlations with IMCL measurements have been observed.14-16 
Chemical shift MRI is also widely used to measure hepatic fat fraction in NAFLD 
patients making it possible to accurately measure hepatic and muscle fat 
fraction with a single examination.  
The association between myosteatosis and chronic liver disease has been the 
subject of several studies. Most studies investigate myosteatosis in an advanced 
disease setting including liver cirrhosis, HCC and liver transplant patients. The 
degree of myosteatosis is observed to be a prognostic factor of long-term 
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mortality in liver cirrhosis and HCC.17-20 In NAFLD, data concerning 
myosteatosis is scare and contradictory results were found with respect to the 
association between the degree of myosteatosis and the hepatic fat fraction or 
liver fibrosis.21-23  
We here hypothesise that myosteatosis is associated with the amount of hepatic 
fat and the presence of liver fibrosis before sarcopenia is present. For this 
reason, we analysed myosteatosis in well-characterised NAFLD cohort. 
Methods 
Study population  
All data were obtained from a prospective cohort of 63 subjects with NAFLD 
recruited from the Maastricht University Medical Centre (MUMC+) and CO-EUR 
(a second line eating disorder clinic) between September 2015 and November 
2018. Forty-five subjects had 3D fast gradient echo mDixon MRI data available 
for research purpose and were included in this study. All subjects were between 
18 and 65 years old, had a BMI of 25 kg/m2 or higher and proven NAFLD on MRI 
(hepatic fat fraction >5%). Participants with excessive ethanol consumption (>7 
and >14 beverages per week for females and males, respectively) were excluded 
from this cohort. Other exclusion criteria were: causes for secondary hepatic fat 
accumulation (medication, Wilson’s disease, viral infections, starvation or 
parenteral nutrition and microvesicular steatosis on liver biopsy), pregnancy 
and breastfeeding, a history of bariatric surgery, liver cirrhosis and/or 
hepatocellular carcinoma, extrahepatic malignancy within the last 5 years and 
individuals about to undergo or recovering from a surgical or otherwise medical 
procedure. The Medical Ethics Committee of the Maastricht University Medical 
Centre approved the protocol (ClinicalTrials.gov Identifier: NCT02422238) and 
all participants had given written informed consent prior to participation. The 
study was performed according the declaration of Helsinki (latest amendment of 
2013, Fortaleza, Brazil). 
Data collection  
Bodyweight, height, waist and hip circumference were measured in all 
participants. Venous blood was collected after an overnight fast in all 
participants. Aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma‐glutamyl transferase (GGT), alkaline phosphatase (ALP), total 
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cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglyceride, albumin, ferritin, C-reactive 
protein (CRP), fasting plasma glucose, glycosylated haemoglobin type A1c 
(HbA1C) and fasting plasma insulin concentrations were determined. IR was 
defined by means of the homeostasis model of assessment for insulin resistance 
(HOMA-IR). In subjects on insulin therapy (n=2), HOMA-IR was not calculated. 
Metabolic syndrome was diagnosed based on the updated International Diabetes 
Federation (IDF) definition with abdominal obesity (WC ≥94 cm in male and 
≥80 cm in female) not being prerequisite for metabolic syndrome diagnosis.24 
The definition of diabetes at baseline included any patient with a current 
treatment for type 2 diabetes or any patient with an HbA1c ≥6.5% or a fasting 
plasma glucose of ≥7 mmol/l. 25 
Body composition  
Fat mass index (FMI, fat mass/height2), body fat percentage and skeletal muscle 
mass index (SMI) (appendicular skeletal mass/height2) were calculated with 
dual-energy X-ray absorptiometry (DXA). Low SMI was defined as ≤5.67 kg/m2 
in women and ≤7.25 in men based on the cut-off values recommended by the 
European working group on Sarcopenia in Older People (EWGSOP).26 Hand grip 
strength was assessed three times for each hand using a Saehan hand 
dynamometer; the highest measurement of the dominant hand was used for 
analysis. Low grip strength was defined as ≤30 kg for BMI 24.1 to 28 kg/m2 or 
≤32 for BMI > 28 kg/m2 in men; and ≤17.3 kg for BMI 23.1 to 26 kg/m2, ≤18 kg 
for BMI 26.1 to 29 kg/m2 or ≤21 kg for BMI >29 kg/m2 in women.26  
Transient elastography 
In all participants liver stiffness measurements (LSM) were performed using the 
FibroScan® (touch 502, Echosens, Paris, France). Both the M (3.5 MHz) and the 
XL probe (2.5 MHz) were available for this study. The LSM is expressed in kilo 
Pascal (kPa) with a range of 2.5–75 kPa. All participants were in fasting 
condition for at least 3 hours before the examination. Only procedures with at 
least 10 valid measurements, a minimal success rate of 60% and interquartile 
range divided by median for liver stiffness estimation ≤ 30% were accepted for 
further analysis. The final result of LSM was the median of 10 valid individual 
measurements. Based on previous research the FibroScan® cut-off value for 




Magnetic Resonance Imaging  
For research purpose all participant received an MRI analysis after a minimal 
fasting period of 3 hours within one month of the other measurements. 3D fast 
gradient echo mDixon sequence were obtained with a 1.5T or 3T Achieva MRI 
system (Philips, Best, The Netherlands) in all subjects. The parameters 
employed for 1.5T and 3T were respectively: flip angle =15° and 10°, TR =5.8 
and 3.4 ms, TE1/TE2 =2.37/4.75 and 1.19/2.37ms, field-of-view (FOV) =320 x 
320 and 384 x 384 mm, acquisition matrix = 288 x 227 and 252 x 209, slice 
thickness 5 and 3 mm.   
Image analysis  
We followed the region of interest (ROI) segmentation method to determine 
muscle fat as described previously by Crawford et al.28. The multifidus and 
erector spinae muscle were segmented bilaterally at the lumbar 1 (L1) level 
using Weasis software (Figure 5.1). The large fat-filled “tent” which can be 
observed between the longissimus and iliocostalis muscle was not included in 
the ROI. The ROI borders were manually traced on the in-phase image (IP image) 
and copied to the corresponding opposed-phase image (OP image). The average 
ROI signal intensity (SI) for the IP and OP image were calculated. The relative 
signal intensity loss, a measure for muscle fat fraction (MFF) was calculated with 
the following formula: (SI IP – SI OP)/ SI IP*100%.13 Representative images of 
subjects with different MFF percentages are shown in Figure 5.1. 
Hepatic steatosis was assessed similar to muscle fat fraction.29 On three MRI 
sections, four circular ROIs of 5 cm2 were drawn in the liver. Artefact, vascular 
and biliary structures were avoided and the ROI was copied from the IP image to 
the OP image. The mean signal intensity loss of all 12 ROIs was calculated with 
the following formula: (SI IP- SI OP)/ 2*SI IP*100%.30 
Statistical analysis  
Data were analysed with IBM SPSS statistics version 25 (IBM Statistics for 
Macintosh, Chicago, IL, USA). Results were expressed as median and 
interquartile range for continuous variables and as absolute number and 
percentages for categorical variables. Mann‐Whitney U tests was used to 
determine statistically significant differences between two groups. Partial 
correlation controlling for gender were evaluated by partial spearman’s rho 
correlation coefficients. Multiple linear regression analysis in which sex and age 
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were considered as covariate was performed to analyse the associations between 
MFF as a dependent variable and liver function test, IR or body composition as 
independent variables. Due to skewed data, liver transaminases AST and ALT 
were LN transformed prior to analysis. A two-sided P-value of <0.05 was 
considered statistically significant. Bonferroni-Holm correction was used to 
correct for multiple testing.31 
Figure 5.1 Muscle fat fraction calculation. A represents a subject with a relative low muscle fat 
fraction (MFF) of the multifidus and erector spinae muscle (right 7.41%, left 8.75%, 
average 8.08%) and B represents a subject with a relative high MFF of the multifidus 
and erector spinae muscle (right 47.13%, left 44.67%, average 45.90%). 
Results 
Baseline characteristics 
In total, 45 subjects with proven NAFLD were included of whom 21 were female. 
Median age was 53 years and median BMI was 33.3 kg/m2. Furthermore, 
median MRI hepatic fat fraction was 15.64% (IQR 12.05-25.13) and significant 
(F2-F3) liver fibrosis (liver stiffness ≥7kPa) was diagnosed in 18 NAFLD patients 
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(40%). None of the NAFLD subjects had a low SMI, consequently none of the 
participant were diagnosed with sarcopenia.26 Only two subjects had a low grip 
strength. Median MFF (p=0.003) and SMI (p=0.003) differed significantly 
between male and female subjects (see table 1). In five subjects HOMA-IR results 
were not available, due to missing fasting insulin concentrations. In two male 
participants FibroScan® results were not obtained as the FibroScan® was 
unavailable because of regular maintenance of the device. Anthropometric and 
biochemical parameters of all participants are presented in Table 5.1. 
Table 5.1 Baseline characteristics of the study cohort 
Female (n=21) Male (n=24) Total (n=45) 
Age (years) 54 (50-61) 52 (39-60) 53 (43-61) 
BMI (kg/m2) 33.7 (31.3-36.7) 31.5 (27.4-35.7) 33.3 (28.4-35.9) 
Waist Circumference (cm) 106.3 (100.5-114.9) 109.8 (99.3-118.7) 106.7 (100.5-117.0) 
FMI (kg/m2) 13.75 (12.43-6.20)** 9.85 (7.45-10.65)** 10.80 (9.07-14.58) 
Body Fat (%) 41.54 (37.53-45.91)** 29.47 (27.21-34.67)** 36.31 (28.62- 41.79) 
HOMA-IR (n = 38) 2.65 (1.48-4.15) 3.25 (2.72-4.15) 3.05 (2.18-4.15) 
Diabetic Mellitus Type 2 (Yes) 5 (24%) 4 (17%) 9 (20%) 
Total cholesterol (mmol/L) 5.4 (4.5-6.1) 5.1 (4.3-5.7) 5.1 (4.5-5.9) 
LDL-C (mmol/L) 2.8 (2.6-4.0) 3.2 (2.5-3.9) 3.0 (2.4-3.9) 
HDL-C (mmol/L) 1.5 (1.1-1.7)* 1.1 (0.9-1.3)* 1.2 (1.0-1.6) 
Triglycerides (mmol/L) 1.50 (1.27-2.43) 1.51 (1.19-2.38) 1.51 (1.22-2.36) 
ALT (U/L) 31.0 (19.5-39.5)* 41.0 (29.3-62.5)* 37.0 (22.5-50.5) 
AST (U/L) 24.0 (20.0-30.0) 27.0 (24.0-80.0) 27.0 (22.5-33.0) 
GGT (U/L) 30.0 (20.5-57.0) 41.0 (27.8-80.0) 33 (25.0-66.5) 
ALP (U/L) 89.0 (83.0-119.5) 84.0 (69.5-105.3) 89.0 (74.5-106.0) 
Ferritin (ug/L) 118.0 (45.5-145.5)* 196.0 (63.3-274.2)* 122.0 (61.0-224.0) 
Albumin (g/L) 39.0 (36.7-41.0) 41.1 (39.5-43.3) 40.5 (37.8-42.2) 
CRP (mg/L) 3 (1-5) 2 (1-4) 3 (1-5) 
Hepatic fat fraction (%) 13.55 (11.12-24.95) 17.04 (12.96-23.52) 15.64 (12.05-25.13) 
LSM (kPa) (n=43) 
F2 (7- 8.7 kPa) (yes/total) 










SMI (kg/m2) 8.10 (7.19-8.89)** 9.42 (8.25-9.83)** 8.57 (7.90-9.56) 
Hand Grip Strength (cm) 28.0 (22.5-33.5)** 41.5 (38.0-50.25)** 36 (28-42) 
Low Grip Strength  2 (10%) 0 (0%) 2 (4%) 
MFF 40.75 (31.04-47.59)** 31.04 (23.51-38.99)** 35.57 (29.98-43.46) 
Continuous	 variables	 are	 expressed	 as	 median	 Q1‐Q3 .	 Categorical	 variables	 are	 expressed	 as	
number	 percentage	 of	 the	 total	 group .	 Mann‐Whitney	 test	 was	 used	 to	 determine	 statistically	
significant	 differences	 p 0.05 	 between	 male	 and	 female	 subjects.	 *	 p 0.05,	 **	 p 0.01.	
Abbreviations:	 	body	mass	index	 BMI ,	 	fat	mass	index	 FMI ,	 	Homeostatic	model	assessment	for	
insulin	resistance	 HOMA‐IR ,	low‐density	lipoprotein	cholesterol	 LDL‐C ,	high	density	lipoprotein	
cholesterol	 HDL‐C ,	alanine	aminotransferase	 ALT ,	 	aspartate	aminotransferase	 AST ,	gamma‐
glutamyl	 transferase	 GGT ,	alkaline	phosphatase	 ALP ,	 	 c‐reactive	protein	 CRP ,	 	 liver	 stiffness	
measurement	 LSM ,		skeletal	muscle	mass	index	 SMI ,	muscle	fat	fraction	 MFF . 
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Muscle fat infiltration and skeletal muscle mass index are not 
correlated with hepatic fat fraction or the presence of significant 
fibrosis 
To investigate possible correlation between the hepatic fat fraction and MFF and 
SMI partial correlation controlling for gender was used. No significant 
correlations were found between MFF or SMI and hepatic fat fraction (Figure 
5.2A-C). Furthermore, no difference in MFF (p=0.980) or SMI (p=0.291) 
between NAFLD patients with significant fibrosis (F2-F3) and NAFLD patients 
without fibrosis was observed (Figure 5.2B-D). Results were not adjusted for 
gender because gender was evenly divided across both groups (F0-F1 vs. F2-F3).  
Insulin sensitivity is correlated with the degree of hepatic steatosis 
and the presence of significant fibrosis. 
Insulin sensitivity was defined by means of HOMA-IR. We observed a moderate 
positive correlation (r=0.528, p=0.001) between HOMA-IR and hepatic fat 
fraction in our cohort (Figure 5.2E). Furthermore HOMA-IR was significantly 
elevated in NAFLD patients with significant fibrosis (p=0.039) (Figure 5.2F).   
MFF is not associated with  the metabolic syndrome, liver 
transaminases and insulin sensitivity but is associated with body 
composition  
A multiple linear regression analysis in which sex and age were considered as 
covariates was performed to investigate the association between body 
composition and MFF. BMI, fat mass index (FMI, fat mass/heigt2) and body fat 
percentage were found to be positively associated with MFF (see Table 5.2). The 
metabolic syndrome, HOMA-IR, AST and ALT levels, SMI and hand grip 
strength were not associated with MFF. None of the associations remained 
significant after Bonferroni-Holm correction for multiple testing.   
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Figure 5.2 Hepatic Fat Fraction and liver fibrosis were not associated with MFF or SMI but with 
HOMA-IR. A/C/E Partial Spearman correlation corrected for gender of muscle fat fraction 
(MFF), skeletal muscle mass index (SMI) and Homeostatic model assessment for insulin 
resistance (HOMA-IR) with hepatic fat fraction. Black dots represent female subjects and 
white dots male subjects. B/D/F Boxplot showing the MFF, SMI and HOMA-IR in non-
alcoholic fatty liver disease patients with (F2-3) and without significant fibrosis (F0-F1). 
Mann‐Whitney U tests was used to determine statistically significant differences (p<0.05). 
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Table 5.2  Association between MFF and IR or body composition variables in patients with NAFLD  
Unstandardised B 95% CI p-value
MS (no/yes) 0.082 -6.215; 6.379 0.979 
MS (number of components) -0.337 -2.824; 2.151 0.786
ALT (U/L) -0.305 -12.214; 11.603 0.959 
AST (U/L) 1.898 -14.424; 18.220 0.815 
HOMA-IR 0.277 -1.407; 1.961 0.740
HbA1C (%) -1.556 -4.810; 1.701 0.340 
BMI (kg/m2) 0.714 0.130; 1.299 0.018
FMI (kg/m2) 1.221 0.357; 2.085 0.007
Body Fat (%) 0.879 0.275; 1.484 0.005 
SMI (kg/m2) 1.525 -1.577; 4.626 0.326 
Hand Grip (cm) -0.049 -0.498; 0.399 0.826 
The	 multiple	 linear	 model	 included	 sex	 and	 age	 as	 covariates,	 muscle	 fat	 fraction	 MFF 	 as	
dependent	 variable	 and	 insulin	 resistance	 IR 	 and	 body	 composition	 variables	 as	
independent	 variables.	 Abbreviations:	 metabolic	 syndrome MS ,	 	 alanine	 aminotransferase	
ALT ,	 	 aspartate	 aminotransferase	 AST ,	 Homeostatic	 model	 assessment	 for	 insulin	
resistance	 HOMA‐IR ,	glycosylated	 haemoglobin	 type	 A1c	 HbA1C ,	 body	 mass	 index	 BMI ,	 	
fat	 mass	 index	 FMI ,		skeletal	 muscle	 mass	 index	 SMI , confidence interval (CI).	 Skewed	 data	
ALT	 and	 AST 	 were	 LN	 natural	 logarithm 	transformed	prior	to	analysis. 
Discussion 
Myosteatosis is suggested to be a precursor of sarcopenia and may be an early 
sign of the progression from simple steatosis to NASH.32 In this exploratory 
study, the degree of myosteatosis was not associated with the amount of hepatic 
fat, liver transaminases or the presence of significant liver fibrosis. Our findings 
are in line with those of Machado et al. who found no correlation between biopsy 
proven myosteatosis and the degree of hepatic steatosis and HOMA-IR in 51 
biopsy proven morbidly obese NAFLD patients.22 In contradiction to our results 
they observed a progressive increase in the prevalence of intramyocellular lipids 
and the severity of hepatic fibrosis. Kitajima et al. investigated CT muscle 
attenuation in 208 biopsy proven Japanese NAFLD patients of which 179 had 
NASH.23 The degree of myosteatosis increased significantly with the severity of 
NASH, however the relationship with liver fibrosis was not investigated.23 An 
explanation for the difference in results between studies is at least partially 
explained by the characteristics of the various study populations. In our cohort 
of 45 patients, 18 subjects had elevated liver stiffness measurements, nine had 
type 2 diabetes mellitus (DM2) and in five subjects ALT levels were elevated 
more than 1.5 times upper limit of normal (male >67 U/L; female >51 U/L). In 
addition, only subjects younger than 65 years were included without liver 
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cirrhosis. In the study of Machado et al. morbidly obese patients were studied 
and of them 51% had DM2 and 43% had NASH with significant fibrosis.22 In the 
study of Kitajima et al. 82% of the study population had NASH, mean ALT value 
was 77 IU/L and significant fibrosis was present in 64% of the study 
population.23 Our cohort could be characterised as NAFLD in a less advanced 
phase as NASH prevalence is expected to be lower in our cohort compared to 
previous NAFLD myosteatosis studies. Chronic low grade inflammation and 
ageing are well known risk factors for loss of muscle strength, mass and 
functionality. A correlation between myosteatosis and the expression of 
systemic inflammatory cytokines IL-6 and TNF-a has been observed.33 NASH is 
associated with more pronounced systemic inflammation and may enhance 
myosteatosis. In the presented study, we were not able to investigate the link 
between hepatic inflammation and myosteatosis because liver biopsies were not 
available. While myosteatosis may possibly be an important hallmark for 
hepatic inflammation and NASH, based on our data the relevance of 
myosteatosis for the degree of hepatic steatosis or fibrosis is minimal.  
Furthermore, we showed that insulin resistance, the possible link between liver- 
and myosteatosis, was not correlated with the amount of myosteatosis. On the 
other hand, IR was associated with the hepatic fat fraction and the presence of 
significant fibrosis. Our results are in line with previous NAFLD myosteatosis 
studies.21,22 In DM2 populations however, a positive association between degree 
of myosteatosis and IR or DM2 has been observed by several authors.7,34,35 Our 
results are not in line with these findings.  A possible explanation for this 
difference in results might be that only nine DM2 patients were included in our 
study. To date, it is still uncertain if myosteatosis is a causal mechanism in IR 
development.  
IMCL and intermyocellular-intrafascial adipose tissue have both been associated 
with IR development in numerous studies.7,11,12,36 However, the accumulation of 
IMCL (stored as lipid droplet inside myocytes) is believed to have a more crucial 
role in this process. Among other, morphological characteristics, protein 
coating and composition (diacylglycerol and cermides) of these lipid droplets 
have been observed to influence insulin sensitivity via unknown mechanisms.36 
IR increases free fatty acid (FFA) delivery to the liver and stimulates de novo 
lipogenesis both resulting in the development of hepatic steatosis. In this study, 
however, we were not able to discriminate between IMCL and intermyocellular-
intrafascial adipose. This may explain why the hypothesised positive association 
between the degree of hepatic steatosis and myosteatosis was not observed. 
IMCL might be associated with the degree of hepatic steatosis and IR, while 
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myosteatosis in general is not. To further understand the role of myosteatosis in 
IR and NAFLD development future studies using advanced imaging techniques 
(e.g. magnetic resonance spectroscopy) and muscle biopsies with detailed 
analysis are needed.  
In addition, we found associations between body composition and the amount 
of myosteatosis. BMI, DXA measured FMI and body fat percentage were 
positively associated with MFF. This positive association between body fatness 
and MFF is in line with previous research data.21,37  
Finally, none of the NAFLD subjects in our cohort were diagnosed with 
sarcopenia and similar to the MFF no association between SMI and hepatic fat 
fraction or significant fibrosis was observed. The association between NAFLD 
and sarcopenia has been more widely investigated than the association between 
NAFLD and myosteatosis. Large Korean population studies focussing on 
sarcopenia in the NAFLD population showed that sarcopenia is more prevalent 
in NAFLD compared to healthy controls and is related to NAFLD severity 
including liver fibrosis.5,38 In contrast to these studies, our population is 
relatively young with a median age of 53 years which may explain why 
sarcopenia was not observed. In a recent Dutch population based study, an 
independent association between SMI and overweight NAFLD was not found. In 
line with our results a low SMI was only present in 3% of the 1462 overweight 
NAFLD subjects.39 Myosteatosis on the other hand is believed to be a precursor 
of sarcopenia and it may be an early sign of the progression from simple liver 
steatosis to NASH.32  
With regards to our cohort, several factors need to be taken into account. First, 
the number of patients with hepatic fibrosis was probably overestimated with 
the FibroScan® because the positive predictive value of the FibroScan® for F2 is 
only 70%.27 Second, the MRI images were targeted to the liver and because of 
this MFF was calculated at L1 level instead of the more commonly used L3 level. 
However, in previous research MFF of L1 correlated very well with MFF of the 
complete lumbar spine (L1-L5).40 Third, both T1.5 and T3 MRI images were 
used. In previous research, no significant difference between MFF 
measurements across field strengths (1.5T and 3.0T) was observed.41 Fourth, 
our cohort was relatively small in numbers and no control group was available 
which limits the generalisability of the study. However, in this exploratory 
study we aimed to investigate the association between the degree of 
myosteatosis and different prognostic factors within the NAFLD population for 
which a control group is not needed. Furthermore, a control group without 
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hepatic steatosis and BMI matched to the NAFLD population is difficult to 
obtain. 
A strength of our study is that all NAFLD subjects are well characterised with 
biochemical parameters, imaging (MRI and FibroScan®), and tests for muscle 
mass (DXA) and function (hand grip strength). In this way, we were able to 
evaluate muscle fat fraction, muscle mass and muscle function. Second, 
chemical shift MRI is known to have a very good diagnostic accuracy for hepatic 
steatosis and is widely available in the clinical setting.29,30 Third, hepatic 
steatosis, insulin sensitivity and MFF were all measured as a continuous 
variable, which is ideal for correlation analysis.  
Conclusion 
Myosteatosis was not associated with the degree of hepatic steatosis or fibrosis 
in this NAFLD cohort but was associated with factors related to body 
composition. Further research with longitudinal studies focussing on the 
complete spectrum of muscle wasting including myosteatosis, sarcopenia and 
muscle functionality are necessary to investigate in more depth the role of 
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Pauline Verhaegh, Roisin Bavalia, Bjorn Winkens, Ad Masclee, Daisy Jonkers, Ger Koek 





Non-alcoholic fatty liver disease (NAFLD) is a rapidly increasing health problem. 
Liver biopsy analysis is the most sensitive test to differentiate between non-
alcoholic steatohepatitis (NASH) and simple steatosis (SS), but non-invasive 
diagnostics are needed. We performed a systematic review on non-invasive tests 
for differentiating NASH from SS, focusing on blood markers.   
Methods 
We performed a systematic search in PubMed, Medline and Embase (1990-2016) 
using defined keywords, limited to full-text papers in English and human 
adults, resulted in 2608 hits. Two independent reviewers screened the articles 
an identified 122 eligible articles that used liver biopsy as gold standard. If at 
least 2 studies were available, pooled sensitivity (sensp) and specificity (specp) 
were determined using the Meta-Analysis Package for R (metafor). 
Results 
In the 122 studies analysed, 219 different blood markers (107 single markers 
and 112 scoring systems) were identified to differentiate NASH from SS. 
Markers identified related to several pathophysiological mechanisms. The 
markers analysed in the largest proportion of studies were alanine 
aminotransferase (sensp 63.5%, specp 74.4%) within routine biochemical tests, 
adiponectin (sensp 72.0%, specp 75.7%) within inflammatory markers, CK18-
M30 (sensp 68.4%, specp 74.2%) within markers of cell death/proliferation and 
homeostatic model assessment of insulin resistance (sensp 69.0%, specp 72.7%) 
within the metabolic markers. Two scoring systems could also be pooled: the 
NASH test (NASH vs borderline NASH plus SS with sensp 22.9%, specp 95.3%) 
and the GlycoNASH test (sensp 67.1%, specp 63.8%). 
Conclusion 
In the meta-analysis, we found no test to differentiate NASH from SS with a high 
level of pooled sensitivity and specificity (≥80%). However, some blood 
markers, when included in scoring systems in single studies, identified patients 
with NASH with ≥80% sensitivity and specificity. Replication studies and more 
standardised study designs are urgently needed. At present, no marker or 
scoring system can be recommended for use in clinical practice to differentiate 
NASH from SS.  




Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic 
liver disorders in the world with a prevalence of 25%,1 and is expected to 
increase further in line with the worldwide overweight and obesity epidemic.2-5 
NAFLD encompasses simple steatosis and non-alcoholic steatohepatitis 
(NASH).6 NASH is the early stage of progression that develops to cirrhosis in 15-
25% of patients and can lead to the development of hepatocellular carcinoma.7-9 
In the near future NASH accounts for the majority of liver transplantations.10 Of 
the NASH-related cirrhosis patients, 30-40% die of a liver-related cause over a 
10-year period7. To date, liver-related mortality is the third most common cause 
of death after cardiovascular diseases and malignancies.11 
NAFLD is mostly asymptomatic, generally resulting in ‘silent’ disease 
progression. Liver biopsy is the gold standard to diagnose NASH but has several 
limitations. Its invasiveness, high costs, and risk of complications make it 
unsuitable for diagnosis in large populations or disease monitoring.12 In clinical 
practice, only subjects at high risk of NASH, usually based upon elevated 
aminotransferase levels, undergo a liver biopsy. This may lead to under-
diagnosis of NASH.13 Screening large numbers of subjects with NAFLD will 
provide more detailed insight in pathophysiological factors and early 
identification of patients at risk for developing NASH. Therefore, an accurate 
non-invasive test to diagnose NASH is highly warranted. 
Imaging techniques have potential to assess and quantify hepatic fat but cannot 
accurately diagnose hepatic inflammation.14 Several biomarkers have been 
studied, ranging from liver enzymes to markers for specific pathophysiologic 
processes associated with NASH, such as glucose and lipid metabolism, 
oxidative stress and inflammation. In addition, attention has been given to 
scoring systems based on combinations of markers and/or omics approaches. 
We conducted a systematic review with meta-analyses to identify the best 
performing non-invasive diagnostic test for NASH in (suspected) NAFLD 
patients with liver biopsy as a reference test. We specifically focused on blood 





A systematic literature search was conducted in PubMed, Embase and Medline 
(1990 until July 2016), using the following (truncated) keywords and MeSH 
terms: ‘non*alcoholic fatty liver disease, NAFL, fatty liver, NASH or 
non*alcoholic steatohepatitis’, in any combination with ‘routine diagnostic 
tests, diagnosi*, diagnosti*, diagnostic imaging, radiography, radiograph*, 
radiol*, *marker*, biological marker or genetic markers’ (see supplementary file 
Search). The search was limited to full-text papers in English language and 
human adults (3398 hits) (see supplementary data, search strategy). Double hits 
were excluded leaving 2608 single hits.  
Inclusion and exclusion criteria 
Studies on non-invasive markers and/or tests to diagnose NASH in (suspected) 
NAFLD patients with liver biopsy as a reference test were eligible for inclusion. 
In case of inclusion of a population of suspected NAFLD patients, studies were 
eligible if at least the majority had biopsy proven NAFLD.  Studies had to present 
one of the following values for diagnosing NASH: sensitivity, specificity, 
likelihood ratio (LR), Area Under the Receiver Operating Characteristic curve 
(AUROC) or diagnostic accuracy (DA). Studies performed in vitro, in animals, in 
children (≤18 years), reviews, case reports/series, studies on alcoholic or other 
chronic liver diseases and studies in patients with liver diseases of mixed 
aetiologies not reporting on NAFLD separately, were excluded. Studies not 
differentiating NASH from simple steatosis, but focusing only on steatosis or 
fibrosis in NAFLD were also excluded. Studies on the diagnosis of NAFLD or 
NASH versus other causes of chronic liver diseases were not eligible for 
inclusion. 
Selection process  
This systematic review and meta-analyses were performed according to the 
PRISMA statement.15 
Titles and abstracts were screened for eligibility, leaving 438 articles, of which 
full texts were checked by two independent reviewers. For 18 abstracts, a 
request for the full text was sent to the corresponding authors to a maximum of 
three attempts; only one author replied. In case of disagreement on eligibility, 
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the two reviewers came to consensus after discussing the article with a third 
reviewer. Scrutinizing full texts resulted in exclusion of 324 articles. Eight 
additional papers were found by crosschecking references of eligible articles and 
reviews. Finally, 122 articles were included. Details on the selection process can 

























Figure 6.1 Flow chart of the selection process; from identification of all the possible eligible 
articles to the articles included in the review. NAFLD, non-alcoholic fatty liver 
disease; NASH, non-alcoholic steatohepatitis; SS, simple steatosis. 
 
Data extraction 
Two reviewers carried out the data extraction using a standardised data 
extraction form. Seven authors were contacted to clarify their data, one replied. 
As blood analyses are implemented in all clinical practices, the present review 
Chapter 6 
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focuses on serum or plasma markers, either as single marker or as part of 
scoring systems. An overview of additional biochemical markers (i.e. in urine 
and breath) or imaging techniques is provided in the supplementary tables only. 
Quality assessment 
The methodological quality for each of the included studies was assessed using 
phase 3 of the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-
2) scoring system. QUADAS-2, assessing the quality of primary diagnostic 
accuracy studies, consists of four domains covering patient selection, index test, 
reference standard, and flow of patients through the study and timing of the 
index test(s) and reference standard. The QUADAS-2 assesses the risk of bias in 
each domain (low, unclear, high), including selection-, work-up-, and 
expectation bias. The first three domains are also assessed in terms of concerns 
regarding applicability (low, unclear and high) by making use of signalling 
question.16  
Statistical analyses 
A meta-analysis was performed if at least two studies evaluated the same blood 
marker. Sensitivity and specificity, as statistical measures of the performance of 
a binary classification test (NASH vs. simple steatosis), were used for pooling, as 
these data were available or could be calculated in most studies. Furthermore, 
only studies in which all subjects underwent liver biopsy as reference, were 
included in the meta-analysis. The histological criteria used to diagnose NASH 
and the stages of fibrosis in the individual studies are indicated in 
Supplementary Tables S6.1-S6.3.  
When different cut-offs were given in one study, those resulting in the best 
overall sensitivity and specificity (smallest Euclidean distance) were used for 
pooling. Different cut-offs between studies had to cover largely the same range 
to be eligible for pooling. In case of mutually exclusive cut-offs, no meta-
analysis was performed. When available, sub-analyses for highest sensitivity 
and highest specificity were performed using respective cut-offs. In case of 
largely overlapping cohorts analysing the same marker, those showing the best 
diagnostic values (smallest Euclidean distance) were included in the meta-
analysis.  
Meta-analyses were performed using a random effect model by the metafor 
package in R (version 3.2.2).
17 When the sensitivity or specificity for all markers 
included in the meta-analysis was between 30-70%, proportion for raw data (PR) 
Non-invasive tests do not accurately differentiate NASH from SS 
125 
6 
was used for calculation of pooled sensitivity and specificity. When either 
sensitivities or specificities of one of the markers included in the meta-analysis 
was <30% or >70%, Freeman-Tukey double Arcsine transformed proportion 
(PFT) was used, to overcome confidence limits outside the 0-100% range and 
variance instability.18  
Analyses of sensitivity and specificity were performed univariate, as less than 
6 studies is a contra-indication for a bivariate random effects model.19 However, 
sensitivity analyses, using this bivariate random effects model (mada package R, 
version 3.2.2.), were performed for those markers evaluated in at least 6 studies 
to check the robustness of the univariate analyses.20 
All calculations were rounded off to one decimal. The estimates of pooled 
sensitivities and specificities with 95% confidence intervals (CIs) were presented 
in forest plots. Heterogeneity was indicated by the I-squared test. 
Results 
Study characteristics 
In total, 122 studies were identified (see supplementary data, list of included 
articles), in which 219 different blood markers, either as single marker (n=107) 
or as part of scoring systems (n=112), and 22 other diagnostic tests (i.e., 
imaging, breath and urine tests) were evaluated to diagnose biopsy proven 
NASH versus simple steatosis.  Meta-analyses could be performed, for 19 blood 
markers (and 41 studies), including 1 glycomics approach and 1 scoring system. 
Studies including (healthy) subjects without liver biopsy in the control group 
used to calculate the diagnostic values were included in the review and 
supplementary tables (16 studies21-36), but not in the meta-analysis, as for a 
substantial part no appropriate gold standard was available.  
The studies on blood markers were categorised as follows: routine blood 
markers (e.g., liver enzymes); markers related to inflammation, immune system 
and oxidative stress; markers of cell death, proliferation and cell structure; 
metabolic parameters; and -omics approaches. An overview of all diagnostic 
tests is given in Supplementary Table S6.1 for blood markers as single markers, 
Supplementary Table S6.2 for blood markers as part of scoring systems and in 
Supplementary Table S6.3 for other tests. The supplementary tables provide 
information on histologic scoring methods, fibrosis stages, definition and 
number of patients included and the study design. 
Chapter 6 
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Individual studies on blood markers showing both sensitivity and specificity 
≥80% and results of the meta-analyses will be discussed in the sections below. 
Data on other biochemical markers and imaging tests can be found in the 
supplementary tables only.  
Quality assessment 
The results of the QUADAS-2 assessment for each domain (i.e., patient 
selection, index test, reference standard, and patient flow and timing of the 
tests) are summarised in Table 6.1 and Supplementary Figure S6.1. Sixty-two 
studies scoring “high” for risk of bias on the domain ‘Patient Selection’ as well as 
on ‘Flow and Timing’, also included (healthy) controls without biopsy. However, 
most of these studies (46/62 studies) did not include the controls in the analyses 
to calculate the diagnostic values. 
Studies scoring “unclear” on the domain ‘Patient Selection’, did not state 
whether consecutive or random patients were used (25 studies). In the domain 
‘Flow and Timing’, “unclear” scores were mainly due to not describing the time 
interval between liver biopsy and index test (17 studies). 
Routine blood markers 
Liver enzymes are widely used to diagnose and monitor liver diseases. Alanine 
aminotransferase (ALT),13,21,22,37-58 aspartate aminotransferase 
(AST),21,38,39,41,42,44,46-48,51,53-55,57,59-65 gamma-glutamyl transferase (GGT),41,44,47,49,53,57 
and alkaline phosphatase (ALP)44,53 have been studied to diagnose NASH. 
Pirvulescu et al.44 showed both sensitivities and specificities over 80% for ALT 
and AST, as did Hendrikx et al.21 for ALT (Supplementary Table S6.1). 
Eight studies on ALT,13,38,41,44,53,54,56,58 5 on AST,41,44,47,53,54 4 on GGT,41,44,47,53 and 
2 on ALP,44,53 could be pooled. ALT, AST, GGT and ALP showed pooled 
sensitivity (sensp) and specificity (specp) of 63.5% and 74.4%, 76.9% and 61.9% 
(Figure 6.2), 63.7% and 64.2%, and 68.5% and 64.6% (Supplementary Figure 
S6.2), respectively, for the diagnosis of NASH versus SS (Table 6.2). 




















































































































































Could the selection of patients have 
introduced bias? 
Is there concern that the included patients 
do not match the review question? 
Could the conduct or interpretation of the 
index test have introduced bias? 
Is there concern that the index test, its 
conduct or interpretation differ from review 
question? 
Could the reference test, its conduct or its 
interpretation have introduced bias? 
Is there a concern that the target condition 
as defined by the reference test does not 
match the review question? 
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Table 6.2  An overview of the pooled sensitivity and specificity of biomarkers and scoring system 
pooled in the meta-analyses











ALT 8 63.5 (44.1-81.0) 447 74.4 (59.7-86.8) 566 
AST 5 76.9 (62.3-88.9) 185 61.9 (35.7-85.0) 323 
GGT 4 63.7 (41.1-83.7) 125 64.2 (49.5-77.6) 185 
ALP 2 68.5 (57.8-79.2) 73 64.6 (54.0-75.1) 79 
Ferritin 2 79.1 (49.2-97.9) 126 71.9 (60.7-82.0) 71 
N/L ratio 2 73.0 (66.0-79.5) 170 75.3 (72.3-78.3) 804 
Adiponectin 4 72.0 (46.3-92.0) 210 75.7 (64.5-85.6) 172 
IL-6 3 60.6 (51.7-69.6) 114 83.9 (44.7-100.0) 94 
CK18-M30  15 68.4 (62.4-74.0) 1017 74.2 (68.3-79.7) 839 
CK18-M65 5 76.2 (62.8-87.5) 198 73.7 (66.9-80.0) 192 
CK18-M65ED 2 91.2 (63.7-100.0) 81 64.1 (44.5-81.7) 88 
FGF-21 2 67.0 (40.3-89.0) 150 75.5 (68.8-81.7) 175 
HOMA IR 6 69.0 (56.9-80.0) 274 72.7 (63.6-81.1) 230 
Fuc-Hpt 2 66.9 (60.4-73.4) 202 79.4 (66.4-90.1) 48 
Mac2bp 2 79.4 (68.9-88.2) 204 70.4 (56.2-83.0) 47 
Triglycerides 2 73.7 (65.3-81.4) 126 59.9 (47.9-71.8) 110 
Total cholesterol 2 72.6 (44.5-94.2) 25 55.7 (45.8-65.6) 97 
Omics approach 
   GlycoNASH test 2 67.1 (24.7-97.5) 100 63.8 (18.1-98.4) 153 
Subanalyses 
   CK18-M30 highest  
   sensitivity 
7 82.5 (75.1-88.8) 303 61.5 (43.6-78.0) 316 
   CK18-M30 highest  
   specificity 
7 53.2 (35.1-70.9) 303 93.3 (83.4-99.2) 316 
2 22.9 (7.2-43.9) 148 95.3 (93.1-97.0) 603 
Scoring system 
NASH Test 
NASH vs.  
borderline NASH + SS* 
NASH Test 
NASH + borderline 
NASH  vs. SS* 
2 90.9 (85.6-95.2) 371 41.3 (25.4-57.3) 380 
Non‐alcoholic steatohepatitis NASH  is the number of patients diagnosed with NASH via liver 
biopsy. Simple steatosis SS  is the number of patients with biopsy proven simple steatosis Whether 
or not this includes SS or the combination of SS and normal NL  depends on the individual studies . 
Due to interstudy variation with regards to the classification used to define NASH, whether or not 
borderline NASH was included in the NASH group or in the SS group depends on the individual 
studies and classification system used supplementary tables . *Classification based on NAS score: 
0‐2 no NASH, 3‐4 borderline NASH, 5 NASH. Abbreviations: alanine aminotransferase 
ALT , aspartate aminotransferase AST , gamma‐glutamyl transferase GGT , alkaline 
phosphatase ALP , neutrophil/lymphocyte ratio N/L ratio , interleukin IL , cytokeratin CK , 
fibroblast growth factor FGF , Homeostatic model assessment for insulin resistance HOMA‐IR , 
Fucosylated‐haptoglobin Fuc‐Hpt , Mac2 binding protein Mac2bp , confidence interval (CI). 
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Figure 6.2  Forest plots for pooled sensitivity of alanine aminotransferase (ALT) (A), pooled 
specificity of ALT (B), pooled sensitivity of aspartate aminotransferase (AST) (C), pooled 
specificity of AST (D), pooled sensitivity of interleukin-6 (IL-6) (E) and pooled specificity 
of IL-6 (F). Any discrepancy between the sensitivity and specificity for an individual 
study given in the forest plot and the original article is due to rounding off and/or 
reported missing data. A difference of ≤2% was accepted. Abbreviations: non-alcoholic 
steatohepatitis (NASH), confidence interval (CI). 
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Inflammation, immunologic and oxidative stress parameters 
As NASH is considered the inflammatory entity of NAFLD, several 
inflammatory-, oxidative stress-, and immune parameters have been 
investigated. Sensitivity and specificity ≥80% was only reported for adiponectin 
in one study44, showing a sensitivity of 92.3% and a specificity of 86.7%. 
Ferritin,61,66 Neutrophil/Lymphocyte (N/L) ratio,60,67 Interleukin(IL)-6,43,44,68 and 
adiponectin43,44,69,70 could be pooled (Table 6.2), resulting in a sensp of 79.1% 
and specp of 71.9% for ferritin (Supplementary Figure S6.2), sensp of 73.0% and 
specp of 75.3% for N/L ratio (supplementary figure S6.3), sensp of 60.6% and 
specp of 83.9% for IL-6 (Figure 6.2), and sensp of 72.0% and specp of 75.7% for 
adiponectin (Supplementary Figure S6.3).  
Markers of cell death, proliferation and cell structure 
Among markers of cell death, cytokeratin 18 (CK18) has been studied 
extensively. This is the major intermediate filament protein of the liver, which is 
cleaved by caspases during apoptosis of hepatocytes, generating several 
fragments.71 Assays measure either the cleaved CK18-M30 or the cleaved and 
intact CK18-M65.72 
CK18-M30 was evaluated in 29 studies;26,27,37,39,41,44,49,73-94 of which 1541,44,73-
75,77,79,82,84,86-88,91,93,94 could be combined, resulting in 68.4% sensp and 74.2% 
specp (Table 6.2, Figure 6.3). Two studies showed both a sensitivity and 
specificity of ≥80% for CK18-M30.26,92 Since various cut-offs for CK18-M30 were 
investigated within studies, sub-analyses were conducted for cut-offs optimising 
sensitivity or specificity,41,84,86-88,90,92 resulting in a highest sensp of 82.5% (with 
61.5% specificity) and highest specp of 93.3% (with 53.2% sensitivity; Table 
6.2, Supplementary Figure S6.4).   
Five43,44,82,83,91 out of six studies27,43,44,82,83,91 on CK18-M65 could be pooled, 
showing 76.2% sensp and 73.7% specp (Table 6.2, Figure 6.3). Two studies82,83 
assessing CK18-M65ED, which differs from CK18-M65 in the way of analysis,72 
showed a sensp of 91.2% and a specp of 64.1% (Table 6.2, Figure 6.3).   
Only one study showed a sensitivity of 100% and specificity of 80%, for CK18-




































Figure 6.3  Forest plots for pooled sensitivity of cytokeratin (CK) 18-M30 (A), pooled specificity of 
CK18-M30 (B), pooled sensitivity of CK18-M65 (C), pooled specificity of CK18-M65 (D), 
pooled sensitivity of CK18-M65ED (E) and pooled specificity of CK18-M65ED (F). Any 
discrepancy between the sensitivity and specificity for an individual study given in the 
forest plot and the original article is due to rounding off and/or reported missing data. 
A difference of ≤2% was accepted. Abbreviations: non-alcoholic steatohepatitis 
(NASH), confidence interval (CI). 
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Several growth factors (fibroblast growth factor 21 (FGF-21),73,84 vascular 
endothelial growth factor,68 insulin-like growth factor,95 and pigment 
epithelium-derived factor (PEDF)73) were studied, of which data for FGF-21 could 
be pooled, showing a sensp of 67.0% and a specp of 75.5% (Table 6.2, 
Supplementary Figure S6.3).  
Additional markers to diagnose NASH can be found in table S6.1. None of these 
could be pooled. Sensitivities and specificities ≥80% were reported for tissue 
polypeptide specific antigen (91.7%/95.8%)56 and tissue inhibitor 
metalloproteases(TIMP)-1 (96.7%/100%) and TIMP-2 (93.3%/100%).30 
Metabolic parameters  
Of the glycaemic and lipidaemic parameters studied, Gulsen et al.96 showed a 
sensitivity of 91.67% and specificity of 95.65% for homocysteine to diagnose 
NASH in a biopsy proven NAFLD population (Supplementary Table S6.1). 
A meta-analysis of 6 studies44,53,69,70,95,97 investigating HOMA-IR could be 
performed; showing 69.0% sensp and 72.7% specp (Table 6.2). Furthermore, 
pooling fucosylated-haptoglobin (Fuc-Hpt),78,98 Mac2 binding protein 
(Mac2bp),77,98 triglycerides (TG)38,44 and total cholesterol (TC)44,47 resulted in a 
sensp of 66.9% and specp of 79.4% for Fuc-Hpt, sensp of 79.4% and specp of 
70.4% for Mac2bp, sensp of 73.7% and specp of 59.9% for TG, and sensp of 
72.6% and specp of 55.7% for TC for diagnosing NASH (Supplementary Figures 
S6.5-6.6 and table 6.2). For Fuc-Hpt and Mac2bp, it should be noted that 
potential overlap between cohorts was unclear.77,78,98 
Omics approaches and scoring systems 
The application of –omics approaches to identify discriminating molecules or 
profiles for disease diagnosis is emerging. The Glycomarker81/GlycoNASH test99 
data could be pooled, showing a sensp of 67.1% and specp of 63.8% (Table 6.2, 
Supplementary Figure S6.6). The clinical and phosphoproteomic model of 
Younossi et al.100 showed a sensitivity of 81.3% and specificity of 87.0%. The 
MiRNA profile (MiR-122, -192, -21) combined with CK18-asp396 by Beckers et 
al. also showed good sensitivity and specificity (91% and 83%, resp.).37 None of 
the other (combinations of) markers identified by the -omics approaches did 
result in both sensitivities and specificities of ≥80% (Supplementary Table S6.1).  
Additionally, blood markers were often combined in scoring systems. The 
NASHTest,45,57 combining 10 markers with age, gender, weight, height, and a 
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positive result on the SteatoTest, showed a specp of 95.3% for differentiating 
NASH from borderline NASH and SS (sensp 22.9%), and 90.9% sensp and 41.3% 
specp for differentiating NASH plus borderline NASH from SS (Table 6.2, 
Supplementary Figure S6.7).  
Another 12 studies reporting on various scoring systems showing both 
sensitivities and specificities ≥80% (Supplementary Table 
S6.2),21,35,43,44,49,67,73,85,91,101-103 however, none of these could be pooled. 
Sensitivity analysis 
For the markers evaluated in at least six studies (i.e., ALT, CK18-M30, HOMA-IR 
and CK18-M30), sensp and specp were also calculated by the bivariate random 
effects model (Supplementary Table S6.4). Results were comparable to 
univariate analyses, indicating robustness of the findings. 
Discussion 
NASH is a rapidly increasing health problem, for which non-invasive 
diagnostics are crucial due to its progressive nature and the fact that liver biopsy 
is unsuitable for diagnosis in large populations. To provide an overview on the 
current status, we performed this systematic review with meta-analysis on non-
invasive diagnostic tests for NASH versus simple steatosis with biopsy as 
standard. A wide variety of blood markers, either as single marker or as part of 
scoring systems have been studied, but only for a limited number sensitivity and 
specificity were evaluated in at least two studies. None of the pooled markers 
showed both sensitivity and specificity ≥80%. However, it should be noted that 
the diagnostic tests that could be pooled, covered largely the same range in cut-
off values, with the largest range for AP, CK18, FGF21, Adiponectin and Fuc-
Hpt. Furthermore, the majority of studies contained only limited numbers of 
patients with significant fibrosis (F3-4) or did not provide the stages of fibrosis. 
The above should be taken into account when interpreting the meta-analysis 
results and shows the urgent need for more standardised study designs, 
including histological scoring. 
Although the exact pathogenesis is still unclear, it is generally accepted that 
multiple hits (in parallel) play a role in the progression to NASH.104 They include 
e.g., altered metabolic make up, inflammation, oxidative stress, and 
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fibrogenesis (Figure 6.4). Due to the complexity of the disease, it is unlikely that 
a single marker will be able to differentiate between NASH and simple steatosis. 
This is supported by the meta-analysis results showing that none of the pooled 
markers showed both sensitivity and specificity ≥80%.  However, several 
scoring systems49,73,91,101 and –omics approaches,37 that combine markers of at 
least two domains related to specific pathophysiologic processes associated with 
NASH (Figure 6.4) in well-designed studies, showed promising findings 
(sensitivities and specificities ≥80%). Although internal validation was included 
in some studies, external validation of promising markers and scores (including 
previously studied cut-off values) are urgently needed. When applying the 
sensitivity and specificity of these promising scores49,73,91,101 and omics 
approaches37 to hypothetical high (50%) and low (10%) prevalence NASH 
populations, false positive and false negative rates would vary between 4.4 and 
16.7% and between 10 and 20%, respectively, for the low prevalence 
population, and between 4 and 16% and between 6 and 18%, respectively, for 
the high prevalence population. 
The major strengths of our systematic review with meta-analysis include the 
comprehensive search, adherence to criteria for conducting a meta-analysis, 
and the qualitative assessment of the studies. Furthermore, an extensive 
overview of all studied diagnostic tests is provided.   
With regard to the individual studies included in this review, study methods 
vary widely. Different criteria have been used for patient recruitment; many 
studies included subjects with suspected NAFLD (based on elevated liver 
enzymes, steatosis on US or suffering from one or more components of the 
metabolic syndrome, 40%), being overweight/obese and undergoing a liver 
biopsy (whether or not during bariatric surgery, 20%) or proven NAFLD without 
further specification (about 30%). It should be noted that the selection criterion, 
having elevated liver enzymes and/or steatosis on US, could lead to work-up 
bias. Furthermore, selection bias should be taken into account, as not all NAFLD 
patients have elevated liver enzymes and more severely ill patients are more 
likely to undergo a liver biopsy. However, liver biopsy still is the current gold 
standard to diagnose NASH. Therefore, studies including (healthy) subjects 
without liver biopsy in the calculation of the diagnostic values (n=16), were 
included in the review and supplementary tables, but not in the meta-analysis, 
as for a substantial part of the subjects in the analysis no appropriate gold 
standard was available. Although the majority of studies used the criteria by 
Brunt et al.105 or Kleiner et al.106 to score liver biopsies (see supplementary 
tables),  the criteria applied did differ between studies. Furthermore, not all 
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studies reported data on the quality of histology (e.g. adequate biopsy length, 
number of portal tracts) and/or fibrosis stage. Expectation bias is thought to be 
low, as in 60% of studies the liver biopsy results were interpreted without 





















Figure 6.4  Domains that play an important role in the progression of NAFLD to NASH, such as 
inflammation, metabolic make up and fibrogenesis. A marker set combining markers 
from these processes could help to non-invasively diagnose NASH. Pooled markers 
(evaluated in at least 2 studies) and high potential markers, showing both sensitivity 
and specificity ≥80% in single studies, are indicated in the respective domains. 
Abbreviations: Cytokeratin (CK), Fibroblast growth factor (FGF), Tissue polypeptide 
specific antigen (TPS), Tissue inhibitor of metalloproteinase (TIMP), 
Neutrophil/lymphocyte ratio (N/L ratio),  Interleukin (IL), Homeostatic model 
assessment-insulin resistance (HOMA-IR),  Fucosylated-haptoglobin (Fuc-Hpt), Mac2 
binding protein (Mac2bp). 
 
 
Furthermore, it should be noted that this review focused on diagnostic tests that 
could replace liver biopsy (test replacement strategy), and was not aiming to 
identify subjects at risk for NASH, as these risk scores usually have a large grey 
area in which patients cannot be classified and liver biopsies are still necessary. 
When calculating the positive and negative predictive values (PPV and NPV 
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respectively) of the promising scores49,73,91,101 and omics approaches37 in 
hypothetical high (50%) and low (10%) prevalence NASH populations, PPV and 
NPV would be 37.5-69.2% and 97.0-98.7%, respectively, for the low prevalence 
population and 84.3-95.9% and 84.2-94.1%, respectively, for the high 
prevalence population. This indicates that especially in the low prevalence 
population the promising tools could serve as screening tools to identify patients 
with only steatosis and thereby avoid liver biopsy in these patients. 
 
Although promising scoring systems as non-invasive diagnostic tests for NASH 
were found in single studies, none of the pooled results revealed both good 
sensitivity and specificity (≥80%). Replication studies and more standardised 
study designs on non-invasive diagnostics for NASH are urgently needed; as 
methodological differences and limitations hinder comparisons between 
studies. Based on the results and the multifactorial pathogenesis, combining 
markers related to various pathophysiologic processes is anticipated to have the 
highest potential to non-invasively diagnose NASH. For the time being, no 
blood marker, either as single marker or as part of a scoring system, can be 
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Figure S6.1 QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) assessment; an 
overview with regards to risk of bias (low, unclear, high) and concerns regarding 
applicability (low, unclear, high) is shown. 
 










































Figure S6.2  Forest plots for pooled sensitivity of gamma-glutamyl transferase (GGT) (A), pooled 
specificity of GGT (B), pooled sensitivity of alkaline phosphatase (ALP) (C), pooled 
specificity of ALP (D), pooled sensitivity of ferritin (E), pooled specificity of ferritin (F). 
Any discrepancy between the sensitivity and specificity for an individual study given in 
the forest plot and the original article is due to rounding off and/or reported missing 
data. A difference of ≤2% was accepted. Abbreviations: non-alcoholic steatohepatitis 






































Figure S6.3 Forest plots for pooled sensitivity of neutrophil/lymphocyte ratio (N/L ratio) (A), pooled 
specificity of N/L ratio (B), pooled sensitivity of adiponectin (C), pooled specificity of 
adiponectin (D), pooled sensitivity of fibroblast growth factor (FGF) 21(E), pooled 
specificity of FGF-21(F). Any discrepancy between the sensitivity and specificity for an 
individual study given in the forest plot and the original article is due to rounding off 
and/or reported missing data. A difference of ≤2% was accepted. Abbreviations: non-
alcoholic steatohepatitis (NASH), confidence interval (CI). 
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Figure S6.4 Forest plots for pooled sensitivity of cytokeratin (CK) 18-M30 (highest sensitivity) (A), 
pooled specificity of CK18-M30 (for highest sensitivity cut-offs) (B), pooled sensitivity of 
CK18-M30 (for highest specificity cut-offs) (C) and pooled specificity of CK18-M30 
(highest specificity) (D). Abbreviations: non-alcoholic steatohepatitis (NASH), 







































Figure S6.5 Forest plots for pooled sensitivity of homeostatic model assessment for insulin 
resistance (HOMA-IR) (A), pooled specificity of HOMA-IR (B), pooled sensitivity of 
fucosylated-haptoglobin (Fuc-Hpt) (C), pooled specificity of Fuc-Hpt (D), pooled 
sensitivity of Mac2 binding protein (Mac2bp) (E), pooled specificity of Mac2bp (F). Any 
discrepancy between the sensitivity and specificity for an individual study given in the 
forest plot and the original article is due to rounding off and/or reported missing data. 
A difference of ≤2% was accepted. Abbreviations: non-alcoholic steatohepatitis 
(NASH), confidence interval (CI). 
 



































Figure S6.6 Forest plots for pooled sensitivity of triglycerides (TG) (A), pooled specificity of TG (B), 
pooled sensitivity of total cholesterol (TC) (C), pooled specificity of TC (D), pooled 
sensitivity of GlycoNASH test (E), pooled specificity of GlycoNASH test (F). Any 
discrepancy between the sensitivity and specificity for an individual study given in the 
forest plot and the original article is due to rounding off and/or reported missing data. 
A difference of ≤2% was accepted. Abbreviations: non-alcoholic steatohepatitis 




Figure S6.7 Forest plots for pooled sensitivity of NASHTest (NASH vs bNASH+SS) (A), pooled 
specificity of NASHTest (NASH vs bNASH+SS) (B), pooled sensitivity of NASHTest 
(NASH+bNASH vs SS) (C) and pooled specificity of NASHTest (NASH+bNASH vs SS) (D). 
Abbreviations: non-alcoholic steatohepatitis (NASH), simple steatosis (SS), borderline 
(b), confidence interval (CI). Any discrepancy between the sensitivity and specificity for 
an individual study given in the forest plot and the original article is due to rounding off 
and/or reported missing data. A difference of ≤2% was accepted. 
Due to the extent of Supplementary Tables S6.1-S6.3 (128 pages), they were not 
printed in this thesis. The tables can be accessed on https://ars.els-
cdn.com/content/image/1-s2.0-S1542356517309904-mmc3.pdf 
(Supplementary Table S6.1), https://ars.els-cdn.com/content/image/1-s2.0-
S1542356517309904-mmc4.pdf (Supplementary Table S6.2) and 
https://ars.els-cdn.com/content/image/1-s2.0-S1542356517309904-
mmc5.pdf (Supplementary Table S6.3). 
Non-invasive tests do not accurately differentiate NASH from SS 
165
6 
Table S6.4  Sensitivity analysis: an overview of the pooled sensitivity and specificity using the mada 
package of R 









8 63.0 (40.0-81.3) 447 74.4 (55.2-87.3) 566 
15 68.3 (62.5-73.5) 1017 71.8 (67.2-76.0) 839 
ALT    
CK18-M30     
HOMA-IR 6 68.4 (55.5-79.0) 274 69.6 (62.5-76.0) 230 
Subanalyses 
   CK18-M30 highest sensitivity 7 80.8 (72.9-86.7) 303 60.5 (41.0-77.2) 316 
   CK18-M30 highest specificity 7 53.2 (34.9-70.7) 303 91.4 (79.9-96.6) 316 
Non-alcoholic steatohepatitis (NASH) is the number of patients diagnosed with NASH via liver 
biopsy. Simple steatosis (SS) is the number of patients with biopsy proven simple steatosis (Whether 
or not this includes SS or the combination of SS and normal (NL) depends on the individual studies). 
Due to interstudy variation with regards to the classification used to define NASH, whether or not 
borderline NASH was included in the NASH group or in the NoNASH group depends on the 
individual studies and classification system used (supplementary tables). Abbreviations: alanine 
aminotransferase (ALT),  cytokeratin (CK), homeostatic model assessment for insulin 






Crashing NASH in patients listed for  
bariatric surgery 
Toon De Munck, Pauline Verhaegh, Jef Verbeek, Joanne Verheij, Jan Willem Greve,  
Daisy Jonkers, Ad Masclee, Ger Koek 
Obes Surg. 2019;29(3):1012-1014 
Chapter 7 
168
Crashing NASH in patients listed for bariatric surgery 
169
7 
We read, with great interest, the publication of Ooi et al. describing the 
prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic 
steatohepatitis (NASH) in a bariatric population.1 They discussed the fact that 
there is a large variation in NASH prevalence in bariatric studies ranging from 
7.3% to 56%. In their cohort they found a NASH prevalence of 17.1%, which 
was lower-than-expected based on previous literature. This lower than expected 
NASH prevalence was in line with our observation. We intra-operatively 
collected liver needle and wedge biopsies from 20 obese patients undergoing 
bariatric surgery (Table 7.1).  
Table 7.1 Patient characteristics 
Total group n=20 
Age (years) 51 (37.8-57.0) 
Female gender  13/20 (65%) 
BMI before crash (kg/m2) 41.2 (40.1-42.5) 
BMI after crash (kg/m2) 38.6 (37.5-40.3) 
Weight loss (kg) 8.0 (6.0-8.8) 
Weight loss (%)  6.2 (5.3-7.6) 
Hypertension (y/n) 9/20 (45%) 
Type 2 diabetes mellitus (y/n) 4/20 (25%) 
Dyslipidemia (y/n) 6/20 (30%) 
Obstructive sleep apnoea (y/n) 8 (40%) 
Total Cholesterol  (5.0-6.4 mmol/L) 4.3 (4.0-4.6) 
LDL-C (3.5-4.4 mmol/L) 2.7  (2.2-2.9) 
HDL-C (>0,9 mmol/l) 1.0 (0.8-1.2) 
Triglycerides (0.80-1.94 mmol/l) 1.3 (0.9-2.3) 
ALT (F <34, M <45U/L) 31.0 (19.0-39.8) 
AST (F <31, M <35U/L) 26.5 (19.0-30.8) 
GGT (F <38, M <55U/L) 22.5 (17.3-28.0) 
ALP (F <98, M <115U/L) 82.5 (73.3-96.8) 
Fasting glucose  (3.1-6.1mmol/L) 5.4 (5.0-5.9) 
HbA1C  (25-44 mmol/mol) 35.0 (33.0-42.8) 
Continuous variables are expressed as median (Q1-Q3). Categorical variables are expressed as 
number (percentage of the total group). Abbreviations: Body mass index (BMI), Alanine 
aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-glutamyl transferase (GGT), 
Alkaline phosphatase (ALP), Low-density lipoprotein cholesterol (LDL-C), High-density lipoprotein 
cholesterol (HDL-C), glycosylated haemoglobin, type A1c (HbA1c).  
Patients with significant alcohol use (>14 standard beverages a week for men 
and >7 for women), secondary causes of hepatic fat accumulation and chronic 
inflammatory diseases other than NASH were excluded. Strikingly, NASH, 
defined as the combined presence of steatosis, lobular inflammation and 
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hepatocyte ballooning, was not present in any of our obese patients and the 
maximal NAFLD activity score was only three (Table 7.2). 
 
Table 7.2 Histological evaluation of liver biopsies 




Ballooning* Fibrosis NAS SAF 
1 0 0 0 0 0 0 S0A0F0 
2 0 0 0 0 0 0 S0A0F0 
3 0 0 0 0 1 0 S0A0F1 
4 0 1 0 0 0 1 S0A1F0 
5 0 1 0 0 0 1 S0A1F0 
6 0 1 1 0 0 0 S0A1F0 
7 0 1 2 0 1 1 S0A2F1 
8 1 0 1 0 1 1 S1A0F1 
9 1 1 0 0 2 2 S1A1F2 
10 1 1 1 0 0 2 S1A1F0 
11 1 1 1 0 1 2 S1A1F1 
12 1 1 1 0 1 2 S1A1F1 
13 1 1 1 0 1 2 S1A1F1 
14 1 1 2 0 1 2 S1A1F1 
15 1 1 2 0 2 2 S1A1F2 
16 1 1 2 0 2 2 S1A1F2 
17 1 2 2 0 2 3 S1A2F2 
18 2 1 0 0 1 3 S2A1F1 
19 2 1 0 0 1 3 S2A1F1 
20 2 1 0 0 1 3 S2A1F1 
Steatosis: 0: <5%, 1: 5%-33%, 2: 34%-66%, 3: >66%. Lobular Inflammation: 0: no foci, 1: <2 
foci/200 x field, 2: 2-4 foci/200 x field, 3: >4 foci/200 x field. Portal inflammation: 0: none, 1: mild, 
2: moderate, 3: severe. Fibrosis: 0: none, 1: perisinusoidal or periportal, 2: perisinusoidal and 
portal/periportal, 3: bridging fibrosis, 4: Cirrhosis. * Ballooning is scored using the SAF (Steatosis, 
Activity, Fibrosis) and Kleiner scoring system. In both scoring systems all biopsies scored 0. 
Abbreviations: NAFLD activity score (NAS), Steatosis, Activity and Fibrosis score (SAF). 
 
 
Questions arise why none of our patients had NASH. We hypothesise that the 
absence of NASH in our cohort could be related to the pre-operative low-calorie 
diet (so-called crash diet).  All our patients received a 4-week food-based crash 
diet as part of standard clinical care. Crash diets have been shown to reduce liver 
volume by 12% and intrahepatic fat by 40%.2 The median amount of weight loss 
in our cohort after the 4-week crash diet was 8.0 kg or 6.2% of total body 
weight. Recently, it has been shown that this amount of weight loss (5-10% of 
initial body weight) can lead to improvement of lobular inflammation, 
hepatocellular ballooning and NASH resolution in 84%, 64% and 45% of the 
cases respectively.3 Although we cannot prove the presence of NASH before 
initiation of the diet, the presence of fibrosis in 14/20 (70%) patients is 
suggestive for burned-out NASH with resolution of hepatocyte ballooning after 
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the dietary intervention.4 A pre-operative diet is prescribed in numerous 
bariatric centres in order to decrease liver volume, to diminish operation time, 
complexity and post-operative complications.5,6 Although encouraged, pre-
operative weight loss is not obligated in all bariatric centres.7 However, a survey 
among 99 Australian dieticians revealed that all dieticians provide bariatric 
patients with some form of nutritional intervention in the pre-operative stage.8 
Therefore, our question to Ooi et al. is if a crash diet or other type of pre-
operative dietary intervention was prescribed before the operation. 
Taken together, we hypothesise that large variations in NAFLD and NASH 
prevalence between different bariatric studies may be at least partly explained 
by the use of a pre-operative crash diet. In addition, a crash diet may lead to bias 
in NASH biomarker and pathophysiology research. Therefore, we advocate that 
the application of a pre-operative diet or other pre-operative interventions 
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Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of 
chronic liver disease worldwide due to the rising prevalence of obesity, diabetes 
mellitus, and metabolic syndrome. This confronts us with the challenge to 
adequately identify and manage these patients at population level. General 
practitioners (GPs), as the gatekeepers of our health care system, may play a 
major role in this important health issue. We aimed to investigate the 
knowledge and practices concerning NAFLD among Dutch GPs. 
Methods 
A survey, by using a questionnaire, was performed among GPs in the area of 
Maastricht, Netherlands, from April 2016 to May 2016. 
Results 
The acronyms NAFLD and NASH (non-alcoholic steatohepatitis) were not 
known by 34% and 53% of the GPs, respectively. Although 63% of the GPs 
acknowledged NAFLD as an important health problem, most GPs never (33%) or 
rarely (63%) screened for its presence. Referral to specialist care was highly 
dependent on the presence of increased liver enzymes. Lifestyle advice (weight 
loss) and referral to a dietician were mostly applied as treatment. Referral to an 
obesity treatment facility or starting medication rarely occurred. Follow-up of 
patients with NAFLD was usually done on a yearly basis (52%). The need for 
increased awareness and knowledge on NAFLD in the field of primary care was 
endorsed by 84% of the GPs. 
Conclusion 
In dialogue with GPs, we should develop, validate, and communicate, non-
invasive tools and algorithms for the detection, referral, and (parallel) follow-up 
of high-risk individuals of NAFLD progression in the primary care setting in the 
Netherlands, taking into account cost-effectiveness.  




Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of 
chronic liver disease worldwide due to the rising prevalence of obesity, diabetes 
mellitus, and metabolic syndrome.1,2 It is estimated that the global prevalence of 
NAFLD is as high as 1 billion individuals.1 Non-alcoholic steatohepatitis (NASH) 
is the most rapidly growing indication for liver transplantation in the United 
States.3 In order to counter these alarming trends, a better knowledge and 
understanding of factors associated with poor outcomes in NAFLD is needed. 
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD; 
no other histologic features are associated with long-term outcomes of patients 
with NAFLD.4,5 Koehler et al.6 demonstrates the high prevalence of liver fibrosis 
in the context of NAFLD in a large, population-based cohort in the Netherlands. 
These results confront us with the challenge to adequately identify and manage 
these  patients at general population level.7 In this respect, general practitioners 
(GPs), as gatekeepers of our health care system, may play a major role. With the 
rapidly growing health problem of NAFLD, we aimed to investigate the 
knowledge and current medical approach concerning NAFLD among Dutch GPs. 
Methods 
General practitioners 
We performed a survey among GPs in the area of Maastricht, The Netherlands, 
from April 2016 to May 2016. Questionnaires were sent to 120 GPs in the area of 
Maastricht. 
Questionnaire 
The questionnaire consisted of 22 questions of which the first five questions 
were about baseline characteristics. The remaining 17 questions were included 
to get more insight in the knowledge and approaches of GPs concerning NAFLD 
(including e.g. screening and diagnosing NASH/referral/treatment). An 




Data were analysed using SPSS version 23 statistical software (IBM Statistics for 
Macintosh, Chicago, IL, USA). GPs’ baseline characteristics and knowledge and 
practices regarding NAFLD were reported as mean and standard deviation or 
median and range, when appropriate, for continuous variables and as absolute 
numbers and percentages for categorical variables. 
Results 
In total, 64 GPs completed the questionnaire (response rate 53%). Baseline 
characteristics of the participating GPs are depicted in Table 8.1. 
Table 8.1 Baseline characteristics 
Total group of GPs 
Age (years) 44.7 (10.8) 
Gender (F/M [%])* 31/32 (49%/51%) 
Experience (years) 14.0 (10.9) 
Number of patients a week  108  (40.5) 
Continuous variables are expressed as mean ±standard deviation (SD) and categorical variables are 
expressed as absolute numbers and percentages. *one missing value 
Screening for NAFLD and differentiating NASH 
Strikingly, 34% and 53% of the GPs, respectively, were not familiar with the 
acronyms NAFLD and NASH. Although 63% of the GPs acknowledged NAFLD to 
be an important health problem, 33% of the GPs never and 63% only rarely 
screened for its presence. Methods used for screening for NAFLD are shown in 
Figure 8.1.  
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Figure 8.1 Bar chart showing how often (always/often/rarely/never) different methods were used 
to screen for non-alcoholic fatty liver disease (NAFLD). Percentages based on the 
number of GPs that indicated to screen for NAFLD; 42 out of 64 GPs, except for ‘non-
invasive serum markers’ (N=39 GPs). 
GPs were also questioned about the difference between simple steatosis and 
NASH. Although 80% of the GPs acknowledged the importance of 
differentiating simple steatosis from NASH, only 47% of the questioned GPs did 
this in daily practice. 51% of the GPs always or often used liver enzymes and 
44% always or often used liver ultrasound to differentiate between simple 
steatosis and NASH. Non-invasive serum markers/scores other than liver 
enzymes were never (73%) or rarely (22%) used for this purpose (Figure 8.2).  
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Figure 8.2.  Bar chart showing how often (always/often/rarely/never) different methods were used 
to differentiate between simple steatosis and NASH. Percentages based on the number 
of GPs that indicated to differentiate between simple steatosis and NASH; 50 out of 64 
GPs for liver enzymes and ultrasounds and 41 out of 64 GPs for non-invasive serum 
markers. 
Referral 
Referral to specialist care turned out to be highly dependent on the presence of 
increased liver enzymes. Patients with liver steatosis on ultrasound and normal 
liver enzymes were never or rarely referred (53% and 47% respectively). In 
contrast, 57% of patients with liver steatosis and abnormal liver enzymes were 
referred by GPs (being often 47% and always 10%) (Figure 8.3). In case of 
referral, the majority of GPs (95%) referred their patients to gastroenterologists 
or hepatologists. 
The increasing burden of NAFLD in the general population 
181
8 
Figure 8.3.  Bar chart showing how often (always/often/rarely/never) different reasons led to 
referral of a patient to the medical specialist. Percentages based on the number of GPs 
that indicated to refer to a medical specialist; 51 out of 64 GPs, 48 out of 64 GPs, 52 out 
of 64 GPs respectively for ‘abnormal liver enzymes’, ‘steatosis on ultrasound’ and 
‘cirrhosis on ultrasound’. 
Treatment 
In case GPs would start treatment for NAFLD, lifestyle advice (weight loss) (often 
in 37% and always in 60%) and referral to a dietician (often in 64% and always 
in 10%) were mostly applied as treatment. Referring a patient to a physical 
therapist was less common (never in 32% and rarely in 59%) and referral to an 
obesity treatment facility (never in 8% and rarely in 78%) or starting medication 
(never in 80% and rarely in 18%) was seldom done (Figure 8.4). Follow-up of 
patients with NAFLD was usually done once a year (52%) compared to never 
(19%), twice a year (24%) or more than twice a year (5%). 
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Figure 8.4.  Bar chart showing how often (always/often/rarely/never) different treatment options 
were chosen to treat NAFLD patients. Percentages based on the number of GPs that 
indicated to start treatment; 63 out of 64 GPs, except for ‘Start medication’ (N=61 GPs). 
Awareness and guidelines 
GPs are not familiar with current clinical practice guidelines on NAFLD as 
developed by our national and international hepatology medical societies. Only 
one of the questioned GPs consulted the clinical practice guidelines of the 
European Association for the Study of the Liver (EASL) or the American 
Association for the Study of Liver Diseases. However, 86% of the GPs consulted 
the Dutch general practitioners guidelines for liver diseases. The need for 
increased awareness and knowledge on NAFLD in the field of primary care was 
endorsed by 84% of the GPs. 
Discussion 
Our aim was to obtain a snapshot of the knowledge and current approaches 
concerning NAFLD in primary care. The results of our questionnaire indicate the 
need for increased awareness and knowledge on NAFLD in primary care. Our 
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findings, together with those of Koehler et al.,6 demonstrate the urgent need for 
the gastroenterology and hepatology societies to reach out and start training and 
informing GPs.  
The growing burden of obesity has resulted in a global prevalence of NAFLD of 
more than 25%.8 The number of patients diagnosed and referred with NAFLD is 
expected to rise even further in the near future. Although there is substantial 
evidence that some NAFLD patients have an increased risk to develop 
progressive liver disease that can lead to cirrhosis and liver cancer or to develop 
diabetes, specific risk factors to identify these patients are currently lacking.9 
Due to the high prevalence but low severity of NAFLD evidence based guidelines 
with regard to selection of patients for referral to secondary care and for follow-
up of patients in primary care are urgently needed. Only by doing so, we will be 
able to manage this health issue in the coming years.  
The current Dutch general practitioners guideline for liver diseases has also 
included NAFLD in their guideline for liver disease. It states that NAFLD is the 
most common cause of asymptomatic, mildly elevated liver enzymes and should 
be suspected in patients with obesity, diabetes mellitus or dyslipidaemia. 
However, it is a diagnosis of exclusion. Lifestyle advice is the recommended 
treatment. Furthermore, a cardiovascular risk profile should be assessed and 
yearly follow-up of alanine aminotransferase (ALT) levels should be performed. 
Referral to a gastroenterologist should only be considered in case of persistent 
elevated ALT levels (1.5-10 times upper limit of normal) or in case of doubt 
about the diagnosis.10 While this guideline focusses on elevated liver enzymes, it 
is known that the entire histologic spectrum of NAFLD can be seen in individuals 
with normal ALT values.11 
The EASL guideline (2016) “Clinical Practice Guidelines for the management of 
non-alcoholic fatty liver disease” provides a flow-chart (Figure 1 in the EASL 
guideline, p 1393)12 for the proposed assessment and monitoring in the 
presence of suspected NAFLD and metabolic risk factors both in the presence 
and absence of liver enzyme elevation.  
The EASL guideline advises screening for NAFLD by use of an abdominal 
ultrasound in individuals with obesity, type 2 diabetes mellitus, metabolic 
syndrome, or incidentally discovered abnormal aminotransferase levels. In case 
significant fibrosis cannot be ruled out non-invasively by using fibrosis scores, 
e.g. Fibrosis-4 score (FIB-4),13 a patient should be referred to a specialist.12 The
use of transient elastography (FibroScan®) in secondary care could be useful in
this group to rule out or confirm significant fibrosis. Then a liver biopsy is only
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indicated in patients with invalid FibroScan® measurements or in case of doubt 
about the diagnosis. 
In addition, the EASL guideline advises for all cases with diabetes or diabetes 
risk to go to a diabetes clinic for optimal management. Those with diabetes risk 
and patients with obesity should be included in structured lifestyle modification 
programs. Finally, all cases should receive cardiovascular disease work-up.12  
The optimal follow-up regimen of patients with NAFLD still needs to be 
determined. In this respect, risk of progression and workload for healthcare 
providers need to be considered. The EASL guideline advises to monitor patients 
with NAFLD without worsening of metabolic risk factors at 2-3 years intervals. 
Patients with NASH and/or fibrosis should be monitored more frequently, once 
a year. This group should most probably be followed up by a hepatologist, and 
not in primary care. Monitoring should include routine biochemistry, 
assessment of comorbidities and non-invasive monitoring of liver fibrosis.12  
It is crucial to get a better insight in patients at risk for disease progression. Until 
specific risk factors or risk profiles have been identified, the flowchart provided 
by the EASL guideline should be followed to help route patients to the right 
healthcare professional. 
In conclusion, our survey showed the need for increased awareness and 
knowledge on NAFLD in primary care. We should validate and communicate 
algorithms for the detection, referral, and (parallel) follow-up of NAFLD patients 
in the primary care setting in the Netherlands with GPs. Thereby, taking into 
account cost-effectiveness. Only close harmony between primary care and 
hepatologists will decrease the number of patients with undiagnosed 
NAFLD/NASH and insufficient referral. 
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Survey General Practitioners -  Liver disease  
Dear colleague, 
We are researchers of the department gastroenterology and hepatology at the 
MUMC+. At this moment we are investigating, in cooperation with the 
department of primary care, diagnosis and treatment of common liver diseases 
in primary care. Our goal is to improve the collaboration between primary care 
and secondary/tertiary care. We are looking for general practitioners (GP) that 
are willing to fill in a short questionnaire on this topic. All records will be 
handled anonymously. Filling in the questionnaire will take about 5 minutes of 
your time. After completing the questionnaire you can return it in the attached 
return envelope.   
Thank you in advance for your cooperation! 
M. van Asten, final year medical student
Dr. J. Verbeek, Gastroenterologist in training
Dr. G. Koek, Gastroenterologist
DATE: …………………………………………………………………………………… 
NAME GENERAL PRACTITIONER: 
Sir/Madam…………………………………………...............…………………. 
NAME GP practice: 
………………………………………………………………………………….…………. 
CITY GP practice: 
……………………………………………………………………………………………… 
……………………………………………………………………………………………… 
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1. What is your age? 
 ………….. years old 
2. How many years are you working as a trained GP? 
…………. years. In case of GP in training, number of years working as a GP in training: 
………… years.  
3. How many patients do you see on average in a week? 
……………………………………………………………………………………………………….. 
4. Are you familiar with the abbreviation NAFLD (circle your answer)
a) no b) yes; what does the abbreviation stand for:
 ……………………………………………………….. 
5. Are you familiar with the abbreviation NASH? (circle your answer) 
a) no b) yes; what does the abbreviation stand for:
……………………………………………………… 
The following questions are on fatty liver/steatosis hepatis in the context of metabolic 
syndrome. 
6. Do you have an idea what percentage of the general adult Dutch population has liver 
fat in the context of metabolic syndrome?
Answer: ……….. % 
7. The following questions are on screening for the presence of steatosis hepatis.
Do you actively screen for steatosis hepatis? (circle your answer)
a) never (continue to question 10)   b) rarely 
c) often d) always
8. In case you do screen, what is your motivation to screen for steatosis hepatis? (circle 
your answer) 
 Obesity never / rarely / often / always 
Hypertension never / rarely / often / always 
Hypercholesterolaemia  never / rarely / often / always 




9. In case you screen, do you never, rarely, often or always using (circle your answer): 
a) Liver enzymes never / rarely / often / always 
b) Ultrasound of the liver never / rarely / often / always 
c) Excluding other causes of liver disease 
(HBV, HCV, EBV, CMV, HEV) never / rarely / often / always 
d) Non-invasive blood markers/scores,
other than routine liver enzymes never / rarely / often / always
e) Other, namely …………………………………………………………………………… 
10. Do you think it is important to differentiate between simple steatosis and chronic 
liver inflammation? (circle your answer)
a) no b) yes 
11. Do you differentiate between simple steatosis and chronic liver inflammation? (circle 
your answer) 
a) no b) yes 
12. How do you differentiate between simple steatosis and chronic liver inflammation?
Are you never, rarely, often or always using (circle your answer): 
a) Liver enzymes never / rarely / often / always 
b) Imaging (ultrasound) of the liver never / rarely / often / always 
c) Non-invasive serum markers/scores never / rarely / often / always 
d) Other, namely ……………………………………………………………………………… 
13. In case you suspect steatosis hepatis in the context of metabolic syndrome in a 
patient, do you never, rarely, often or always refer this patient to a medical 
specialist? (circle your answer)
a) never b) rarely c) often d) always 
14. In case you refer a patient, what are your motives for referral? (circle your answer) 
a) Elevated liver enzymes never / rarely / often / always 
b) Steatosis on ultrasound never / rarely / often / always 
c) cirrhosis / portal hypertension on ultrasound never / rarely / often / always 
d) Other, namely …………………………………………………………………………………. 
15. How often do you refer a patients with steatosis hepatis on ultrasound and normal 
liver enzymes to a medical specialis? (circle your answer) 
a) never b) rarely c) often d) always 
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16. How many patients with steatosis hepatis on ultrasound and abnormal liver enzymes 
do you refer to a specialis? (circle your answer)
a) never b) rarely c) often d) always 




c) Other, namely………………………………………………………………………………………… 
18. Do you consult the following guidelines on diagnosis and treatment of steatosis
hepatis (circle your answer): 
a) Dutch general practitioner guideline yes / no 
b) AASLD (American Association for the Study of Liver Diseases)
guideline on NAFLD yes / no
c) EASL (European Association for the Study of Liver)
guideline on NAFLD yes / no 
d) Other, namely ………………………………………………………………………………….. 
19. The following questions are on the treatment of patients with steatosis hepatis.
Do you never, rarely, often or always (circle your answer): 
a) Give the advice to lose weight never / rarely / often / always 
b) Refer to a dietician never / rarely / often / always 
c) Refer to a physical therapist never / rarely / often / always 
d) Refer to a medical specialist never / rarely / often / always 
e) Refer to an obesity clinic (e.g. CO-EUR) never / rarely / often / always 
f) Start medication never / rarely / often / always 
g) In case you start medication, what do you start?………………………………………..  
e) Other, namely ..…………………………………………………………………….…………….. 
20. How often per year do you follow-up patients with steatosis hepatis? (circle your 
answer) 
a) never b) once a year c) twice a year d) more than twice a year 
21. Is steatosis hepatis/NAFLD in your opinion an important health problem? (circle 
your answer)
a) no b) yes 
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22. Should something about the awareness and knowledge on steatosis hepatis be 
improved in primary care, according to you? In case your answer is yes, what and 
how? (circle your answer) 
a) no b) yes, 
 namely………………………………………………………………………………… 
 …………………………………………………………………………………………… 
This is the end of the questionnaire. Thank you very much for your cooperation! 















In this thesis, we aimed to gain further insight in underlying pathophysiological 
mechanisms  and non-invasive diagnostic tools for non-alcoholic steatohepatitis 
(NASH). 
With regard to pathophysiological mechanisms, this thesis addressed hepatic 
factors, namely liver sinusoidal endothelial cells and the role of ferritin, but also 
extrahepatic factors, namely the skeletal muscles. Furthermore, an extensive 
overview of non-invasive biomarkers and scores was presented. Finally, the role 
of general practitioners (GPs) in identifying and managing NAFLD patients was 
discussed. 
Pathophysiology: How far have we reached? 
Getting further insight in factors contributing to the onset and development of 
NASH is relevant to help identifying NAFLD patients at risk for disease 
progression.  
Although the exact pathophysiology of NAFLD is not yet clear, much progress 
has been made in the last three decades.  
In 1998, the two-hit theory was proposed to explain NAFLD disease 
progression.1 According to this theory, the first hit is triggered by lipid 
accumulation in hepatocytes. This would predispose the liver to a second hit, for 
example oxidative stress, which would be required for the development of 
NASH.  
Growing interest in NAFLD led to an increase in research and the concept 
evolved to a ‘parallel multiple hit theory’,2 in which it was suggested that not 
simple steatosis but insulin resistance (IR) may induce inflammation in NAFLD. 
In this theory, steatosis is only seen as a marker of insulin resistance, since 
insulin resistance is the most important factor predisposing to hepatic free fatty 
acid (FFA) accumulation due to lipolysis of peripheral fat and exacerbated 
hepatic lipogenesis.3 After initial hepatic fat infiltration, the liver becomes 
vulnerable for parallel hits such as oxidative damage and gut- and adipose 
tissue-derived signals, which play a central role in the cascade of inflammation 
in NASH.2 This theory conceptualises NASH as a condition which is generally 
preceded by simple steatosis from a histological point of view and insulin 
resistance from a pathophysiological point of view.  
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Thereafter, the ‘distinct hit theory’ emerged, in which simple steatosis and 
NASH are regarded as two separate pathological entities caused by IR. Hereby, 
NASH may present without any or with much steatosis. Steatosis in NASH is 
considered a benign epiphenomenon rather than a causal factor of inflammation 
and fibrosis, which are the two main hallmarks of NASH.3,4 Triglyceride 
accumulation as lipid droplets, as seen in simple steatosis, seems to be an 
adaptive, beneficial response in situations where hepatocytes are exposed to 
potentially toxic cholesterol and FFA metabolites due to IR and increased caloric 
consumption.2 Accumulation of triglycerides is not a pre-requisite for the 
development of NASH. In NASH, it is thought that hepatic metabolism of FFAs 
and cholesterol leads to the formation of toxic metabolites i.e. ceramides, 
diacylglycerols, lysophosphatidylcholine (lipotoxicity), which are considered to 
be responsible for oxidative stress, inflammation and liver cell injury.2,3 
However, the exact underlying mechanisms of the formation of lipotoxic 
intermediates at molecular levels remain to be elucidated.5 As triglyceride 
accumulation often is a process parallel to the development of lipotoxic injury, it 
is however difficult to separate the respective roles of triglycerides and FFA 
metabolites in causing inflammation and cell injury.5 
In chapter 2, the ultrastructure of the liver in human NAFLD samples was 
studied, focusing on liver sinusoidal endothelial cells (LSECs) and their 
fenestrae. LSECs form the liver endothelium and are highly specialised cells, 
being at the interface between blood derived from the visceral adipose tissue and 
the gut on the one side and hepatic stellate cells and hepatocytes on the other 
side. LSECs have a unique phenotype, they lack a basement membrane and have 
fenestrae organised into sieves that regulate the transport of macromolecules, 
including lipids and lipoproteins across the sinusoid.6 We showed that 
defenestration is more common in patients with simple steatosis compared to 
patients with NASH. This finding can be supportive for the ‘distinct hit theory’ 
as it could be argued that defenestration is a protective mechanism to handle the 
excess in lipids and perhaps other toxic substances provided to the liver. By 
inhibiting the entry of chylomicron remnants into the space of Disse,7 
defenestration could protect the liver from receiving more lipids. However, 
defenestration could also contribute to triglyceride accumulation as it impairs 
the passage of VLDL excretion towards the sinusoidal lumen, thereby 
contributing to hepatic lipid accumulation.6 Additionally, inhibition of lipid 
uptake due to defenestration has been proposed to lead to stimulation of de novo 




that hydroxymethylglutaryl-CoA reductase (HMGCR), the rate limiting enzyme 
for hepatocyte cholesterol synthesis, is no longer inhibited when chylomicron 
remnants and dietary cholesterol do not cross the fenestrae into the liver, 
thereby activating endogenous cholesterol synthesis in hepatocytes.8 However, 
one can speculate that in case of defenestration as seen in simple steatosis, DNL 
could be performed at a pace that does not overwhelm beta-oxidation and re-
esterification within the liver. This would enable the liver to store the fat as 
‘innocent’ triglycerides in lipid droplets, instead of metabolising the lipids. 
Metabolization of FFA and cholesterol is suggested to cause the lipotoxic injuries 
in NASH.2,3  
The finding of defenestration in patients without NASH provides support for the 
distinct hit theory, because a distinct aetiological mechanism, that might 
contribute to the development of NASH, was shown. However, even if the 
‘distinct hit theory’ applies within NAFLD pathophysiology, multiple hits will 
probably be needed to lead to NASH.  
Another possible hit has been suggested in this thesis, namely ferritins. Ferritin 
is an iron storage protein, it comprises of 24 units of ferritin heavy and light 
chains and can store up to 4500 iron atoms bound to oxygen.9 Serum ferritin 
was associated with having NASH with significant fibrosis (F2-4) and being 
p.C2828Y or p.H63D heterozygote, in the presence and absence of
hepatocellular iron, in a cross-sectional study in biopsy proven NAFLD patients
(chapter 4). Whether ferritin levels are a consequence of inflammation or may
contribute to inflammation in NAFLD is not completely clear. A possible
mechanism via which ferritin might cause inflammation in NAFLD has been
proposed by Hevi et al. These authors studied the regulation of apolipoprotein B
(apoB) secretion from hepatocytes. It was shown that ferritin heavy and light
chains in the absence of iron, post-translationally inhibit the secretion of
apolipoprotein B.10 This caused significantly elevated amount of lipids in cells
loaded with both heavy and light chain ferritins.10 This can contribute to NAFLD
progression by increase ROS due to enhanced free fatty acid metabolism via
mitochondrial β-oxidation.3,11 Future longitudinal research projects are needed
and should include the patterns of hepatic iron depositions, to elucidate the
relation between inflammation, iron and NAFLD severity.
Extrahepatic involvement 
Even though the term NAFLD refers to a disease of the liver, there is growing 
evidence to support the concept of NAFLD as a multisystem disease. To date, 
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many studies have pointed to associations of NAFLD with cardiovascular disease 
and type 2 diabetes mellitus. Also associations of NAFLD with colorectal cancer, 
obstructive sleep apnoea, chronic kidney disease and hypothyroidism have been 
suggested.12 Since the prevalence of NAFLD is higher among patients with type 2 
diabetes mellitus, it is interesting to study the skeletal muscle because of its role 
in glucose regulation. Insulin resistance is known to play a role in the 
pathophysiology of NAFLD, as is also suggested by both the distinct hit and the 
multiple parallel hit theory.2,4 Intramyocellular lipid storage (myosteatosis) has 
been associated with the development of type 2 diabetes mellitus.13 It has been 
suggested that alterations in the muscle-liver axis, due the hepatic steatosis, 
initiate a vicious circle in which liver disease favours defective muscle protein 
growth and in which muscle loss favours metabolic alterations as well as hepatic 
steatosis and inflammation.14 
In our well characterised cohort of NAFLD patients, myosteatosis did not 
correlate with the degree of hepatic steatosis or fibrosis, but a positive 
correlation was shown with total body fat percentage and BMI (chapter 5) 
Furthermore, insulin resistance was not correlated with the amount of 
myosteatosis in our study.15  
In contrast to our study, other studies found a positive association between 
myosteatosis and the severity of hepatic steatosis16 or NASH.17 The differences 
in results compared to our study could partially be explained by differences in 
the characteristics of the study population. Our population had less diabetics, 
was younger, and comprised a smaller number of patients with elevated ALAT 
levels compared to previous studies.17,18 Unfortunately, we were not able to 
investigate the link between hepatic inflammation and myosteatosis as liver 
biopsies were not available. It is possible that myosteatosis is an important 
hallmark in hepatic inflammation but its relevance with respect to the degree of 
hepatic steatosis or fibrosis appears to be minimal. These results might suggest 
that myosteatosis is an “innocent bystander”, a way to safely store triglycerides. 
Furthermore, in our study myosteatosis was not related to insulin resistance. 
This is in line with the “athlete’s paradox”, in which athletes show levels of 
myosteatosis exceeding those of diabetics. This indicates that myosteatosis per 
se does not lead to insulin resistance, and lipid species, fat oxidative capacity 




NAFLD research: human versus animal studies  
NAFLD is a world-wide, multifactorial, lifestyle related disease resulting from a 
complex interplay between different factors such as diet, genetics, metabolic 
factors, and intestinal microbiome perturbations. Due to this complex interplay, 
the involvement of several organs and inter-individual variation in disease 
presentation, human research on NAFLD is important. This can be facilitated by 
a well-characterised cohort of NAFLD patients with bio-sampling, which can be 
followed over a longer period of time. This will help to get a better and more 
complete understanding of the natural disease course and factors that influence 
the development of progressive disease. Therefore, we have set up a 
longitudinal NAFLD cohort, in which extensive phenotyping of a NAFLD 
population was combined with bio-sampling, at 3 time points during a 10 year 
follow-up. 
This type of clinical human research is very demanding, because it takes time 
and requires liver histology obtained by (repeated) liver biopsies to be able 
diagnose NASH. Therefore, non-invasive tools are urgently needed for accurate 
diagnosis and for monitoring over time. For this reason, human studies will be 
supplemented with animal studies. Several well-accepted animal models are 
now available, such as the dietary methionine choline deficient (MCD) model. In 
this model, normal mice (ea. C57/BL6) fed the MCD diet, develop a histologic 
appearance similar to NASH. Other frequently used mouse models in NAFLD 
research are the genetic leptin-deficient (ob/ob) or leptin resistant (db/db) 
mouse.19 
Although relevant lessons about underlying mechanisms have been obtained 
from animal models, it should be noted that these models do not fully replicate 
the human NASH phenotype.19,20 In the dietary MCD model, mice lose rather 
than gain weight and do not develop insulin resistance. Furthermore, patients 
with NASH are not choline deficient.19 In the present thesis, defenestration was 
studied in human liver samples. Defenestration has also been studied in animal 
models. A study in mice deficient of Plasmalemma Vesicle Associated Protein 
(PLVAP), a protein coding gene required for the formation of fenestrae in liver 
sinusoidal endothelial cells (LSECs), showed not only development of extensive 
multivesicular steatosis, but also steatohepatitis and fibrosis at around three 
weeks of life.6,7 In contrast, our study in humans showed defenestration was 
more common in patients with simple steatosis compared to patients with 
NASH. Genetic mouse models (such as leptin-deficient [ob/ob]) are suitable to 
study isolated pathways, but one should keep in mind that these gene mutations 
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are generally not present in patients.21 Furthermore, it should be noted that 
most mouse models fail to develop important morphologic key features of 
NASH, namely hepatocyte ballooning22 and do not reflect the large inter-
individual differences with regard to host genetics, the intestinal microbiota 
composition and exposure to lifestyle factors. Even though, none of the existing 
models reflect the entire NAFLD phenotype as encountered in humans, animal 
models are important in elucidating mechanisms and pathways involved in the 
pathogenesis of the NAFLD spectrum. It remains challenging to translate the 
results from these models to humans.19,20 It is essential that key findings from 
animal experiments are confirmed in the human clinical studies. To improve 
translation into clinical setting, researchers are now using omics data from both 
patients and from animal models, where clinical phenotype, genomic 
heterogeneity, transcriptomics, and metabolomic changes are combined to be 
able to identify the most suitable NAFLD animal model for a specific scientific 
question or to test a particular drug.21,23 
Alcohol in relation to NAFLD: Dual Aetiology Fatty Liver Disease 
(DAFLD) 
NAFLD is defined as hepatic fat accumulation of >5% in the absence of 
secondary causes, including daily alcohol consumption.24 Although, the disease 
is called non-alcoholic fatty liver disease, many patients are not total abstainers. 
A daily alcohol consumption of <30 gram for men and <20 gram for women is 
allowed in case of NAFLD. Many studies on NAFLD are very strict when it comes 
to alcohol use. On the other hand, one may argue whether such differentiation 
is useful in daily clinical practice. Interestingly, administration of a moderate 
amount (20 grams) of alcohol can increase both small bowel and colon 
permeability,25 which has been suggested to play a role in NAFLD.26 Therefore, 
the term Dual Aetiology Fatty Liver Disease has been introduced, and is defined 
as having a fatty liver and consuming >20g/day of alcohol.27  
Studying moderate alcohol use in NAFLD has shown contradictory results.28,29 It 
has been associated with a lower prevalence of NASH and fibrosis when 
compared to abstinence,30,31 whereas another cohort showed less NASH 
resolution in relation to moderate alcohol use.32 Sinn et al. found that moderate 
alcohol use (<20 grams/day) was associated with decreased odds of carotid 
plaque and stenosis on duplex ultrasonography compared to non-drinkers in 
patients with NAFLD.33 However, alcohol intake has also been shown to lead to 




only the amount of alcohol consumed but also the drinking pattern should be 
taken into account, as binge drinking does not appear to have protective 
effects.30 In addition, the type of beverage appears to be relevant: while wine 
consumption is beneficial, beer consumption is not.30,34 This raises the question 
whether the protective effect is due to ethanol itself or other components in the 
beverage, such as antioxidants. With regard to recommendations on alcohol use 
in NAFLD patients, moderate alcohol use as a possible approach to reduce risk of 
disease progression in NAFLD does seem questionable. Apart from hepatotoxic 
effects, alcohol has been shown to disrupt the intestinal barrier, and changes the 
intestinal microbiota composition and activity. With the existing evidence, 
clinicians should advocate against the use of alcohol in health promotion.29 
Although, the importance of studying NAFLD pathophysiology in populations 
that do not consume alcohol for a clear overview of factors involved in NAFLD is 
argumentative, it would be interesting for clinical practice to include DAFLD 
patients in studies on NAFLD, since alcohol use is associated with the lifestyle 
that is related to NAFLD. 
Non-invasive diagnosis of NASH: the importance of early 
diagnosis 
NAFLD is usually asymptomatic, in general resulting in silent disease 
progression. To date, liver biopsy is the gold standard to diagnose NASH, but 
this is not a suitable tool for diagnosing large populations or disease 
monitoring.35 In clinical practice only subjects at increased risk of having NASH, 
usually based on elevated aminotransferase levels, undergo a liver biopsy. This 
may lead to underdiagnosis of NASH.36 Non-invasive diagnosis of NASH enables 
screening of large numbers of patients and early identification of patients at risk 
for disease progression, so early interventions can be taken to prevent 
progression. Therefore, a non-invasive diagnostic tool is urgently needed. It has 
been questioned whether it is necessary to develop a non-invasive tool to 
diagnose NASH, since fibrosis stages 1-4 were found to be the strongest 
predictor for disease-specific mortality in NAFLD.37,38 It should be mentioned 
that NASH is a recognized driver of liver fibrosis and fibrosis progression.39 
Furthermore, NASH is associated with a low grade systemic inflammation and 
with an increased risk of developing type 2 diabetes mellitus compared to 
patients with simple steatosis. In addition, associations have been shown with 
cardiovascular disease and colorectal cancer.40,41  
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A non-invasive diagnostic tool for NASH could benefit both clinical and research 
purposes to help the diagnosing and monitoring of the disease in large patient 
groups. Due to the complexity of the pathogenesis of NASH, as discussed above, 
it is unlikely that a single non-invasive marker will be able to correctly diagnose 
NASH. We showed that none of the single blood markers that were included in 
the meta-analyses, had both a sensitivity and specificity >80%. However, 
several scoring systems and –omics approaches that combined markers for 
different pathophysiological processes in NASH, such as inflammation, lipid 
metabolism and fibrosis, showed promising findings. For example the 
microRNA profile combined with CK18-asp39642 and the clinical and 
phosphoproteomic model.43 However, most of the studied markers were not 
validated and therefore a non-invasive marker for NASH is not yet available for 
clinical practice (chapter 6).44 It is important to perform validation studies, 
preferably in large unselected populations, to avoid selection- and work-up-
bias.45,46 
Interphase between primary and secondary care 
General practitioners (GPs), as gatekeepers of our health care system, are going 
to play a major role in the challenge to adequately identify and manage NAFLD 
patients at population level. Due to the high prevalence and overall low to 
moderate severity of NAFLD, GPs will encounter most of  these patients and 
become actively involved in the screening and management of patients. 
Therefore, GPs should be trained to identify subgroups of patients at risk for 
progressive liver disease and refer these patient to secondary care. Moreover, 
adequate education on the diagnosis, follow-up and treatment of low to 
moderate risk patients should be provided, taking into account cost-
effectiveness. Only by doing so, we will be able to manage this healthcare issue 
in the coming years. A better knowledge and awareness of NAFLD in primary 
care is needed. This was endorsed by 84% of the GPs in our survey (chapter 8),47 
which is in line with Australian48 and urban Western US data.49  Due to the lack 
of non-invasive diagnostic tools to identify patients at risk for disease 
progression, it is difficult for GPs to decide which patients should be referred 
and which patients can be followed in primary care. Both the EASL24 and the 
BASL guideline50 now provide a flow-chart for the proposed assessment and 
monitoring of suspected NAFLD and metabolic risk factors, which can help GPs 




The EASL guideline advises risk-based case finding for NAFLD by use of an 
abdominal ultrasound or steatosis biomarkers, like the Fatty Liver Index (FLI, 
including BMI, waist circumference, gamma-glutamyl transferase, 
triglycerides) in individuals with obesity, type 2 diabetes mellitus, metabolic 
syndrome, or incidentally discovered abnormal aminotransferase 
concentrations.24 The BASL guideline advises screening for NAFLD using the FLI 
in high-risk populations based on the presence of the metabolic syndrome or its 
components (obesity, type 2 diabetes mellitus or patients with a history of 
ischemic cardiovascular disease).50 In case significant fibrosis cannot be ruled 
out non-invasively using fibrosis scores, such as NAFLD Fibrosis Score (NFS) or 
FIB-4, a patient should be referred to a secondary care specialist.24,50 In case no 
significant fibrosis is present, patients should be monitored and periodically 
retested. The EASL recommends a follow-up every 2 years for patients with 
steatosis, but without significant fibrosis. In case steatosis and fibrosis are not 
present, but patients are considered as a high risk population, a 3-5 year follow-
up is recommended.24 The BASL guideline suggests shorter follow-up intervals, 
being one year in case of steatosis without fibrosis and every two years in case of 
absence of steatosis and fibrosis. An easy-to-use web application based on the 
proposed algorithm by the BASL is freely available at 
www.antwerpnafldguide.com.50 
Until early non-invasive diagnostics have been identified, the flowcharts 
provided by the EASL and BASL guideline could be used in primary care to help 
route patients to the right healthcare professional. In the Netherlands, 
flowcharts like these are not yet part of the Dutch Guidelines for GPs (NHG-
standaarden) and therefore not yet used in primary care practice. With the ever-
increasing prevalence of NAFLD, more emphasis should be put on using these 
flowcharts and incorporate them in the Dutch GP guidelines. 
With regards to management of NAFLD in primary care, lifestyle interventions 
with diet and exercise are the key first step for all patients.24,39 Furthermore, 
NAFLD management in primary care should include the treatment of metabolic 
comorbidities, such as dyslipidaemia and elevated glucose levels, to reduce 
cardiovascular risk, which can also prevent the future development of NASH 
and fibrosis.39 Enhancing patient participation and adherence to lifestyle 
intervention and medication is important and might be improved by patients 
being aware of a more progressive state of their disease. Moreover, gathering 
data on the NAFLD population in the primary care will increase the insight in the 
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entire NAFLD population and risk factors, including the group that does not 
need referral to secondary care. This can help direct specific interventions to the 
right patients, being high versus low risk on progressive disease.  
NAFLD: Is it all in the name? 
The increasing knowledge, the heterogeneity of the population with NAFLD and 
pathogenic drivers not being identical among patients20 has led to a discussion 
whether the term NAFLD is still up-to-date and truly reflects the current 
understanding of this disease.  
NAFLD used to be described as a condition of exclusion, meaning it exists only 
when other conditions, such as viral hepatitis, autoimmune disease or excessive 
alcohol intake are absent. The use of this definition has resulted in a one-size-
fits-all approach in treating this disease, despite the heterogeneity seen in 
people affected by the disease. With advancements in our understanding of the 
pathological processes involved, it is now considered a disease that must be 
defined by inclusion, rather than by exclusion. Furthermore, given its high 
prevalence, fatty liver disease is recognized to coexist with other conditions 
such as viral hepatitis, autoimmune disease and alcohol and will have 
synergistic effects on disease progression. Furthermore, linking NAFLD, a 
distinct entity, to alcohol in its name is problematic. Therefore, a new name has 
been suggested, namely ‘MAFLD’ or metabolic associated fatty liver disease.51-53 
MAFLD is present if hepatic steatosis is accompanied by either obesity or 
overweight (BMI >25 kg/m2 in white and >23 kg/m2 in Asian individuals), type 2 
diabetes mellitus or evidence of metabolic dysregulation. At least two metabolic 
risk factors should be present for definition of metabolic dysregulation: waist 
circumference ≥102/88 cm in white men and women or ≥90/80 cm in Asian 
men and women; prediabetes; inflammation with elevated high-sensitive serum 
C-reactive protein level; elevated blood pressure or specific drug treatment;
decreased HDL-cholesterol levels; increased plasma triglycerides levels; and
homeostasis model assessment (HOMA)-insulin resistance score ≥2.5.51,53
Societal impact and future perspectives 
NAFLD is an intensive research field given its public health implications. The 
knowledge on NAFLD is rapidly expanding. It is very likely that certain 
paradigms about the disease will be modified in the next decade. NAFLD shares 
common pathogenic features with cardiovascular disease and type 2 diabetes 




by excess caloric intake and a sedentary lifestyle. Changing this lifestyle will 
demand both a broader societal change in our way of living as well as 
personalised education/counselling for individuals who are at increased risk of 
health problems due to this lifestyle.  
In complicated, progressive liver disease, liver transplantation is the only 
treatment left. Not only will there be an increased need for liver transplantations 
in the near future, with the rapidly growing prevalence of NAFLD, also the pool 
of potential liver donors is impacted, as it is expected that a higher proportion of 
potential liver donors will have steatosis or steatohepatitis and might be 
declined for liver transplantation use.54 This will not only affect those in need of 
a liver transplantation due to NASH, but also patients suffering from liver 
diseases due to other aetiologies. Assuming the actual trends in the prevalence 
of diabetes and obesity, it has been estimated that the overall liver graft 
utilization in 2030 will fall from 78% to 44% .55 Not only will NAFLD shrink the 
pool of potential liver donors if our lifestyle does not change, but patients 
develop recurrent NAFLD after LT, which also puts an extra strain on the 
system. 
To reduce the burden of NAFLD, or should we say MAFLD,  and related diseases, 
a broad effort on social, economic, cultural and medical level is required to solve 
the origin of these problems: “globesity”. 
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This thesis focussed on the highly prevalent non-alcoholic fatty liver disease 
(NAFLD). NAFLD is a lifestyle related disease, associated with overnutrition and 
a sedentary lifestyle. This lifestyle is leading to an escalating global epidemic of 
overweight and obesity, which leads not only to NAFLD, but also to other 
serious non-communicable diseases, including diabetes mellitus, 
cardiovascular disease, hypertension and stroke and specific types of cancer.1 
These diseases undermine health, shorten life expectancy and cause enormous 
suffering, disability and economic costs.2  
Currently, the global prevalence of NAFLD of more than 25%. The number of 
patients diagnosed and referred with NAFLD is expected to rise further in the 
near future. The term NAFLD comprises both simple steatosis and non-alcoholic 
steatohepatitis (NASH). Simple steatosis is a more benign form of fat 
accumulation in the liver, present in the majority of patients. NASH is a chronic 
inflammatory state that develops in about 30% of NAFLD patients and leads to 
an overall increase in morbidity and mortality due to the progression to fibrosis, 
cirrhosis and hepatocellular carcinoma (HCC). The complex pathophysiology of 
NAFLD is multifactorial and not yet completely clear. Furthermore, at this 
moment there are limited therapeutic options available for NAFLD. Lifestyle 
changes, including diet and physical exercise are considered the mainstay 
treatment for the majority of patients with NAFLD.3,4 However, it is common 
knowledge that sustained weight loss is difficult to achieve and especially 
difficult to maintain. Therefore, other treatment options like pharmacotherapy 
also need to be considered as an add-on therapy. Up to now no drug has been 
approved for NASH by regulatory agencies, and any drug treatment is still off-
label. 
In case lifestyle changes and other interventions failed and end-stage liver 
disease has developed, a liver transplantation can be considered. It is thought 
that NAFLD will probably become the leading indication for liver 
transplantation due to the still rising prevalence of NAFLD.5 Additionally, the 
rapidly growing prevalence of NAFLD will also impact the pool of potential 
donors, as it is expected that a higher proportion of potential liver donors will 
have NAFLD and might be declined for liver transplantation use. Not only the 
fact that NAFLD can shrink the pool of potential liver donors, but also patients 
developing recurrent NAFLD after liver transplantation is putting a strain on the 
system.  
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In order to counter these alarming trends, a better knowledge and 
understanding of factors associated with progressive disease in NAFLD is 
needed. These numbers underline the importance of properly routing NAFLD 
patients to the right healthcare professional, meaning referral of patients at risk 
of progressive liver disease to secondary care and follow-up of low-risk NAFLD 
patients in primary care, to lower both the economic and disease burden of this 
disease. In this thesis, we aimed to gain more insight the pathophysiology, non-
invasive diagnostic options and the bridge to primary care, to improve 
healthcare. 
Several pathophysiological factors were studied in this thesis, namely 
defenestration of liver sinusoidal endothelial cells, the role of ferritin and 
myosteatosis. Even though, interesting results were found, they do not explain 
the entire pathophysiology of NAFLD. This has to do with the fact that 
pathophysiology of NAFLD is multifactorial. Due to this complex interplay, such 
as the involvement of several organs and inter-individual variation in disease 
presentation, human research on NAFLD is important. A well-characterised 
cohort of NAFLD patients with bio-sampling, which can be followed over a 
longer period of time, can help to get a better and more complete understanding 
of the natural disease course and factors that influence the development of 
progressive disease. However, this type of clinical research is very demanding, 
therefore it is important to supplement these kind of studies with research, both 
human and animals studies, focussing on specific mechanisms. In this manner, 
the longitudinal studies could be used to validate findings and in this way 
benefit scientific impact. 
To date, liver biopsy is the most sensitive test for detecting and staging NAFLD. 
So far, it is the only reliable method to diagnose NASH.3 Due to its invasiveness, 
high costs and risk of complications, liver biopsy is not a diagnostic method that 
is suitable to apply in large populations or for monitoring the disease. In clinical 
practice, only subjects at high risk of NASH, usually based on elevated liver 
enzymes measured in the blood, will be considered to undergo a liver biopsy. 
This may lead to underdiagnoses of NASH, since a significant part of NASH 
patients do not have elevated liver enzymes. Even though, fibrosis stages 1-4 
were found to be the strongest predictor for disease-specific mortality in NAFLD, 
there is an urgent need for non-invasive methods to detect NASH among the 
general population, since NASH is a recognized driver of liver fibrosis and 
fibrosis progression. A non-invasive diagnostic tool for NASH could benefit both 




the available non-invasive diagnostics studied in recent years. We showed that 
several scores that combined different non-invasive markers showed promising 
results. However, none of the markers or combination of markers identified, 
was able to differentiate NASH from simple steatosis and a non-invasive marker 
for NASH is therefore not yet available in clinical practice. Due to the complexity 
of NAFLD, it is likely that a score consisting of multiple parameters may be able 
to diagnose NASH in the future. It would be of value to use -omics approaches to 
identify interesting parameters that could possibly be used for non-invasively 
diagnosing NASH. Omics aim at the collective characterization and 
quantification of pools of biological molecules that translate into the structure, 
function and dynamic of an organism or organisms. The goal is to find an 
affordable diagnostic tool that includes parameters that both easily as well as 
reliably diagnose NASH non-invasively. Once implemented in clinical care, it 
should enable diagnosing and monitoring of large groups, so the proper 
guidance/treatment can be given to the right patients. Finding and 
implementing such a tool would be of great benefit especially for general 
practitioners (GPs). Due to the high prevalence but low severity of NAFLD in the 
majority of patients, GPs, as gatekeepers of our health care system, are 
confronted with large numbers of NAFLD patients. However, until a non-
invasive diagnostic tool is available, GPs need to be trained to identifying 
patients at risk of progressive liver disease for secondary care referral. 
Furthermore, adequate education on the follow-up and treatment of low-risk 
patients should be provided, taking into account cost-effectiveness. This thesis 
showed that there is a need for increased awareness and knowledge on NAFLD 
in the field of primary care. Until non-invasive diagnostics, to enable early 
diagnosis of NASH, are implemented in clinical care, the flowcharts provided by 
the EASL and BASL guideline should be used in primary care to help route 
patients to the right healthcare professional.3,6 
In conclusion, this thesis proposes possible factors that play a role in the 
pathophysiology of NAFLD, these findings can provide foundation for future 
mechanistic research. Furthermore, we have provided an overview of the non-
invasive diagnostics of NASH studied over the years. Even though a non-
invasive diagnostic tool is not yet available in clinical healthcare, our overview 
has shown that combining various parameters is necessary in the development 
of a non-invasive diagnostic tool for NASH. This can provide leads for 
developing a test that can be implemented in clinical practice and can be used in 
future studies on the identification of risk factors for progressive disease. 
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Finally, this thesis has shown the importance of a collaboration between 
hepatologists and primary care physicians to guide patients to the right 
healthcare professionals, especially as the numbers of NAFLD patients are 
expected to rise even further the coming years.  
A great effort to increase application of public health and interventions to 
reduce prevalence of poor diet and insufficient physical activity, increase 
awareness of NAFLD and promote the use of flowcharts until a non-invasive 
diagnostic tool is available, could substantially reduce the human and economic 
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Non-alcoholic fatty liver disease (NAFLD) is the most widespread liver disease in 
Western society; about 25% of the global population has NAFLD. The term 
NAFLD comprises both simple steatosis and non-alcoholic steatohepatitis 
(NASH). Simple steatosis is a more benign form of fat accumulation, present in 
the majority of patients. NASH is a chronic inflammatory state that develops in 
about 30% of NAFLD patients and can progress to severe liver disease, such as 
cirrhosis, liver failure and hepatocellular cancer. Its pathophysiology is 
multifactorial and not yet fully understood. Overweight and obesity are major 
risk factors for NAFLD, as is also true for other related serious non-
communicable diseases, including diabetes mellitus and cardiovascular disease. 
All these diseases are linked to each other and their prevalence is expected to 
increase even further the coming years due to the western lifestyle, that is 
characterised by overeating and sedentary behaviour, leading to an obesity 
epidemic. In this thesis we have focussed on the pathophysiology of NAFLD and 
non-invasive diagnosis of NASH. 
The pathophysiology of NAFLD is complex and not yet completely understood. 
Several theories have been proposed to explain the progression of NAFLD. The 
most recent concept states that simple steatosis and NASH are two independent 
conditions caused by insulin resistance. In chapter 2, we studied the 
ultrastructural differences between NAFLD patients with and without NASH to 
find leads that might fill the gaps in the pathophysiology of NAFLD. Liver biopsy 
samples of 37 NAFLD patients were studied using light microscopy and 
transmission electron microscopy (TEM). TEM enables visualisation of the 
smallest details within liver cells, with a zoom mode of 1.000-1.500.000 times. 
Using preservation techniques recently developed by our department, we were 
able to study the fenestrae in liver sinusoidal endothelial cells. These are very 
small openings in the cells lining the smallest blood vessels in the liver, that 
serve as a sieve. We showed that patients without NASH had an increased loss of 
fenestration (i.e., defenestration) compared to NASH patients. This study 
provides additional new insights in pathophysiology of NAFLD: one could 
speculate that defenestration might be a protective mechanisms seen in simple 
steatosis, which is lacking in NASH.  
In chapter 3 and 4, we focussed on the role of serum ferritin in NAFLD. In 
chapter 3, we performed an extensive literature search to investigate whether 
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hyperferritinaemia in NAFLD is an expression of iron overload or inflammation. 
These data show that in the majority of cases hyperferritinaemia in NAFLD 
seems to be related to inflammation. However, a limitation of the studies 
included in this review was the heterogeneity with regards to objectives, study 
population and methods used. Therefore, we studied the relation between 
serum ferritin, NAFLD severity and iron in a group of biopsy proven NAFLD 
patient, in collaboration with the Universitair Ziekenhuis Antwerpen (UZA) 
(chapter 4). It was shown that serum ferritin was associated with having NASH 
with significant fibrosis (F2-4) and p.C282Y or p.H63D heterozygosity, in the 
presence and absence of hepatocellular iron. 
Not only the liver is affected in NAFLD, extrahepatic organs can also be affected. 
In chapter 5, we studied fat accumulation in the skeletal muscle (myosteatosis) 
in relation to hepatic fat accumulation and the presence of fibrosis in a well-
characterised cohort of NAFLD patients. Chemical shift Magnetic Resonance 
Imaging (MRI) was used to measure the muscle fat fraction (MFF). In addition, 
the hepatic fat fraction (using MRI), liver stiffness (using FibroScan®) and 
appendicular skeletal muscle mass (using Dual-energy X-ray absorptiometry) 
were measured. We found that myosteatosis did not correlate with the degree of 
hepatic steatosis or fibrosis, but it was  positively correlated with total body fat 
percentage and body mass index (BMI). Insulin resistance (measured as HOMA-
IR) was correlated with hepatic steatosis and fibrosis. These findings suggest 
that fat accumulation in the muscle does not correspond with hepatic disease 
severity. 
To date, liver biopsy is the most sensitive test for detecting and staging steatosis, 
inflammation and fibrosis in NAFLD. Steatosis and fibrosis can also be reliably 
diagnosed using non-invasive techniques. However, liver biopsy is the only 
reliable method to diagnose NASH. Its invasiveness and risk of complications 
make it unsuitable for diagnosing large populations or for monitoring the 
disease. To investigate the reliability of non-invasive markers for NASH, we 
performed a systematic literature search and meta-analyses on available non-
invasive diagnostic blood markers and scores for NASH (chapter 6). An 
extensive overview of all available markers/scores was provided with calculated 
pooled sensitivity and specificity. A reliable non-invasive marker or score to 
differentiate NASH from simple steatosis was not identified. Due to the 
multifactorial pathophysiology of NASH, it is unlikely that a single non-invasive 




approaches that combined markers that are specific for different 
pathophysiological processes in NASH, such as inflammation, lipid metabolism, 
fibrogenesis, showed promising findings (being a sensitivity and specificity 
>80%). However, for the time being, a non-invasive marker for NASH is not yet
available in clinical practice.
NAFLD is a prevalent liver disease, which numbers will only continue to grow 
the coming years. Depending on the study population, the prevalence of NASH 
within a NAFLD population can vary. Within bariatric studies the prevalence of 
NASH has been shown to vary largely. In chapter 7, we studied a cohort of 
patients undergoing bariatric surgery showing zero patients had NASH. We 
suggest the preoperative crash diet (low-caloric diet) might be the cause of this. 
Preoperative diet interventions are common but not obligatory, therefore, this 
diet might at least partly explain the differences between prevalence of NASH in 
bariatric studies. We advocate proper mentioning of preoperative diet 
interventions in bariatric studies.  
General practitioners (GPs), as gatekeepers of our health care system, are going 
to play a major role in the challenge to adequately identify and manage NAFLD 
patients at population level. Due to the high prevalence and overall low to 
moderate severity of NAFLD, GPs will encounter most of  these patients and 
become actively involved in the screening and management of patients. In 
chapter 8, we describe the results of a survey conducted amongst GPs, to 
investigate the knowledge and practices concerning NAFLD in the Dutch GP 
practice. A total of 64 GPs completed the questionnaire. The acronyms NAFLD 
and NASH were not known by 34% and 53% of the GPs, respectively. Although 
63% of the GPs acknowledged NAFLD as an important health problem, most GPs 
never (33%) or rarely (63%) screened for its presence. The results indicate the 
need for increased awareness and knowledge on NAFLD in primary care, which 
was endorsed by 84% of the GPs. Bridging the gap between hepatologists and 
primary care is necessary to improve detecting and managing NAFLD patients. 
Finally, in chapter 9, we provide an overview of the findings of this thesis, 
discussing new insights and future perspectives, focussing on pathophysiology, 










Niet-alcoholische vetleverziekte (NAFLD) is de meest voorkomende leverziekte 
in westerse landen. Wereldwijd komt NAFLD bij ongeveer 25% van de bevolking 
voor. De term NAFLD omvat zowel leververvetting (steatose) als leverontsteking 
(NASH; niet-alcoholische steatohepatitis).Bij leververvetting is er sprake van 
vetophoping in de levercellen. Als leververvetting aanhoudt kan dit leiden tot 
leverontsteking. Leverontsteking ontstaat bij ongeveer 30% van de patiënten 
met leververvetting en kan op den duur levercirrose en leverkanker tot gevolg 
hebben. Bij levercirrose is er ernstige schade aan de lever die ertoe kan leiden 
dat de lever op den duur minder goed functioneert. NAFLD is het gevolg van een 
ongezonde leefstijl, die gekenmerkt wordt door een calorierijke voeding en 
weinig lichaamsbeweging. Overgewicht en obesitas zijn dan ook belangrijke 
risicofactoren voor het ontwikkelen van leververvetting. De precieze manier 
waarop leverontsteking ofwel NASH, ontstaat in patiënten met leververvetting 
is echter nog niet helemaal bekend. In dit proefschrift worden drie onderwerpen 
met betrekking tot NAFLD besproken, namelijk i) factoren die mogelijk een rol 
spelen bij het ontstaan van leverontsteking, ii) het vaststellen van 
leverontsteking op een niet belastende manier en iii) de rol van de huisarts in het 
diagnosticeren van NAFLD. 
Het ontstaan van leververvetting en NASH is complex en nog niet volledig 
duidelijk. Verschillende theorieën zijn beschreven om het ontstaan van NASH te 
verklaren. De meest recente theorie stelt dat leververvetting en NASH twee 
onafhankelijke aandoeningen zijn, die veroorzaakt worden door insuline 
resistentie. In hoofdstuk 2 hebben we de endotheelcellen van de lever bestudeert 
met behulp van een elektronenmicroscoop. Deze endotheelcellen bevatten 
kleine openingen ofwel fenestrae genaamd. Via deze fenestrae kan de lever 
stoffen opnemen en uitscheiden (als een soort zeef). Onderzoek van 
leverbiopten van patiënten met leververvetting en NASH met een 
elektronenmicroscoop, heeft aangetoond dat deze fenestrae vrijwel geheel 
afwezig zijn bij patiënten met alleen leververvetting. Dit duidt mogelijk op een 
beschermingsmechanisme van de lever tegen overtollige vetten en andere 
schadelijke stoffen, dat ontbreekt bij patiënten die NASH ontwikkelen.  
In hoofdstuk 3 en 4, wordt de rol van ferritine in NAFLD onderzocht. Ferritine is 
een eiwit dat betrokken is bij de opslag van ijzer in de lichaamscellen, en komt in 
een kleine hoeveelheid voor in het bloed. Ferritine waardes kunnen niet alleen 
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verhoogd zijn door een teveel aan ijzer in het lichaam, ontsteking kan ook tot 
verhoogde ferritine waardes leiden. Een deel van de patiënten met NAFLD heeft 
een verhoogde ferritine waarde (hyperferritinemie). Hoofdstuk 3 beschrijft een 
literatuuronderzoek naar de oorzaak van hyperferritinemie in NAFLD patiënten. 
Hieruit bleek dat hyperferritinemie in NAFLD patiënten, in de meerderheid van 
de gevallen, een uiting is van ontsteking. Het literatuuronderzoek had echter 
beperkingen, waaronder de variatie tussen de verschillende onderzoeken met 
betrekking tot gebruikte meetmethodes en studiepopulatie. Om deze reden 
hebben we de relatie tussen ferritine, de ernst van de NAFLD en ijzerstapeling in 
leverbiopten bestudeerd in een grote groep NAFLD patiënten in samenwerking 
met het Universitair Ziekenhuis Antwerpen (UZA) (hoofdstuk 4). Dit onderzoek 
toonde dat verhoogde ferritine waardes geassocieerd waren met het hebben van 
leverontsteking met verlittekening (fibrose) van de lever en met het hebben van 
een mutatie in de genen (p.C282Y en p.H63D heterozygotie) die een rol spelen 
bij erfelijke ijzerstapelingsziekten (hereditaire hemochromatose). De 
diagnostische nauwkeurigheid van ferritine is echter onvoldoende om als 
marker voor NASH met fibrose te kunnen dienen. 
Niet alleen de lever is aangedaan bij NAFLD, ook andere organen dan de lever 
worden beïnvloed. In hoofdstuk 5 werd de relatie tussen vetophoping in de 
spieren (myosteatose) en leversteatose en -fibrose onderzocht in een cohort van 
goed gekarakteriseerde NAFLD patiënten. Insuline resistentie speelt een 
belangrijke rol in de ontwikkeling van leververvetting en wordt gelinkt aan 
ophoping van vet in de spieren (myosteatose). Myosteatose werd gemeten 
middels een MRI scan. Leversteatose, -fibrose en skeletspiermassa werden 
gemeten met respectievelijk een MRI scan, FibroScan® en DEXA-scan. Wij 
vonden geen relatie tussen myosteatose en de mate van steatose of fibrose van 
de lever. Myosteatose was wel geassocieerd met het percentage totaal 
lichaamsvet en BMI (body mass index). Insuline resistentie (gemeten middels 
HOMA-IR) was geassocieerd met lever steatose en fibrose.  
Tot op heden is het uitvoeren van een leverbiopt de meest betrouwbare manier 
om de mate van NAFLD vast te stellen. Leversteatose en -fibrose kunnen echter 
ook betrouwbaar met niet-belastende technieken vastgesteld worden, 
bijvoorbeeld de FibroScan®. NASH kan alleen op een betrouwbare manier 
worden vastgesteld met behulp van het leverbiopt. Een leverbiopt is echter een 
belastend (invasief) onderzoek en er bestaat een risico op complicaties. Hierdoor 




over de tijd te volgen. Hoofdstuk 6 beschrijft een literatuuronderzoek met meta-
analyse naar de betrouwbaarheid van niet-invasieve onderzoeken, met name 
bloedonderzoek, om NASH vast te stellen. Ondanks dat vele markers voor het 
vaststellen van NASH onderzocht zijn, bleek geen van deze onderzoeken in staat 
om NASH op een betrouwbare manier vast te stellen. Aangezien er vele 
verschillende factoren betrokken zijn bij het ontstaan van NASH lijkt het 
waarschijnlijk dat een combinatie van verschillende bloedonderzoeken wel kan 
leiden tot een betrouwbare diagnose van NASH. Aanvullend onderzoek is nodig 
om dit uit te zoeken. 
NAFLD is een veelvoorkomende aandoening en gedacht wordt dat de aantallen 
alleen maar zullen groeien de komende jaren, aangezien overgewicht en 
obesitas steeds meer voorkomen. Het voorkomen van NASH in een groep van 
NAFLD patiënten varieert afhankelijk van de gekozen studiepopulatie. In 
hoofdstuk 7 onderzoeken we het voorkomen van NASH in een groep patiënten 
met fors overgewicht die een operatie ondergaan om gewicht te verliezen 
(bariatrische ingreep). In deze groep bleek geen van de patiënten NASH te 
hebben. Andere onderzoeken in een gelijksoortige patiëntengroep toonden dat 
NASH vaker voorkwam in deze groep. Gedacht wordt dat het crash dieet dat in 
Nederland voorafgaand aan de bariatrische ingreep gevolgd wordt, het 
ontbreken van NASH in deze groep, ten minste deels, verklaard. Om deze reden 
is het belangrijk om preoperatieve diëten duidelijk te beschrijven in toekomstige 
studies.  
Aangezien NAFLD vaak een goedaardig beloop heeft en slechts een deel van de 
patiënten NASH en de gevolgen van NASH (fibrose/cirrose en leverkanker) 
ontwikkelt, spelen huisartsen een belangrijke rol bij het identificeren en 
opvolgen van NAFLD patiënten. In hoofdstuk 8 worden de resultaten van een 
vragenlijst over de kennis en werkwijze rondom NAFLD in de huisartsenpraktijk 
beschreven. De vragenlijsten werden ingevuld door 64 huisartsen in Zuid-
Limburg. Het bleek dat de termen NAFLD en NASH onbekend waren bij 
respectievelijk 34% en 53% van de huisartsen. Hoewel huisartsen aangeven 
NAFLD een belangrijk gezondheidsprobleem te vinden, screenen de meeste 
huisartsen nooit (33%) of zelden (63%) naar de aanwezigheid van NAFLD. De 
resultaten laten zien dat er behoefte is aan meer bewustzijn en kennis rondom 
NAFLD in de huisartsenzorg. Dit werd onderschreven door 84% van de 
huisartsen. Het is nodig om het gat tussen huisartsen en hepatologen te 
verkleinen om de identificatie en opvolging van NAFLD patiënten te verbeteren.  
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Tot slot wordt in hoofdstuk 9 een overzicht van de belangrijkste bevindingen 
van dit proefschrift gegeven. Daarnaast worden verschillende concepten 
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